symbol	chrom	hgvsp	consequence	evidence_id	variant_name	clinical_significance	pubmed_html_link	cancer_type	evidence_type	evidence_level	disease_ontology_id	codon	exon	therapeutic_context	variant_name_2	name	hgvsc	genomic_change	ensembl_transcript_id	refseq_mrna	start	end
ERRFI1	1	E384X	stop_gained	EID1724	E384*	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24550739' target='_blank'>Borad et al., 2014, PLoS Genet.</a>	Cholangiocarcinoma	Predictive	C: Case study	DOID:4947	384	NA	Erlotinib	E384X	civic:EID1724:ERRFI1:p.E384	c.1150G>T	1_8073509_C_A	ENST00000377482	NM_018948	8073503	8073514
MTOR	1	M2327I	missense_variant	EID1544	M2327I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27279227' target='_blank'>Rodrik-Outmezguine et al., 2016, Nature</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	2327	NA	AZD8055	M2327I	civic:EID1544:MTOR:p.M2327	c.6981G>T	1_11177096_C_A	ENST00000361445	NM_004958	11177090	11177101
MTOR	1	M2327I	missense_variant	EID1545	M2327I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27279227' target='_blank'>Rodrik-Outmezguine et al., 2016, Nature</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	2327	NA	Rapamycin (Sirolimus), RapaLink-1	M2327I	civic:EID1545:MTOR:p.M2327	c.6981G>T	1_11177096_C_A	ENST00000361445	NM_004958	11177090	11177101
MTOR	1	S2215Y	missense_variant	EID1319	S2215Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24631838' target='_blank'>Grabiner et al., 2014, Cancer Discov</a>	Endometrial Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:2870	2215	NA	Rapamycin (Sirolimus)	S2215Y	civic:EID1319:MTOR:p.S2215	c.6644C>A	1_11184573_G_T	ENST00000361445	NM_004958	11184567	11184578
MTOR	1	P2213S	missense_variant	EID722	P2213S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26490311' target='_blank'>Kong et al., 2016, Clin. Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	2213	NA	LY294002, AZD5363	P2213S	civic:EID722:MTOR:p.P2213	c.6637C>T	1_11184580_G_A	ENST00000361445	NM_004958	11184574	11184585
MTOR	1	F2108L	missense_variant	EID1110	F2108L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25295501' target='_blank'>Wagle et al., 2014, N. Engl. J. Med.</a>	Thyroid Carcinoma	Predictive	C: Case study	DOID:3963	2108	NA	Everolimus	F2108L	civic:EID1110:MTOR:p.F2108	c.6324C>A	1_11187094_G_T	ENST00000361445	NM_004958	11187088	11187099
MTOR	1	F2108L	missense_variant	EID1543	F2108L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27279227' target='_blank'>Rodrik-Outmezguine et al., 2016, Nature</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	2108	NA	Rapamycin (Sirolimus)	F2108L	civic:EID1543:MTOR:p.F2108	c.6324C>A	1_11187094_G_T	ENST00000361445	NM_004958	11187088	11187099
MTOR	1	A2034V	missense_variant	EID1547	A2034V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27279227' target='_blank'>Rodrik-Outmezguine et al., 2016, Nature</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	2034	NA	Rapamycin (Sirolimus)	A2034V	civic:EID1547:MTOR:p.A2034	c.6101C>T	1_11187796_G_A	ENST00000361445	NM_004958	11187790	11187801
MTOR	1	A2034V	missense_variant	EID1548	A2034V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27279227' target='_blank'>Rodrik-Outmezguine et al., 2016, Nature</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	2034	NA	RapaLink-1, AZD8055	A2034V	civic:EID1548:MTOR:p.A2034	c.6101C>T	1_11187796_G_A	ENST00000361445	NM_004958	11187790	11187801
MTOR	1	H1968Y	missense_variant	EID713	H1968Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26490311' target='_blank'>Kong et al., 2016, Clin. Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	1968	NA	AZD5363, LY294002	H1968Y	civic:EID713:MTOR:p.H1968	c.5902C>T	1_11188519_G_A	ENST00000361445	NM_004958	11188513	11188524
MTOR	1	E1799K	missense_variant	EID1321	E1799K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24631838' target='_blank'>Grabiner et al., 2014, Cancer Discov</a>	Clear Cell Renal Cell Carcinoma	Predictive	D: Preclinical evidence	DOID:4467	1799	NA	Rapamycin (Sirolimus)	E1799K	civic:EID1321:MTOR:p.E1799	c.5395G>A	1_11190804_C_T	ENST00000361445	NM_004958	11190798	11190809
MTOR	1	C1483Y	missense_variant	EID1320	C1483Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24631838' target='_blank'>Grabiner et al., 2014, Cancer Discov</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	1483	NA	Rapamycin (Sirolimus)	C1483Y	civic:EID1320:MTOR:p.C1483	c.4448G>A	1_11217230_C_T	ENST00000361445	NM_004958	11217224	11217235
ARID1A	1	Q456X	stop_gained	EID4487	Q456*	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27364904' target='_blank'>Miller et al., 2016, Mol. Cancer Ther.</a>	Ovarian Clear Cell Carcinoma	Predictive	D: Preclinical evidence	DOID:0050934	456	NA	Dasatinib	Q456X	civic:EID4487:ARID1A:p.Q456	c.1366C>T	1_27057658_C_T	ENST00000324856	NM_006015	27057652	27057663
CSF3R	1	T618I	missense_variant	EID6380	T618I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24081659' target='_blank'>Fleischman et al., 2013, Blood</a>	Chronic Neutrophilic Leukemia	Predictive	D: Preclinical evidence	DOID:0080187	618	NA	Ruxolitinib	T618I	civic:EID6380:CSF3R:p.T618	c.1853_1854delinsTT, c.1853_1854delinsTA, c.1853C>T	1_36933433_GG_AA, 1_36933433_GG_TA, 1_36933434_G_A	ENST00000373103	NM_156039	36933427	36933439
CSF3R	1	T618I	missense_variant	EID6381	T618I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25180155' target='_blank'>Dao et al., 2014, Leuk Res Rep</a>	Chronic Neutrophilic Leukemia	Predictive	C: Case study	DOID:0080187	618	NA	Ruxolitinib	T618I	civic:EID6381:CSF3R:p.T618	c.1853_1854delinsTT, c.1853_1854delinsTA, c.1853C>T	1_36933433_GG_AA, 1_36933433_GG_TA, 1_36933434_G_A	ENST00000373103	NM_156039	36933427	36933439
JAK1	1	S703I	missense_variant	EID1900	S703I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26701727' target='_blank'>Yang et al., 2016, Oncotarget</a>	Hepatocellular Carcinoma	Predictive	D: Preclinical evidence	DOID:684	703	NA	Ruxolitinib	S703I	civic:EID1900:JAK1:p.S703	c.2108G>T	1_65311203_C_A	ENST00000342505	NM_002227	65311197	65311208
JAK1	1	Q503X	stop_gained	EID1567	Q503*	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27433843' target='_blank'>Zaretsky et al., 2016, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	503	NA	Pembrolizumab	Q503X	civic:EID1567:JAK1:p.Q503	c.1507C>T	1_65321333_G_A	ENST00000342505	NM_002227	65321327	65321338
NRAS	1	Q61L	missense_variant	EID22	Q61L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21576590' target='_blank'>Soon et al., 2011, Arch Dermatol</a>	Melanoma	Predictive	C: Case study	DOID:1909	61	NA	Temozolomide	Q61L	civic:EID22:NRAS:p.Q61	c.182A>T	1_115256529_T_A	ENST00000369535	NM_002524	115256523	115256534
NRAS	1	Q61R	missense_variant	EID23	Q61R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21576590' target='_blank'>Soon et al., 2011, Arch Dermatol</a>	Melanoma	Predictive	C: Case study	DOID:1909	61	NA	Temozolomide	Q61R	civic:EID23:NRAS:p.Q61	c.182A>G	1_115256529_T_C	ENST00000369535	NM_002524	115256523	115256534
NRAS	1	Q61K	missense_variant	EID1002	Q61K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26821351' target='_blank'>Kiessling et al., 2016, PLoS ONE</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	61	NA	Everolimus, Binimetinib (MEK162)	Q61K	civic:EID1002:NRAS:p.Q61	c.181C>A	1_115256530_G_T	ENST00000369535	NM_002524	115256524	115256535
NRAS	1	Q61K	missense_variant	EID1474	Q61K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22194965' target='_blank'>Atefi et al., 2011, PLoS ONE</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	61	NA	Vemurafenib	Q61K	civic:EID1474:NRAS:p.Q61	c.181C>A	1_115256530_G_T	ENST00000369535	NM_002524	115256524	115256535
NRAS	1	Q61K	missense_variant	EID1475	Q61K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22194965' target='_blank'>Atefi et al., 2011, PLoS ONE</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	61	NA	Selumetinib (AZD6244)	Q61K	civic:EID1475:NRAS:p.Q61	c.181C>A	1_115256530_G_T	ENST00000369535	NM_002524	115256524	115256535
NRAS	1	Q61K	missense_variant	EID2192	Q61K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	61	NA	Selumetinib (AZD6244), BEZ235	Q61K	civic:EID2192:NRAS:p.Q61	c.181C>A	1_115256530_G_T	ENST00000369535	NM_002524	115256524	115256535
NRAS	1	Q61K	missense_variant	EID2907	Q61K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23515407' target='_blank'>Ohashi et al., 2013, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	61	NA	Trametinib, Selumetinib (AZD6244)	Q61K	civic:EID2907:NRAS:p.Q61	c.181C>A	1_115256530_G_T	ENST00000369535	NM_002524	115256524	115256535
NRAS	1	NA	NA	EID6959	Q61	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25448848' target='_blank'>Muzza et al., 2015, Mol. Cell. Endocrinol.</a>	Follicular Thyroid Carcinoma	Prognostic	B: Clinical evidence	DOID:3962	61	NA	NA	Q61	civic:EID6959:NRAS:p.Q61	NA	NA	NA	NA	115256527	115256530
NRAS	1	NA	NA	EID1473	Q61	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18390968' target='_blank'>Adjei et al., 2008, J. Clin. Oncol.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	61	NA	Selumetinib (AZD6244)	Q61	civic:EID1473:NRAS:p.Q61	NA	NA	NA	NA	115256527	115256530
NRAS	1	NA	NA	EID1226	Q61	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23414587' target='_blank'>Ascierto et al., 2013, Lancet Oncol.</a>	Skin Melanoma	Predictive	B: Clinical evidence	DOID:8923	61	NA	Binimetinib (MEK162)	Q61	civic:EID1226:NRAS:p.Q61	NA	NA	NA	NA	115256527	115256530
NRAS	1	NA	NA	EID124	Q61	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	61	NA	Cetuximab	Q61	civic:EID124:NRAS:p.Q61	NA	NA	NA	NA	115256527	115256530
NRAS	1	NA	NA	EID36	Q61	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	61	NA	Cetuximab	Q61	civic:EID36:NRAS:p.Q61	NA	NA	NA	NA	115256527	115256530
NRAS	1	NA	NA	EID10	Q61	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23861977' target='_blank'>Tschandl et al., 2013, PLoS ONE</a>	Melanoma	Diagnostic	B: Clinical evidence	DOID:1909	61	NA	NA	Q61	civic:EID10:NRAS:p.Q61	NA	NA	NA	NA	115256527	115256530
NRAS	1	NA	NA	EID14	Q61	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23569304' target='_blank'>Trunzer et al., 2013, J. Clin. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	61	NA	Vemurafenib	Q61	civic:EID14:NRAS:p.Q61	NA	NA	NA	NA	115256527	115256530
NRAS	1	G13D	missense_variant	EID21	G13D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18375819' target='_blank'>Banerji et al., 2008, Mol. Cancer Ther.</a>	Melanoma	Predictive	C: Case study	DOID:1909	13	NA	17-AAG	G13D	civic:EID21:NRAS:p.G13	c.38G>A	1_115258744_C_T	ENST00000369535	NM_002524	115258738	115258749
NRAS	1	G12D	missense_variant	EID3693	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25666295' target='_blank'>Kaczirek et al., 2015, Clin Colorectal Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Cetuximab	G12D	civic:EID3693:NRAS:p.G12	c.35G>A	1_115258747_C_T	ENST00000369535	NM_002524	115258741	115258752
NRAS	1	NA	NA	EID1516	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27276561' target='_blank'>Papaemmanuil et al., 2016, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	12	NA	NA	G12	civic:EID1516:NRAS:p.G12	NA	NA	NA	NA	115258743	115258748
NRAS	1	NA	NA	EID1516B	G13	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27276561' target='_blank'>Papaemmanuil et al., 2016, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	13	NA	NA	G13	civic:EID1516B:NRAS:p.G13	NA	NA	NA	NA	115258743	115258748
DDR2	1	L63V	missense_variant&splice_region_variant	EID271	L63V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	63	NA	Dasatinib	L63V	civic:EID271:DDR2:p.L63	c.187C>G	1_162724415_C_G	ENST00000367922	NM_001014796	162724409	162724420
DDR2	1	L239R	missense_variant	EID270	L239R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	239	NA	Dasatinib	L239R	civic:EID270:DDR2:p.L239	c.716T>G	1_162729630_T_G	ENST00000367922	NM_001014796	162729624	162729635
DDR2	1	G253C	missense_variant	EID266	G253C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	253	NA	Dasatinib	G253C	civic:EID266:DDR2:p.G253	c.757G>T	1_162729671_G_T	ENST00000367922	NM_001014796	162729665	162729676
DDR2	1	G505S	missense_variant	EID267	G505S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	505	NA	Dasatinib	G505S	civic:EID267:DDR2:p.G505	c.1513G>A	1_162741822_G_A	ENST00000367922	NM_001014796	162741816	162741827
DDR2	1	I638F	missense_variant	EID269	I638F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	638	NA	Dasatinib	I638F	civic:EID269:DDR2:p.I638	c.1912A>T	1_162745497_A_T	ENST00000367922	NM_001014796	162745491	162745502
DDR2	1	S768R	missense_variant	EID272	S768R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	768	NA	Erlotinib, Dasatinib	S768R	civic:EID272:DDR2:p.S768	c.2304T>A	1_162748390_T_A	ENST00000367922	NM_001014796	162748384	162748395
DDR2	1	G774V	missense_variant	EID268	G774V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22328973' target='_blank'>Hammerman et al., 2011, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	774	NA	Dasatinib	G774V	civic:EID268:DDR2:p.G774	c.2321G>T	1_162748407_G_T	ENST00000367922	NM_001014796	162748401	162748412
AKT3	1	E17K	missense_variant&splice_region_variant	EID4521	E17K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	17	NA	Vemurafenib	E17K	civic:EID4521:AKT3:p.E17	c.49G>A	1_243859016_C_T	ENST00000366539	NA	243859010	243859021
RET	10	C634W	missense_variant	EID75	C634W	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21422803' target='_blank'>Coxon et al., 2012, J. Endocrinol. Invest.</a>	Thyroid Medullary Carcinoma	Predictive	D: Preclinical evidence	DOID:3973	634	NA	Motesanib	C634W	civic:EID75:RET:p.C634	c.1902C>G	10_43609950_C_G	ENST00000355710	NM_020975	43609944	43609955
RET	10	M918T	missense_variant	EID1365	M918T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20368568' target='_blank'>Lam et al., 2010, J. Clin. Oncol.</a>	Thyroid Medullary Carcinoma	Predictive	B: Clinical evidence	DOID:3973	918	NA	Sorafenib	M918T	civic:EID1365:RET:p.M918	c.2753T>C	10_43617416_T_C	ENST00000355710	NM_020975	43617410	43617421
RET	10	M918T	missense_variant	EID74	M918T	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18073307' target='_blank'>Elisei et al., 2008, J. Clin. Endocrinol. Metab.</a>	Thyroid Medullary Carcinoma	Diagnostic	B: Clinical evidence	DOID:3973	918	NA	NA	M918T	civic:EID74:RET:p.M918	c.2753T>C	10_43617416_T_C	ENST00000355710	NM_020975	43617410	43617421
RET	10	M918T	missense_variant	EID76	M918T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21422803' target='_blank'>Coxon et al., 2012, J. Endocrinol. Invest.</a>	Thyroid Medullary Carcinoma	Predictive	D: Preclinical evidence	DOID:3973	918	NA	Motesanib	M918T	civic:EID76:RET:p.M918	c.2753T>C	10_43617416_T_C	ENST00000355710	NM_020975	43617410	43617421
RET	10	M918T	missense_variant	EID77	M918T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23056499' target='_blank'>Couto et al., 2012, PLoS ONE</a>	Thyroid Medullary Carcinoma	Predictive	D: Preclinical evidence	DOID:3973	918	NA	AZD1480	M918T	civic:EID77:RET:p.M918	c.2753T>C	10_43617416_T_C	ENST00000355710	NM_020975	43617410	43617421
RET	10	M918T	missense_variant	EID78	M918T	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9839497' target='_blank'>Egawa et al., 1998, Jpn. J. Clin. Oncol.</a>	Thyroid Medullary Carcinoma	Prognostic	B: Clinical evidence	DOID:3973	918	NA	NA	M918T	civic:EID78:RET:p.M918	c.2753T>C	10_43617416_T_C	ENST00000355710	NM_020975	43617410	43617421
PTEN	10	R233X	stop_gained	EID317	R233*	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20085938' target='_blank'>Courtney et al., 2010, J. Clin. Oncol.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	233	NA	MTOR Inhibitors	R233X	civic:EID317:PTEN:p.R233	c.697C>T	10_89717672_C_T	ENST00000371953	NM_000314	89717666	89717677
PTEN	10	R233X	stop_gained	EID343	R233*	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22479427' target='_blank'>Carico et al., 2012, PLoS ONE</a>	Glioblastoma Multiforme	Prognostic	B: Clinical evidence	DOID:3068	233	NA	NA	R233X	civic:EID343:PTEN:p.R233	c.697C>T	10_89717672_C_T	ENST00000371953	NM_000314	89717666	89717677
PTEN	10	NA	NA	EID1534	V317FS	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24504448' target='_blank'>Turajlic et al., 2014, Ann. Oncol.</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	317	NA	PD184352, MK-2206	V317	civic:EID1534:PTEN:p.V317	NA	NA	NA	NA	89720798	89720802
NT5C2	10	D407A	missense_variant	EID632	D407A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	407	NA	6-thioguanine, 6-mercaptopurine	D407A	civic:EID632:NT5C2:p.D407	c.1220A>C	10_104850745_T_G	ENST00000343289	NM_012229&NM_001134373	104850739	104850750
NT5C2	10	D407A	missense_variant	EID635	D407A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	407	NA	Arabinosylguanine, Nelarabine	D407A	civic:EID635:NT5C2:p.D407	c.1220A>C	10_104850745_T_G	ENST00000343289	NM_012229&NM_001134373	104850739	104850750
NT5C2	10	R367Q	missense_variant	EID630	R367Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	367	NA	6-thioguanine, 6-mercaptopurine	R367Q	civic:EID630:NT5C2:p.R367	c.1100G>A	10_104852955_C_T	ENST00000343289	NM_012229&NM_001134373	104852949	104852960
NT5C2	10	R367Q	missense_variant	EID633	R367Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	367	NA	Arabinosylguanine, Nelarabine	R367Q	civic:EID633:NT5C2:p.R367	c.1100G>A	10_104852955_C_T	ENST00000343289	NM_012229&NM_001134373	104852949	104852960
NT5C2	10	K359Q	missense_variant	EID631	K359Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	359	NA	6-thioguanine, 6-mercaptopurine	K359Q	civic:EID631:NT5C2:p.K359	c.1075A>C	10_104852980_T_G	ENST00000343289	NM_012229&NM_001134373	104852974	104852985
NT5C2	10	K359Q	missense_variant	EID636	K359Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	T-cell Acute Lymphoblastic Leukemia	Predictive	D: Preclinical evidence	DOID:5603	359	NA	Nelarabine, Arabinosylguanine	K359Q	civic:EID636:NT5C2:p.K359	c.1075A>C	10_104852980_T_G	ENST00000343289	NM_012229&NM_001134373	104852974	104852985
NT5C2	10	K359Q	missense_variant	EID667	K359Q	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23377281' target='_blank'>Tzoneva et al., 2013, Nat. Med.</a>	Acute Lymphocytic Leukemia	Prognostic	B: Clinical evidence	DOID:9952	359	NA	NA	K359Q	civic:EID667:NT5C2:p.K359	c.1075A>C	10_104852980_T_G	ENST00000343289	NM_012229&NM_001134373	104852974	104852985
FGFR2	10	N550K	missense_variant	EID1322	N550K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18757403' target='_blank'>Byron et al., 2008, Cancer Res.</a>	Endometrial Cancer	Predictive	D: Preclinical evidence	DOID:1380	550	NA	PD173074	N550K	civic:EID1322:FGFR2:p.N550	c.1650T>A	10_123258034_A_T	ENST00000457416	NM_022970	123258028	123258039
HRAS	11	G13D	missense_variant	EID3851	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22256804' target='_blank'>Su et al., 2012, N. Engl. J. Med.</a>	Skin Squamous Cell Carcinoma	Predictive	C: Case study	DOID:3151	13	NA	Vemurafenib	G13D	civic:EID3851:HRAS:p.G13	c.38G>A	11_534285_C_T	ENST00000451590	NM_001130442&NM_005343	534279	534290
HRAS	11	G13D	missense_variant	EID3852	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26561417' target='_blank'>Boidot et al., 2016, Int J Colorectal Dis</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	13	NA	Cetuximab	G13D	civic:EID3852:HRAS:p.G13	c.38G>A	11_534285_C_T	ENST00000451590	NM_001130442&NM_005343	534279	534290
HRAS	11	G13D	missense_variant	EID699	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26561417' target='_blank'>Boidot et al., 2016, Int J Colorectal Dis</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	13	NA	EGFR Inhibitor	G13D	civic:EID699:HRAS:p.G13	c.38G>A	11_534285_C_T	ENST00000451590	NM_001130442&NM_005343	534279	534290
WT1	11	NA	NA	EID210	EXON 9 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18559874' target='_blank'>Paschka et al., 2008, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	9	NA	EXON 9 MUTATION	civic:EID210:WT1:exon9	NA	NA	NA	NA	32413517	32413610
WT1	11	NA	NA	EID203	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19221039' target='_blank'>Gaidzik et al., 2009, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	civic:EID203:WT1:exon7	NA	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID204	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18559874' target='_blank'>Paschka et al., 2008, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	civic:EID204:WT1:exon7	NA	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID205	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18591546' target='_blank'>Virappane et al., 2008, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	civic:EID205:WT1:exon7	NA	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID206	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18591546' target='_blank'>Virappane et al., 2008, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	civic:EID206:WT1:exon7	NA	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID201	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19536888' target='_blank'>Renneville et al., 2009, Cancer</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	civic:EID201:WT1:exon7	NA	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID202	EXON 7 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19536888' target='_blank'>Renneville et al., 2009, Cancer</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	7	NA	EXON 7 MUTATION	civic:EID202:WT1:exon7	NA	NA	NA	NA	32417802	32417953
WT1	11	NA	NA	EID139	EXON 7 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18591546' target='_blank'>Virappane et al., 2008, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	7	Cytarabine, Daunorubicin	EXON 7 MUTATION	civic:EID139:WT1:exon7	NA	NA	NA	NA	32417802	32417953
ATM	11	NA	NA	EID647	V2288FS*1	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26510020' target='_blank'>Mateo et al., 2015, N. Engl. J. Med.</a>	Prostate Cancer	Predictive	C: Case study	DOID:10283	2288	NA	Olaparib	V2288	civic:EID647:ATM:p.V2288	NA	NA	NA	NA	108196839	108196841
ATM	11	N2875H	missense_variant	EID648	N2875H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26510020' target='_blank'>Mateo et al., 2015, N. Engl. J. Med.</a>	Prostate Cancer	Predictive	C: Case study	DOID:10283	2875	NA	Olaparib	N2875H	civic:EID648:ATM:p.N2875	c.8623A>C	11_108218044_A_C	ENST00000278616	NM_000051	108218038	108218049
KRAS	12	A146V	missense_variant	EID2209	A146V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	146	NA	Selumetinib (AZD6244), BEZ235 (NVP-BEZ235, Dactolisib)	A146V	civic:EID2209:KRAS:p.A146	c.437C>T	12_25378561_G_A	ENST00000256078	NM_033360	25378555	25378566
KRAS	12	A146V	missense_variant	EID794	A146V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24836576' target='_blank'>Van Allen et al., 2014, Nat. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	146	NA	LY2835219	A146V	civic:EID794:KRAS:p.A146	c.437C>T	12_25378561_G_A	ENST00000256078	NM_033360	25378555	25378566
KRAS	12	A146P	missense_variant	EID2225	A146P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603018' target='_blank'>Loupakis et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	146	NA	Cetuximab	A146P	civic:EID2225:KRAS:p.A146	c.436G>C	12_25378562_C_G	ENST00000256078	NM_033360	25378556	25378567
KRAS	12	A146T	missense_variant	EID2206	A146T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	146	NA	BEZ235, Selumetinib (AZD6244)	A146T	civic:EID2206:KRAS:p.A146	c.436G>A	12_25378562_C_T	ENST00000256078	NM_033360	25378556	25378567
KRAS	12	A146T	missense_variant	EID2943	A146T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20570890' target='_blank'>Janakiraman et al., 2010, Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	146	NA	Cetuximab	A146T	civic:EID2943:KRAS:p.A146	c.436G>A	12_25378562_C_T	ENST00000256078	NM_033360	25378556	25378567
KRAS	12	A146T	missense_variant	EID3858	A146T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25666295' target='_blank'>Kaczirek et al., 2015, Clin Colorectal Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	146	NA	FOLFOX4, Cetuximab	A146T	civic:EID3858:KRAS:p.A146	c.436G>A	12_25378562_C_T	ENST00000256078	NM_033360	25378556	25378567
KRAS	12	Q61H	missense_variant	EID3862	Q61H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22722830' target='_blank'>Misale et al., 2012, Nature</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	61	NA	Cetuximab	Q61H	civic:EID3862:KRAS:p.Q61	c.183A>C	12_25380275_T_G	ENST00000256078	NM_033360	25380269	25380280
KRAS	12	NA	NA	EID489	Q61	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18528420' target='_blank'>Chng et al., 2008, Leukemia</a>	Multiple Myeloma	Prognostic	B: Clinical evidence	DOID:9538	61	NA	NA	Q61	civic:EID489:KRAS:p.Q61	NA	NA	NA	NA	25380274	25380277
KRAS	12	NA	NA	EID1208	EXON 2 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27037411' target='_blank'>Azuara et al., 2016, Mol. Cancer Ther.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	2	EGFR Inhibitor	EXON 2 MUTATION	civic:EID1208:KRAS:exon2	NA	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID1326	EXON 2 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25322874' target='_blank'>Hochster et al., 2015, Cancer Chemother. Pharmacol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	2	Selumetinib (AZD6244), Irinotecan	EXON 2 MUTATION	civic:EID1326:KRAS:exon2	NA	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID993	EXON 2 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18946061' target='_blank'>Karapetis et al., 2008, N. Engl. J. Med.</a>	Colorectal Cancer	Predictive	A: Validated	DOID:9256	NA	2	Cetuximab	EXON 2 MUTATION	civic:EID993:KRAS:exon2	NA	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID916	EXON 2 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23435671' target='_blank'>Boeck et al., 2013, J. Gastroenterol.</a>	Pancreatic Carcinoma	Predictive	B: Clinical evidence	DOID:4905	NA	2	Erlotinib	EXON 2 MUTATION	civic:EID916:KRAS:exon2	NA	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID917	EXON 2 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23435671' target='_blank'>Boeck et al., 2013, J. Gastroenterol.</a>	Pancreatic Carcinoma	Prognostic	B: Clinical evidence	DOID:4905	NA	2	NA	EXON 2 MUTATION	civic:EID917:KRAS:exon2	NA	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID1219	EXON 2 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21862683' target='_blank'>Kim et al., 2011, Mol. Cancer Ther.</a>	Pancreatic Cancer	Predictive	B: Clinical evidence	DOID:1793	NA	2	Erlotinib, Gemcitabine	EXON 2 MUTATION	civic:EID1219:KRAS:exon2	NA	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID250	EXON 2 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16618717' target='_blank'>Lièvre et al., 2006, Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	2	Cetuximab	EXON 2 MUTATION	civic:EID250:KRAS:exon2	NA	NA	NA	NA	25398207	25398329
KRAS	12	NA	NA	EID87	EXON 2 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24559322' target='_blank'>Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	2	Regorafenib	EXON 2 MUTATION	civic:EID87:KRAS:exon2	NA	NA	NA	NA	25398207	25398329
KRAS	12	Q22X	stop_gained	EID1131	Q22*	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19661358' target='_blank'>Palmirotta et al., 2009, Anticancer Res.</a>	Colon Mucinous Adenocarcinoma	Predictive	C: Case study	DOID:3029	22	NA	Panitumumab	Q22X	civic:EID1131:KRAS:p.Q22	c.64C>T	12_25398255_G_A	ENST00000256078	NM_033360	25398249	25398260
KRAS	12	G13V	missense_variant	EID6312	G13V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	13	NA	Panitumumab, Cetuximab	G13V	civic:EID6312:KRAS:p.G13	c.38_39delinsTT	12_25398280_GC_AA	ENST00000256078	NM_033360	25398274	25398286
KRAS	12	G13D	missense_variant	EID1180	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26371285' target='_blank'>Schirripa et al., 2015, Ann. Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Cetuximab	G13D	civic:EID1180:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	NM_033360	25398275	25398286
KRAS	12	G13D	missense_variant	EID1181	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26812186' target='_blank'>Rowland et al., 2016, Eur. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Cetuximab	G13D	civic:EID1181:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	NM_033360	25398275	25398286
KRAS	12	G13D	missense_variant	EID145	G13D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20978259' target='_blank'>De Roock et al., 2010, JAMA</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	13	NA	Cetuximab	G13D	civic:EID145:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	NM_033360	25398275	25398286
KRAS	12	G13D	missense_variant	EID2183	G13D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	13	NA	Selumetinib (AZD6244), BEZ235	G13D	civic:EID2183:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	NM_033360	25398275	25398286
KRAS	12	G13D	missense_variant	EID2231	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	13	NA	Panitumumab	G13D	civic:EID2231:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	NM_033360	25398275	25398286
KRAS	12	G13D	missense_variant	EID306	G13D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20978259' target='_blank'>De Roock et al., 2010, JAMA</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Cetuximab	G13D	civic:EID306:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	NM_033360	25398275	25398286
KRAS	12	G13D	missense_variant	EID3878	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22722830' target='_blank'>Misale et al., 2012, Nature</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	13	NA	Cetuximab	G13D	civic:EID3878:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	NM_033360	25398275	25398286
KRAS	12	G13D	missense_variant	EID3882	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25666295' target='_blank'>Kaczirek et al., 2015, Clin Colorectal Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Cetuximab	G13D	civic:EID3882:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	NM_033360	25398275	25398286
KRAS	12	G13D	missense_variant	EID6320	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	13	NA	Cetuximab, Panitumumab	G13D	civic:EID6320:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	NM_033360	25398275	25398286
KRAS	12	G13D	missense_variant	EID6322	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	13	NA	Panitumumab, Cetuximab	G13D	civic:EID6322:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	NM_033360	25398275	25398286
KRAS	12	G13D	missense_variant	EID806	G13D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26623049' target='_blank'>Osumi et al., 2015, Mol Clin Oncol</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Cetuximab	G13D	civic:EID806:KRAS:p.G13	c.38G>A	12_25398281_C_T	ENST00000256078	NM_033360	25398275	25398286
KRAS	12	G12A	missense_variant	EID2004	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	12	NA	Panitumumab	G12A	civic:EID2004:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12A	missense_variant	EID2008	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17409929' target='_blank'>Endoh et al., 2006, J Thorac Oncol</a>	Lung Cancer	Predictive	B: Clinical evidence	DOID:1324	12	NA	Gefitinib	G12A	civic:EID2008:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12A	missense_variant	EID2009	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19284554' target='_blank'>Greco et al., 2009, J. Exp. Clin. Cancer Res.</a>	Multiple Myeloma	Predictive	B: Clinical evidence	DOID:9538	12	NA	Melphalan	G12A	civic:EID2009:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12A	missense_variant	EID2012	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11050000' target='_blank'>Rowley et al., 2000, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12A	civic:EID2012:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12A	missense_variant	EID2013	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12483530' target='_blank'>Rowley et al., 2002, Oncogene</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12A	civic:EID2013:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12A	missense_variant	EID2014	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16497971' target='_blank'>Hoang et al., 2006, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12A	civic:EID2014:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12A	missense_variant	EID251	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19794967' target='_blank'>Marchetti et al., 2009, Neoplasia</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	12	NA	Gefitinib, Erlotinib	G12A	civic:EID251:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12A	missense_variant	EID3710	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Regorafenib	G12A	civic:EID3710:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12A	missense_variant	EID6319	G12A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	12	NA	Cetuximab, Panitumumab	G12A	civic:EID6319:KRAS:p.G12	c.35G>C	12_25398284_C_G	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID1215	G12D	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22948721' target='_blank'>Modest et al., 2012, Oncology</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	12	NA	NA	G12D	civic:EID1215:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID1300	G12D	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27010960' target='_blank'>Bournet et al., 2016, Clin Transl Gastroenterol</a>	Pancreatic Cancer	Prognostic	B: Clinical evidence	DOID:1793	12	NA	NA	G12D	civic:EID1300:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID1311	G12D	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23565280' target='_blank'>Rachakonda et al., 2013, PLoS ONE</a>	Tumor Of Exocrine Pancreas	Prognostic	B: Clinical evidence	DOID:1795	12	NA	NA	G12D	civic:EID1311:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID1580	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26352686' target='_blank'>Tiacci et al., 2015, N. Engl. J. Med.</a>	Hairy Cell Leukemia	Predictive	C: Case study	DOID:285	12	NA	Vemurafenib	G12D	civic:EID1580:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID1732	G12D	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27010960' target='_blank'>Bournet et al., 2016, Clin Transl Gastroenterol</a>	Pancreatic Ductal Carcinoma	Prognostic	B: Clinical evidence	DOID:3587	12	NA	NA	G12D	civic:EID1732:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID1898	G12D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27959684' target='_blank'>Tran et al., 2016, N. Engl. J. Med.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	12	NA	Adoptive T-cell Transfer	G12D	civic:EID1898:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID2218	G12D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Selumetinib (AZD6244), BEZ235	G12D	civic:EID2218:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID2236	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	12	NA	Panitumumab	G12D	civic:EID2236:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID2240	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17409929' target='_blank'>Endoh et al., 2006, J Thorac Oncol</a>	Lung Cancer	Predictive	B: Clinical evidence	DOID:1324	12	NA	Gefitinib	G12D	civic:EID2240:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID2247	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19284554' target='_blank'>Greco et al., 2009, J. Exp. Clin. Cancer Res.</a>	Multiple Myeloma	Predictive	B: Clinical evidence	DOID:9538	12	NA	Melphalan	G12D	civic:EID2247:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID2250	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11050000' target='_blank'>Rowley et al., 2000, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12D	civic:EID2250:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID2251	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12483530' target='_blank'>Rowley et al., 2002, Oncogene</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12D	civic:EID2251:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID2252	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16497971' target='_blank'>Hoang et al., 2006, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12D	civic:EID2252:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID228	G12D	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23014527' target='_blank'>Dogan et al., 2012, Clin. Cancer Res.</a>	Lung Cancer	Diagnostic	B: Clinical evidence	DOID:1324	12	NA	NA	G12D	civic:EID228:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID305	G12D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19029981' target='_blank'>Engelman et al., 2008, Nat. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	12	NA	ARRY-142886, BEZ235 (NVP-BEZ235, Dactolisib)	G12D	civic:EID305:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID3946	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Regorafenib	G12D	civic:EID3946:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID3957	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	12	NA	Vemurafenib	G12D	civic:EID3957:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID3958	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22246397' target='_blank'>Sato et al., 2012, Oncol. Rep.</a>	Ovarian Cancer	Predictive	D: Preclinical evidence	DOID:2394	12	NA	Cetuximab	G12D	civic:EID3958:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID6316	G12D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	12	NA	Panitumumab, Cetuximab	G12D	civic:EID6316:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12D	missense_variant	EID937	G12D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22025163' target='_blank'>Yap et al., 2011, J. Clin. Oncol.</a>	Pancreatic Carcinoma	Predictive	C: Case study	DOID:4905	12	NA	MK-2206	G12D	civic:EID937:KRAS:p.G12	c.35G>A	12_25398284_C_T	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12V	missense_variant	EID1143	G12V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26125448' target='_blank'>Jänne et al., 2015, Br. J. Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	12	NA	Docetaxel, Selumetinib (AZD6244)	G12V	civic:EID1143:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12V	missense_variant	EID136	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20978259' target='_blank'>De Roock et al., 2010, JAMA</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Cetuximab	G12V	civic:EID136:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12V	missense_variant	EID1715	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25232318' target='_blank'>Palma et al., 2014, Case Rep Oncol</a>	Cancer	Predictive	C: Case study	DOID:162	12	NA	Crizotinib	G12V	civic:EID1715:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12V	missense_variant	EID2001	G12V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Selumetinib (AZD6244), BEZ235	G12V	civic:EID2001:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12V	missense_variant	EID2232	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	12	NA	Panitumumab	G12V	civic:EID2232:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12V	missense_variant	EID2268	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17409929' target='_blank'>Endoh et al., 2006, J Thorac Oncol</a>	Lung Cancer	Predictive	C: Case study	DOID:1324	12	NA	Gefitinib	G12V	civic:EID2268:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12V	missense_variant	EID3924	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Regorafenib	G12V	civic:EID3924:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12V	missense_variant	EID6323	G12V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	12	NA	Panitumumab, Cetuximab	G12V	civic:EID6323:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12V	missense_variant	EID795	G12V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20609353' target='_blank'>Puyol et al., 2010, Cancer Cell</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	12	NA	PD0332991	G12V	civic:EID795:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	G12V	missense_variant	EID987	G12V	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26372703' target='_blank'>Renaud et al., 2015, Br. J. Cancer</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	12	NA	NA	G12V	civic:EID987:KRAS:p.G12	c.35G>T	12_25398284_C_A	ENST00000256078	NM_033360	25398278	25398289
KRAS	12	NA	NA	EID194	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18202412' target='_blank'>Lièvre et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Prognostic	D: Preclinical evidence	DOID:9256	12	NA	NA	G12	civic:EID194:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID194B	G13	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18202412' target='_blank'>Lièvre et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Prognostic	D: Preclinical evidence	DOID:9256	13	NA	NA	G13	civic:EID194B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6292	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	12	NA	NA	G12	civic:EID6292:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6292B	G13	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	13	NA	NA	G13	civic:EID6292B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6293	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Oxaliplatin	G12	civic:EID6293:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6293B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Oxaliplatin	G13	civic:EID6293B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6363	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Panitumumab, Cetuximab	G12	civic:EID6363:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6363B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Panitumumab, Cetuximab	G13	civic:EID6363B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6296	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Cetuximab	G12	civic:EID6296:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6296B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Cetuximab	G13	civic:EID6296B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6295	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Bevacizumab	G12	civic:EID6295:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6295B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Bevacizumab	G13	civic:EID6295B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6294	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Irinotecan	G12	civic:EID6294:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID6294B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Irinotecan	G13	civic:EID6294B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID990	G12	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24915778' target='_blank'>Infante et al., 2014, Eur. J. Cancer</a>	Pancreatic Adenocarcinoma	Predictive	B: Clinical evidence	DOID:4074	12	NA	Trametinib	G12	civic:EID990:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID990B	G13	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24915778' target='_blank'>Infante et al., 2014, Eur. J. Cancer</a>	Pancreatic Adenocarcinoma	Predictive	B: Clinical evidence	DOID:4074	13	NA	Trametinib	G13	civic:EID990B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID135	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18202412' target='_blank'>Lièvre et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Cetuximab	G12	civic:EID135:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID135B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18202412' target='_blank'>Lièvre et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	13	NA	Cetuximab	G13	civic:EID135B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID134	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Cetuximab	G12	civic:EID134:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID134B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	13	NA	Cetuximab	G13	civic:EID134B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID35	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15696205' target='_blank'>Pao et al., 2005, PLoS Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	12	NA	Erlotinib, Gefitinib	G12	civic:EID35:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID35B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15696205' target='_blank'>Pao et al., 2005, PLoS Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	13	NA	Erlotinib, Gefitinib	G13	civic:EID35B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID622	G12	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24915778' target='_blank'>Infante et al., 2014, Eur. J. Cancer</a>	Pancreatic Adenocarcinoma	Predictive	B: Clinical evidence	DOID:4074	12	NA	Trametinib, Gemcitabine	G12	civic:EID622:KRAS:p.G12	NA	NA	NA	NA	25398279	25398285
KRAS	12	NA	NA	EID622B	G13	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24915778' target='_blank'>Infante et al., 2014, Eur. J. Cancer</a>	Pancreatic Adenocarcinoma	Predictive	B: Clinical evidence	DOID:4074	13	NA	Trametinib, Gemcitabine	G13	civic:EID622B:KRAS:p.G13	NA	NA	NA	NA	25398279	25398285
KRAS	12	G12C	missense_variant	EID1142	G12C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26125448' target='_blank'>Jänne et al., 2015, Br. J. Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	12	NA	Docetaxel, Selumetinib (AZD6244)	G12C	civic:EID1142:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID1173	G12C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26739882' target='_blank'>Patricelli et al., 2016, Cancer Discov</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	12	NA	ARS-853, EGFR Inhibitor	G12C	civic:EID1173:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID1216	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23313110' target='_blank'>Fiala et al., Cancer Genet</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	12	NA	Gefitinib, Erlotinib	G12C	civic:EID1216:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID1217	G12C	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22247021' target='_blank'>Ihle et al., 2012, J. Natl. Cancer Inst.</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	12	NA	NA	G12C	civic:EID1217:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID2212	G12C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22392911' target='_blank'>Migliardi et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Selumetinib (AZD6244), BEZ235	G12C	civic:EID2212:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID2253	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	12	NA	Panitumumab	G12C	civic:EID2253:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID2257	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17409929' target='_blank'>Endoh et al., 2006, J Thorac Oncol</a>	Lung Cancer	Predictive	B: Clinical evidence	DOID:1324	12	NA	Gefitinib	G12C	civic:EID2257:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID2258	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19284554' target='_blank'>Greco et al., 2009, J. Exp. Clin. Cancer Res.</a>	Multiple Myeloma	Predictive	B: Clinical evidence	DOID:9538	12	NA	Melphalan	G12C	civic:EID2258:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID2261	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11050000' target='_blank'>Rowley et al., 2000, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12C	civic:EID2261:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID2262	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12483530' target='_blank'>Rowley et al., 2002, Oncogene</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12C	civic:EID2262:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID2263	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16497971' target='_blank'>Hoang et al., 2006, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12C	civic:EID2263:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID227	G12C	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23014527' target='_blank'>Dogan et al., 2012, Clin. Cancer Res.</a>	Lung Cancer	Diagnostic	B: Clinical evidence	DOID:1324	12	NA	NA	G12C	civic:EID227:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12C	missense_variant	EID3973	G12C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Regorafenib	G12C	civic:EID3973:KRAS:p.G12	c.34G>T	12_25398285_C_A	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12R	missense_variant	EID1298	G12R	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22983505' target='_blank'>Ogura et al., 2013, J. Gastroenterol.</a>	Pancreatic Cancer	Prognostic	B: Clinical evidence	DOID:1793	12	NA	NA	G12R	civic:EID1298:KRAS:p.G12	c.34G>C	12_25398285_C_G	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12R	missense_variant	EID2264	G12R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	12	NA	Panitumumab	G12R	civic:EID2264:KRAS:p.G12	c.34G>C	12_25398285_C_G	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12R	missense_variant	EID3989	G12R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22722830' target='_blank'>Misale et al., 2012, Nature</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Cetuximab	G12R	civic:EID3989:KRAS:p.G12	c.34G>C	12_25398285_C_G	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12R	missense_variant	EID3991	G12R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Regorafenib	G12R	civic:EID3991:KRAS:p.G12	c.34G>C	12_25398285_C_G	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12S	missense_variant	EID2269	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18316791' target='_blank'>Amado et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	12	NA	Panitumumab	G12S	civic:EID2269:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12S	missense_variant	EID2273	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17409929' target='_blank'>Endoh et al., 2006, J Thorac Oncol</a>	Lung Cancer	Predictive	B: Clinical evidence	DOID:1324	12	NA	Gefitinib	G12S	civic:EID2273:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12S	missense_variant	EID2274	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19284554' target='_blank'>Greco et al., 2009, J. Exp. Clin. Cancer Res.</a>	Multiple Myeloma	Predictive	B: Clinical evidence	DOID:9538	12	NA	Melphalan	G12S	civic:EID2274:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12S	missense_variant	EID2277	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11050000' target='_blank'>Rowley et al., 2000, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12S	civic:EID2277:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12S	missense_variant	EID2278	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12483530' target='_blank'>Rowley et al., 2002, Oncogene</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12S	civic:EID2278:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12S	missense_variant	EID2279	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16497971' target='_blank'>Hoang et al., 2006, Blood</a>	Multiple Myeloma	Predictive	D: Preclinical evidence	DOID:9538	12	NA	Melphalan	G12S	civic:EID2279:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12S	missense_variant	EID4012	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26161928' target='_blank'>Camaj et al., 2015, Future Oncol</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	12	NA	Regorafenib	G12S	civic:EID4012:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	G12S	missense_variant	EID6314	G12S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	12	NA	Cetuximab, Panitumumab	G12S	civic:EID6314:KRAS:p.G12	c.34G>A	12_25398285_C_T	ENST00000256078	NM_033360	25398279	25398290
KRAS	12	NA	NA	EID488	G13	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18528420' target='_blank'>Chng et al., 2008, Leukemia</a>	Multiple Myeloma	Prognostic	B: Clinical evidence	DOID:9538	13	NA	NA	G13	civic:EID488:KRAS:p.G13	NA	NA	NA	NA	25398280	25398282
KRAS	12	NA	NA	EID487	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18528420' target='_blank'>Chng et al., 2008, Leukemia</a>	Multiple Myeloma	Prognostic	B: Clinical evidence	DOID:9538	12	NA	NA	G12	civic:EID487:KRAS:p.G12	NA	NA	NA	NA	25398283	25398285
KRAS	12	NA	NA	EID377	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18528420' target='_blank'>Chng et al., 2008, Leukemia</a>	Multiple Myeloma	Prognostic	B: Clinical evidence	DOID:9538	12	NA	NA	G12	civic:EID377:KRAS:p.G12	NA	NA	NA	NA	25398283	25398285
KRAS	12	NA	NA	EID378	G12	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15597105' target='_blank'>Mascaux et al., 2005, Br. J. Cancer</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	12	NA	NA	G12	civic:EID378:KRAS:p.G12	NA	NA	NA	NA	25398283	25398285
KRAS	12	NA	NA	EID215	G12	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18794081' target='_blank'>Riely et al., 2008, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Diagnostic	B: Clinical evidence	DOID:3908	12	NA	NA	G12	civic:EID215:KRAS:p.G12	NA	NA	NA	NA	25398283	25398285
KRAS	12	NA	NA	EID8	G12	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24571676' target='_blank'>Andrade et al., 2014, BMC Cancer</a>	Acute Leukemia	Diagnostic	B: Clinical evidence	DOID:12603	12	NA	NA	G12	civic:EID8:KRAS:p.G12	NA	NA	NA	NA	25398283	25398285
ERBB3	12	R103G	missense_variant	EID1747	R103G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27044931' target='_blank'>Choudhury et al., 2016, J. Clin. Oncol.</a>	Urothelial Carcinoma	Predictive	B: Clinical evidence	DOID:2671	103	NA	Afatinib	R103G	civic:EID1747:ERBB3:p.R103	c.307C>G	12_56478851_C_G	ENST00000267101	NM_001982	56478845	56478856
ERBB3	12	V104M	missense_variant	EID1746	V104M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27044931' target='_blank'>Choudhury et al., 2016, J. Clin. Oncol.</a>	Urothelial Carcinoma	Predictive	B: Clinical evidence	DOID:2671	104	NA	Afatinib	V104M	civic:EID1746:ERBB3:p.V104	c.310G>A	12_56478854_G_A	ENST00000267101	NM_001982	56478848	56478859
ERBB3	12	G284R	missense_variant	EID1748	G284R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27044931' target='_blank'>Choudhury et al., 2016, J. Clin. Oncol.</a>	Urothelial Carcinoma	Predictive	B: Clinical evidence	DOID:2671	284	NA	Afatinib	G284R	civic:EID1748:ERBB3:p.G284	c.850G>A	12_56481922_G_A	ENST00000267101	NM_001982	56481916	56481927
ERBB3	12	V855A	missense_variant	EID1845	V855A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26689995' target='_blank'>Umelo et al., 2016, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	855	NA	Pertuzumab, Afatinib	V855A	civic:EID1845:ERBB3:p.V855	c.2564T>C	12_56491672_T_C	ENST00000267101	NM_001982	56491666	56491677
CDK4	12	R24C	missense_variant	EID1376	R24C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24495407' target='_blank'>Young et al., 2014, Pigment Cell Melanoma Res</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	24	NA	Palbociclib (PD0332991)	R24C	civic:EID1376:CDK4:p.R24	c.70C>T	12_58145431_G_A	ENST00000257904	NM_000075	58145425	58145436
POLE	12	S679F	missense_variant	EID5019	S459F	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28404093' target='_blank'>Domingo et al., 2016, Lancet Gastroenterol Hepatol</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	679	NA	NA	S459F	civic:EID5019:POLE:p.S679	c.2035_2037delinsTTC, c.2035_2036delinsTT	12_133245078_ACT_GAA, 12_133245079_CT_AA	ENST00000320574	NM_006231	133245072	133245085
POLE	12	S459F	missense_variant	EID5019	S459F	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28404093' target='_blank'>Domingo et al., 2016, Lancet Gastroenterol Hepatol</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	459	NA	NA	S459F	civic:EID5019:POLE:p.S459	c.1376_1377delinsTC, c.1376C>T	12_133249846_AG_GA, 12_133249847_G_A	ENST00000320574	NM_006231	133249840	133249852
POLE	12	V411L	missense_variant	EID5018	V411L	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28404093' target='_blank'>Domingo et al., 2016, Lancet Gastroenterol Hepatol</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	411	NA	NA	V411L	civic:EID5018:POLE:p.V411	c.1231_1233delinsCTA, c.1231_1233delinsCTT, c.1231_1233delinsCTC, c.1231_1233delinsTTA, c.1231G>T, c.1231G>C	12_133250287_CAC_TAG, 12_133250287_CAC_AAG, 12_133250287_CAC_GAG, 12_133250287_CAC_TAA, 12_133250289_C_A, 12_133250289_C_G	ENST00000320574	NM_006231	133250281	133250294
POLE	12	P286R	missense_variant	EID5017	P286R	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28404093' target='_blank'>Domingo et al., 2016, Lancet Gastroenterol Hepatol</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	286	NA	NA	P286R	civic:EID5017:POLE:p.P286	c.857_858delinsGG, c.857_858delinsGC, c.857_858delinsGA, c.856_858inv, c.856_858delinsAGA, c.857C>G	12_133253183_AG_CC, 12_133253183_AG_GC, 12_133253183_AG_TC, 12_133253183_AGG_CCT, 12_133253183_AGG_TCT, 12_133253184_G_C	ENST00000320574	NM_006231	133253177	133253190
FLT3	13	D835H	missense_variant	EID1557	D835H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23969938' target='_blank'>Baker et al., 2013, Clin. Cancer Res.</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	835	NA	Sorafenib	D835H	civic:EID1557:FLT3:p.D835	c.2503_2505delinsCAC, c.2503G>C	13_28592640_ATC_GTG, 13_28592642_C_G	ENST00000241453	NM_004119	28592634	28592647
FLT3	13	D835Y	missense_variant	EID1557B	D835Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23969938' target='_blank'>Baker et al., 2013, Clin. Cancer Res.</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	835	NA	Sorafenib	D835Y	civic:EID1557B:FLT3:p.D835	c.2503_2505delinsTAC, c.2503G>T	13_28592640_ATC_GTA, 13_28592642_C_A	ENST00000241453	NM_004119	28592634	28592647
FLT3	13	D835V	missense_variant	EID3007	D835V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15256420' target='_blank'>Clark et al., 2004, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	835	NA	MLN518	D835V	civic:EID3007:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	NM_004119	28592635	28592646
FLT3	13	D835V	missense_variant	EID3008	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15304385' target='_blank'>Yee et al., 2004, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	835	NA	SU11248	D835V	civic:EID3008:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	NM_004119	28592635	28592646
FLT3	13	D835V	missense_variant	EID3009	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15304385' target='_blank'>Yee et al., 2004, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	835	NA	Cytarabine, SU11248	D835V	civic:EID3009:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	NM_004119	28592635	28592646
FLT3	13	D835V	missense_variant	EID3010	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15304385' target='_blank'>Yee et al., 2004, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	835	NA	Daunorubicin, SU11248	D835V	civic:EID3010:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	NM_004119	28592635	28592646
FLT3	13	D835V	missense_variant	EID3012	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23497317' target='_blank'>Kampa-Schittenhelm et al., 2013, Mol. Cancer</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	835	NA	Quizartinib	D835V	civic:EID3012:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	NM_004119	28592635	28592646
FLT3	13	D835V	missense_variant	EID3034	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17330097' target='_blank'>Griessinger et al., 2007, Leukemia</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	835	NA	AG1296, AS602868	D835V	civic:EID3034:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	NM_004119	28592635	28592646
FLT3	13	D835V	missense_variant	EID4022	D835V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15459012' target='_blank'>Fiedler et al., 2005, Blood</a>	Acute Myeloid Leukemia	Predictive	C: Case study	DOID:9119	835	NA	Sunitinib	D835V	civic:EID4022:FLT3:p.D835	c.2504A>T	13_28592641_T_A	ENST00000241453	NM_004119	28592635	28592646
FLT3	13	D835H	missense_variant	EID1556	D835H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23969938' target='_blank'>Baker et al., 2013, Clin. Cancer Res.</a>	Acute Myeloid Leukemia	Predictive	C: Case study	DOID:9119	835	NA	Sorafenib	D835H	civic:EID1556:FLT3:p.D835	c.2503G>C	13_28592642_C_G	ENST00000241453	NM_004119	28592636	28592647
FLT3	13	D835Y	missense_variant	EID1036	D835	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23430109' target='_blank'>Smith et al., 2013, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	835	NA	Quizartinib (AC220), Ponatinib	D835	civic:EID1036:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	NM_004119	28592636	28592647
FLT3	13	D835Y	missense_variant	EID1037	D835	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19318574' target='_blank'>von Bubnoff et al., 2009, Cancer Res.</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	835	NA	SU5614	D835	civic:EID1037:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	NM_004119	28592636	28592647
FLT3	13	D835Y	missense_variant	EID1038	D835	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22504184' target='_blank'>Smith et al., 2012, Nature</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	835	NA	Quizartinib (AC220), Sorafenib	D835	civic:EID1038:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	NM_004119	28592636	28592647
FLT3	13	D835Y	missense_variant	EID1039	D835	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22368270' target='_blank'>Man et al., 2012, Blood</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	835	NA	Sorafenib	D835	civic:EID1039:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	NM_004119	28592636	28592647
FLT3	13	D835Y	missense_variant	EID1295	TKD MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20733134' target='_blank'>Fischer et al., 2010, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	835	NA	Midostaurin	TKD MUTATION	civic:EID1295:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	NM_004119	28592636	28592647
FLT3	13	D835Y	missense_variant	EID171	TKD MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17965322' target='_blank'>Bacher et al., 2008, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	835	NA	NA	TKD MUTATION	civic:EID171:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	NM_004119	28592636	28592647
FLT3	13	D835Y	missense_variant	EID214	TKD MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11290608' target='_blank'>Yamamoto et al., 2001, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	835	NA	NA	TKD MUTATION	civic:EID214:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	NM_004119	28592636	28592647
FLT3	13	D835Y	missense_variant	EID247	TKD MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22368270' target='_blank'>Man et al., 2012, Blood</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	835	NA	Sorafenib	TKD MUTATION	civic:EID247:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	NM_004119	28592636	28592647
FLT3	13	D835Y	missense_variant	EID248	TKD MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18230792' target='_blank'>Zhang et al., 2008, J. Natl. Cancer Inst.</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	835	NA	Sorafenib	TKD MUTATION	civic:EID248:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	NM_004119	28592636	28592647
FLT3	13	D835Y	missense_variant	EID373	TKD MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17940205' target='_blank'>Whitman et al., 2008, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	835	NA	NA	TKD MUTATION	civic:EID373:FLT3:p.D835	c.2503G>T	13_28592642_C_A	ENST00000241453	NM_004119	28592636	28592647
BRCA2	13	M1?	start_lost	EID2879	M1R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	1	NA	Rucaparib	M1R	civic:EID2879:BRCA2:p.M1?	c.2T>G	13_32890599_T_G	ENST00000544455	NM_000059	32890593	32890604
BRCA2	13	M1?	start_lost	EID2880	M1I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	1	NA	Rucaparib	M1I	civic:EID2880:BRCA2:p.M1?	c.3G>T	13_32890600_G_T	ENST00000544455	NM_000059	32890594	32890605
BRCA2	13	V159M	missense_variant&splice_region_variant	EID2881	V159M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	159	NA	Rucaparib	V159M	civic:EID2881:BRCA2:p.V159	c.475G>A	13_32900287_G_A	ENST00000544455	NM_000059	32900281	32900292
BRCA2	13	.	splice_donor_variant	EID2882	V211L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	V211L	civic:EID2882:BRCA2:c.631+1G>C	c.631+1G>C	13_32900751_G_C	ENST00000544455	NM_000059	32900745	32900756
BRCA2	13	.	splice_donor_variant	EID2883	V211I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	NA	NA	Rucaparib	V211I	civic:EID2883:BRCA2:c.631+1G>A	c.631+1G>A	13_32900751_G_A	ENST00000544455	NM_000059	32900745	32900756
BRCA2	13	R2336H	missense_variant&splice_region_variant	EID2885	R2336H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	2336	NA	Rucaparib	R2336H	civic:EID2885:BRCA2:p.R2336	c.7007G>A	13_32921033_G_A	ENST00000544455	NM_000059	32921027	32921038
BRCA2	13	R2336P	missense_variant&splice_region_variant	EID2884	R2336P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	2336	NA	Rucaparib	R2336P	civic:EID2884:BRCA2:p.R2336	c.7007G>C	13_32921033_G_C	ENST00000544455	NM_000059	32921027	32921038
RB1	13	M695fs	frameshift_variant	EID1630	M695FS*26	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27020857' target='_blank'>Herrera-Abreu et al., 2016, Cancer Res.</a>	Estrogen-receptor Positive Breast Cancer	Predictive	D: Preclinical evidence	DOID:0060075	695	NA	Palbociclib (PD0332991)	M695fs*26	civic:EID1630:RB1:p.M695	c.2083dup	13_49033946_A_AA	ENST00000267163	NM_000321	49033940	49033952
DICER1	14	E1813Q	missense_variant	EID5535	E1813Q	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26428316' target='_blank'>Conlon et al., 2015, Mod. Pathol.</a>	Malignant Sertoli-Leydig Cell Tumor	Diagnostic	B: Clinical evidence	DOID:0050618	1813	NA	NA	E1813Q	civic:EID5535:DICER1:p.E1813	c.5437G>C	14_95557630_C_G	ENST00000526495	NA	95557624	95557635
DICER1	14	D1709N	missense_variant	EID5534	D1709N	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26428316' target='_blank'>Conlon et al., 2015, Mod. Pathol.</a>	Malignant Sertoli-Leydig Cell Tumor	Diagnostic	B: Clinical evidence	DOID:0050618	1709	NA	NA	D1709N	civic:EID5534:DICER1:p.D1709	c.5125_5127delinsAAC, c.5125G>A	14_95560462_ATC_GTT, 14_95560464_C_T	ENST00000526495	NA	95560456	95560469
DICER1	14	E1705K	missense_variant	EID5533	E1705K	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26428316' target='_blank'>Conlon et al., 2015, Mod. Pathol.</a>	Malignant Sertoli-Leydig Cell Tumor	Diagnostic	B: Clinical evidence	DOID:0050618	1705	NA	NA	E1705K	civic:EID5533:DICER1:p.E1705	c.5113G>A	14_95560476_C_T	ENST00000526495	NA	95560470	95560481
AKT1	14	Q79K	missense_variant	EID439	Q79K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265152' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	79	NA	Vemurafenib	Q79K	civic:EID439:AKT1:p.Q79	c.235C>A	14_105243048_G_T	ENST00000554581	NA	105243042	105243053
AKT1	14	Q79K	missense_variant	EID4498	Q79K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	79	NA	Vemurafenib	Q79K	civic:EID4498:AKT1:p.Q79	c.235C>A	14_105243048_G_T	ENST00000554581	NA	105243042	105243053
AKT1	14	Q79K	missense_variant	EID6260	Q79K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	C: Case study	DOID:1909	79	NA	Dabrafenib	Q79K	civic:EID6260:AKT1:p.Q79	c.235C>A	14_105243048_G_T	ENST00000554581	NA	105243042	105243053
AKT1	14	E17K	missense_variant&splice_region_variant	EID231	E17K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23888070' target='_blank'>Beaver et al., 2013, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	17	NA	MK-2206	E17K	civic:EID231:AKT1:p.E17	c.49G>A	14_105246551_C_T	ENST00000554581	NA	105246545	105246556
AKT1	14	E17K	missense_variant&splice_region_variant	EID3039	E17K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28489509' target='_blank'>Hyman et al., 2017, J. Clin. Oncol.</a>	Cancer	Predictive	B: Clinical evidence	DOID:162	17	NA	AZD-5363	E17K	civic:EID3039:AKT1:p.E17	c.49G>A	14_105246551_C_T	ENST00000554581	NA	105246545	105246556
AKT1	14	E17K	missense_variant&splice_region_variant	EID4029	E17K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	17	NA	Vemurafenib	E17K	civic:EID4029:AKT1:p.E17	c.49G>A	14_105246551_C_T	ENST00000554581	NA	105246545	105246556
AKT1	14	E17K	missense_variant&splice_region_variant	EID707	E17K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24735930' target='_blank'>Lassen et al., 2014, Mol. Cancer</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	17	NA	GSK2141795	E17K	civic:EID707:AKT1:p.E17	c.49G>A	14_105246551_C_T	ENST00000554581	NA	105246545	105246556
AKT1	14	E17K	missense_variant&splice_region_variant	EID709	E17K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26351323' target='_blank'>Davies et al., 2015, Mol. Cancer Ther.</a>	Breast Cancer	Predictive	C: Case study	DOID:1612	17	NA	AZD5363	E17K	civic:EID709:AKT1:p.E17	c.49G>A	14_105246551_C_T	ENST00000554581	NA	105246545	105246556
B2M	15	NA	NA	EID1569	S14FS	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27433843' target='_blank'>Zaretsky et al., 2016, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	14	NA	Pembrolizumab	S14	civic:EID1569:B2M:p.S14	NA	NA	NA	NA	45003785	45003789
MAP2K1	15	Q56P	missense_variant	EID13	Q56P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19915144' target='_blank'>Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	56	NA	Selumetinib (AZD6244)	Q56P	civic:EID13:MAP2K1:p.Q56	c.167A>C	15_66727451_A_C	ENST00000307102	NM_002755	66727445	66727456
MAP2K1	15	K57N	missense_variant	EID2935	K57N	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25351745' target='_blank'>Arcila et al., 2015, Clin. Cancer Res.</a>	Lung Adenocarcinoma	Diagnostic	C: Case study	DOID:3910	57	NA	NA	K57N	civic:EID2935:MAP2K1:p.K57	c.171G>T	15_66727455_G_T	ENST00000307102	NM_002755	66727449	66727460
MAP2K1	15	K57N	missense_variant	EID2936	K57N	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18632602' target='_blank'>Marks et al., 2008, Cancer Res.</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	57	NA	Selumetinib (AZD6244)	K57N	civic:EID2936:MAP2K1:p.K57	c.171G>T	15_66727455_G_T	ENST00000307102	NM_002755	66727449	66727460
MAP2K1	15	C121S	missense_variant	EID1602	C121S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21383288' target='_blank'>Wagle et al., 2011, J. Clin. Oncol.</a>	Melanoma	Predictive	C: Case study	DOID:1909	121	NA	Vemurafenib	C121S	civic:EID1602:MAP2K1:p.C121	c.362G>C	15_66729154_G_C	ENST00000307102	NM_002755	66729148	66729159
MAP2K1	15	P124S	missense_variant	EID12	P124S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19915144' target='_blank'>Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	124	NA	Selumetinib (AZD6244)	P124S	civic:EID12:MAP2K1:p.P124	c.370C>T	15_66729162_C_T	ENST00000307102	NM_002755	66729156	66729167
PML	15	A216V	missense_variant	EID1093	PML-RARA A216V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21613260' target='_blank'>Goto et al., 2011, Blood</a>	Acute Promyelocytic Leukemia	Predictive	C: Case study	DOID:0060318	216	NA	All-trans Retinoic Acid	PML-RARA A216V	civic:EID1093:PML:p.A216	c.647C>T	15_74315213_C_T	ENST00000268058	NM_033238	74315207	74315218
PML	15	L218P	missense_variant	EID1094	PML-RARA L218P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21613260' target='_blank'>Goto et al., 2011, Blood</a>	Acute Promyelocytic Leukemia	Predictive	C: Case study	DOID:0060318	218	NA	All-trans Retinoic Acid	PML-RARA L218P	civic:EID1094:PML:p.L218	c.653T>C	15_74315219_T_C	ENST00000268058	NM_033238	74315213	74315224
NTRK3	15	G623R	missense_variant	EID1874	ETV6-NTRK3 G623R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26884591' target='_blank'>Drilon et al., 2016, Ann. Oncol.</a>	Breast Cancer	Predictive	C: Case study	DOID:1612	623	NA	Entrectinib	ETV6-NTRK3 G623R	civic:EID1874:NTRK3:p.G623	c.1867G>A	15_88476265_C_T	ENST00000360948	NM_001012338	88476259	88476270
IDH2	15	R172K	missense_variant	EID375	R172K	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21596855' target='_blank'>Green et al., 2011, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	172	NA	NA	R172K	civic:EID375:IDH2:p.R172	c.515G>A	15_90631838_C_T	ENST00000330062	NM_002168	90631832	90631843
IDH2	15	NA	NA	EID483	R172	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19228619' target='_blank'>Yan et al., 2009, N. Engl. J. Med.</a>	Astrocytoma	Prognostic	B: Clinical evidence	DOID:3069	172	NA	NA	R172	civic:EID483:IDH2:p.R172	NA	NA	NA	NA	90631836	90631839
IDH2	15	NA	NA	EID482	R172	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19228619' target='_blank'>Yan et al., 2009, N. Engl. J. Med.</a>	Glioblastoma Multiforme	Prognostic	B: Clinical evidence	DOID:3068	172	NA	NA	R172	civic:EID482:IDH2:p.R172	NA	NA	NA	NA	90631836	90631839
IDH2	15	NA	NA	EID1511	R172	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27276561' target='_blank'>Papaemmanuil et al., 2016, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	172	NA	NA	R172	civic:EID1511:IDH2:p.R172	NA	NA	NA	NA	90631836	90631839
IDH2	15	NA	NA	EID628	R172	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22215888' target='_blank'>Cairns et al., 2012, Blood</a>	Peripheral T-cell Lymphoma	Diagnostic	B: Clinical evidence	DOID:0050749	172	NA	NA	R172	civic:EID628:IDH2:p.R172	NA	NA	NA	NA	90631836	90631839
IDH2	15	NA	NA	EID627	R172	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26268241' target='_blank'>Wang et al., 2015, Blood</a>	Peripheral T-cell Lymphoma	Prognostic	B: Clinical evidence	DOID:0050749	172	NA	NA	R172	civic:EID627:IDH2:p.R172	NA	NA	NA	NA	90631836	90631839
IDH2	15	NA	NA	EID350	R140	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21596855' target='_blank'>Green et al., 2011, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	140	NA	NA	R140	civic:EID350:IDH2:p.R140	NA	NA	NA	NA	90631933	90631934
TSC2	16	Q1178X	stop_gained	EID1108	Q1178*	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25295501' target='_blank'>Wagle et al., 2014, N. Engl. J. Med.</a>	Thyroid Carcinoma	Predictive	C: Case study	DOID:3963	1178	NA	Everolimus	Q1178X	civic:EID1108:TSC2:p.Q1178	c.3532C>T	16_2130300_C_T	ENST00000219476	NM_000548	2130294	2130305
PRKCB	16	D427N	missense_variant	EID6654	D427N	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26437031' target='_blank'>Kataoka et al., 2015, Nat. Genet.</a>	Adult T-cell Leukemia	Diagnostic	D: Preclinical evidence	DOID:0050523	427	NA	NA	D427N	civic:EID6654:PRKCB:p.D427	c.1279G>A, c.1279_1281delinsAAT	16_24183630_G_A, 16_24183630_GAC_AAT	ENST00000303531	NM_002738	24183624	24183637
TP53	17	R282L	missense_variant	EID2818	R282L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14514923' target='_blank'>Bataille et al., 2003, MP, Mol. Pathol.</a>	Stomach Carcinoma	Predictive	C: Case study	DOID:5517	282	NA	EAP Protocol	R282L	civic:EID2818:TP53:p.R282	c.845G>T	17_7577093_C_A	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577087	7577098
TP53	17	R280K	missense_variant	EID4889	R280K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	280	NA	AMGMDS3	R280K	civic:EID4889:TP53:p.R280	c.839_840delinsAG, c.839G>A	17_7577098_TC_CT, 17_7577099_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577092	7577104
TP53	17	R280T	missense_variant	EID4890	R280T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	280	NA	AMGMDS3	R280T	civic:EID4890:TP53:p.R280	c.839_840delinsCT, c.839_840delinsCC, c.839_840delinsCG, c.839G>C	17_7577098_TC_AG, 17_7577098_TC_GG, 17_7577098_TC_CG, 17_7577099_C_G	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577092	7577104
TP53	17	R273H	missense_variant	EID397	R273H	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16489069' target='_blank'>Olivier et al., 2006, Clin. Cancer Res.</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	273	NA	NA	R273H	civic:EID397:TP53:p.R273	c.818G>A	17_7577120_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577114	7577125
TP53	17	R273H	missense_variant	EID398	R273H	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9569050' target='_blank'>Berns et al., 1998, Br. J. Cancer</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	273	NA	NA	R273H	civic:EID398:TP53:p.R273	c.818G>A	17_7577120_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577114	7577125
TP53	17	R273H	missense_variant	EID4882	R273H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	273	NA	AMGMDS3	R273H	civic:EID4882:TP53:p.R273	c.818G>A	17_7577120_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577114	7577125
TP53	17	R273L	missense_variant	EID2286	R273L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11595686' target='_blank'>Reles et al., 2001, Clin. Cancer Res.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	273	NA	Cisplatin, Carboplatin	R273L	civic:EID2286:TP53:p.R273	c.818G>T	17_7577120_C_A	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577114	7577125
TP53	17	R273C	missense_variant	EID2292	R273C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14514923' target='_blank'>Bataille et al., 2003, MP, Mol. Pathol.</a>	Stomach Carcinoma	Predictive	C: Case study	DOID:5517	273	NA	Mitomycin, Etoposide, Cisplatin	R273C	civic:EID2292:TP53:p.R273	c.817C>T	17_7577121_G_A	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577115	7577126
TP53	17	R273C	missense_variant	EID395	R273C	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16489069' target='_blank'>Olivier et al., 2006, Clin. Cancer Res.</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	273	NA	NA	R273C	civic:EID395:TP53:p.R273	c.817C>T	17_7577121_G_A	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577115	7577126
TP53	17	R273C	missense_variant	EID396	R273C	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9569050' target='_blank'>Berns et al., 1998, Br. J. Cancer</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	273	NA	NA	R273C	civic:EID396:TP53:p.R273	c.817C>T	17_7577121_G_A	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577115	7577126
TP53	17	R273C	missense_variant	EID4881	R273C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	273	NA	AMGMDS3	R273C	civic:EID4881:TP53:p.R273	c.817C>T	17_7577121_G_A	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577115	7577126
TP53	17	R249S	missense_variant	EID4888	R249S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	249	NA	AMGMDS3	R249S	civic:EID4888:TP53:p.R249	c.747G>T, c.747G>C, c.745_747delinsTCA, c.745_747delinsTCT, c.745_747delinsTCC, c.745_746delinsTC	17_7577534_C_A, 17_7577534_C_G, 17_7577534_CCT_TGA, 17_7577534_CCT_AGA, 17_7577534_CCT_GGA, 17_7577535_CT_GA	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577528	7577541
TP53	17	R249T	missense_variant	EID393	R249	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9569050' target='_blank'>Berns et al., 1998, Br. J. Cancer</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	249	NA	NA	R249	civic:EID393:TP53:p.R249	c.746G>C	17_7577535_C_G	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577529	7577540
TP53	17	R249T	missense_variant	EID399	R249	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9569050' target='_blank'>Berns et al., 1998, Br. J. Cancer</a>	Breast Cancer	Predictive	B: Clinical evidence	DOID:1612	249	NA	Doxorubicin	R249	civic:EID399:TP53:p.R249	c.746G>C	17_7577535_C_G	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577529	7577540
TP53	17	R248Q	missense_variant	EID3042	R248Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	248	NA	AMGMDS3	R248Q	civic:EID3042:TP53:p.R248	c.743G>A	17_7577538_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577532	7577543
TP53	17	R248Q	missense_variant	EID390	R248Q	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16489069' target='_blank'>Olivier et al., 2006, Clin. Cancer Res.</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	248	NA	NA	R248Q	civic:EID390:TP53:p.R248	c.743G>A	17_7577538_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577532	7577543
TP53	17	R248Q	missense_variant	EID391	R248Q	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/9569050' target='_blank'>Berns et al., 1998, Br. J. Cancer</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	248	NA	NA	R248Q	civic:EID391:TP53:p.R248	c.743G>A	17_7577538_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577532	7577543
TP53	17	R248W	missense_variant	EID392	R248W	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16489069' target='_blank'>Olivier et al., 2006, Clin. Cancer Res.</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	248	NA	NA	R248W	civic:EID392:TP53:p.R248	c.742C>T	17_7577539_G_A	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577533	7577544
TP53	17	R248W	missense_variant	EID4879	R248W	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	248	NA	AMGMDS3	R248W	civic:EID4879:TP53:p.R248	c.742C>T	17_7577539_G_A	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577533	7577544
TP53	17	G245S	missense_variant	EID4883	G245S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	245	NA	AMGMDS3	G245S	civic:EID4883:TP53:p.G245	c.733G>A	17_7577548_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577542	7577553
TP53	17	Y234C	missense_variant	EID2745	Y234C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/11595686' target='_blank'>Reles et al., 2001, Clin. Cancer Res.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	234	NA	Cisplatin, Carboplatin	Y234C	civic:EID2745:TP53:p.Y234	c.701A>G	17_7577580_T_C	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7577574	7577585
TP53	17	Y220C	missense_variant	EID2306	Y220C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14514923' target='_blank'>Bataille et al., 2003, MP, Mol. Pathol.</a>	Stomach Carcinoma	Predictive	C: Case study	DOID:5517	220	NA	Mitomycin, Etoposide, Cisplatin	Y220C	civic:EID2306:TP53:p.Y220	c.659A>G	17_7578190_T_C	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7578184	7578195
TP53	17	Y220C	missense_variant	EID4884	Y220C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	220	NA	AMGMDS3	Y220C	civic:EID4884:TP53:p.Y220	c.659A>G	17_7578190_T_C	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7578184	7578195
TP53	17	R213P	missense_variant	EID2819	R213P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14514923' target='_blank'>Bataille et al., 2003, MP, Mol. Pathol.</a>	Stomach Carcinoma	Predictive	C: Case study	DOID:5517	213	NA	EAP Protocol	R213P	civic:EID2819:TP53:p.R213	c.638G>C	17_7578211_C_G	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7578205	7578216
TP53	17	R175H	missense_variant	EID2310	R175H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14514923' target='_blank'>Bataille et al., 2003, MP, Mol. Pathol.</a>	Stomach Carcinoma	Predictive	C: Case study	DOID:5517	175	NA	EAP Protocol	R175H	civic:EID2310:TP53:p.R175	c.524G>A	17_7578406_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7578400	7578411
TP53	17	R175H	missense_variant	EID319	R175H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22698404' target='_blank'>Jackson et al., 2012, Cancer Cell</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	175	NA	Doxorubicin	R175H	civic:EID319:TP53:p.R175	c.524G>A	17_7578406_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7578400	7578411
TP53	17	R175H	missense_variant	EID389	R175H	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16489069' target='_blank'>Olivier et al., 2006, Clin. Cancer Res.</a>	Breast Cancer	Prognostic	B: Clinical evidence	DOID:1612	175	NA	NA	R175H	civic:EID389:TP53:p.R175	c.524G>A	17_7578406_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7578400	7578411
TP53	17	R175H	missense_variant	EID4880	R175H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	175	NA	AMGMDS3	R175H	civic:EID4880:TP53:p.R175	c.524G>A	17_7578406_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7578400	7578411
TP53	17	R158H	missense_variant	EID4886	R158H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	158	NA	AMGMDS3	R158H	civic:EID4886:TP53:p.R158	c.473G>A	17_7578457_C_T	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7578451	7578462
TP53	17	R158L	missense_variant	EID4891	R158L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	158	NA	AMGMDS3	R158L	civic:EID4891:TP53:p.R158	c.473G>T	17_7578457_C_A	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7578451	7578462
TP53	17	V157F	missense_variant	EID4887	V157F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25730903' target='_blank'>Saiki et al., 2015, Oncotarget</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	157	NA	AMGMDS3	V157F	civic:EID4887:TP53:p.V157	c.469G>T	17_7578461_C_A	ENST00000269305	NM_001126112&NM_001276761&NM_001276760&NM_000546&NM_001126118	7578455	7578466
ERBB2	17	G309A	missense_variant	EID282	G309A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	309	NA	Neratinib	G309A	civic:EID282:ERBB2:p.G309	c.926G>C	17_37868205_G_C	ENST00000269571	NA	37868199	37868210
ERBB2	17	S310F	missense_variant	EID1179	S310F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	310	NA	Lapatinib, Neratinib, Trastuzumab	S310F	civic:EID1179:ERBB2:p.S310	c.929C>T, c.929_930delinsTT	17_37868208_C_T, 17_37868208_CC_TT	ENST00000269571	NA	37868202	37868214
ERBB2	17	S310Y	missense_variant	EID1179B	S310Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	310	NA	Lapatinib, Neratinib, Trastuzumab	S310Y	civic:EID1179B:ERBB2:p.S310	c.929C>A, c.929_930delinsAT	17_37868208_C_A, 17_37868208_CC_AT	ENST00000269571	NA	37868202	37868214
ERBB2	17	R678Q	missense_variant	EID286	R678Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	678	NA	Lapatinib, Neratinib	R678Q	civic:EID286:ERBB2:p.R678	c.2033G>A	17_37879658_G_A	ENST00000269571	NA	37879652	37879663
ERBB2	17	L755S	missense_variant	EID1176	L755S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	755	NA	Lapatinib, Neratinib, Trastuzumab	L755S	civic:EID1176:ERBB2:p.L755	c.2264T>C	17_37880220_T_C	ENST00000269571	NA	37880214	37880225
ERBB2	17	L755S	missense_variant	EID241	L755S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	755	NA	Lapatinib	L755S	civic:EID241:ERBB2:p.L755	c.2264T>C	17_37880220_T_C	ENST00000269571	NA	37880214	37880225
ERBB2	17	L755S	missense_variant	EID283	L755S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	755	NA	Neratinib	L755S	civic:EID283:ERBB2:p.L755	c.2264T>C	17_37880220_T_C	ENST00000269571	NA	37880214	37880225
ERBB2	17	L755W	missense_variant	EID284	L755W	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	755	NA	Neratinib	L755W	civic:EID284:ERBB2:p.L755	c.2264T>G	17_37880220_T_G	ENST00000269571	NA	37880214	37880225
ERBB2	17	D769H	missense_variant&splice_region_variant	EID279	D769H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	769	NA	Lapatinib, Neratinib	D769H	civic:EID279:ERBB2:p.D769	c.2305G>C	17_37880261_G_C	ENST00000269571	NA	37880255	37880266
ERBB2	17	D769Y	missense_variant&splice_region_variant	EID280	D769Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	769	NA	Neratinib	D769Y	civic:EID280:ERBB2:p.D769	c.2305G>T	17_37880261_G_T	ENST00000269571	NA	37880255	37880266
ERBB2	17	V773A	missense_variant	EID1987	V773A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22046346' target='_blank'>Kancha et al., 2011, PLoS ONE</a>	Head And Neck Squamous Cell Carcinoma	Predictive	D: Preclinical evidence	DOID:5520	773	NA	Lapatinib	V773A	civic:EID1987:ERBB2:p.V773	c.2318T>C	17_37880989_T_C	ENST00000269571	NA	37880983	37880994
ERBB2	17	M774delinsWLV	protein_altering_variant	EID1894	M774DELINSWLV	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25899785' target='_blank'>Kris et al., 2015, Ann. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	774	NA	Dacomitinib	M774DELINSWLV	civic:EID1894:ERBB2:p.M774	c.2320delinsTGGCTGG	17_37880991_A_TGGCTGG	ENST00000269571	NA	37880985	37881002
ERBB2	17	Y772_A775dup	inframe_insertion	EID1045	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26559459' target='_blank'>Li et al., 2015, Lung Cancer</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	772	NA	Afatinib	Y772_A775dup	civic:EID1045:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	NA	37880990	37881013
ERBB2	17	Y772_A775dup	inframe_insertion	EID1047	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19122144' target='_blank'>Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3905	772	NA	Afatinib	Y772_A775dup	civic:EID1047:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	NA	37880990	37881013
ERBB2	17	Y772_A775dup	inframe_insertion	EID1125	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25789838' target='_blank'>Weiler et al., 2015, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	772	NA	Trastuzumab Emtansine	Y772_A775dup	civic:EID1125:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	NA	37880990	37881013
ERBB2	17	Y772_A775dup	inframe_insertion	EID1888	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22325357' target='_blank'>De Grève et al., 2012, Lung Cancer</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	772	NA	Afatinib	Y772_A775dup	civic:EID1888:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	NA	37880990	37881013
ERBB2	17	Y772_A775dup	inframe_insertion	EID1893	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25899785' target='_blank'>Kris et al., 2015, Ann. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	772	NA	Dacomitinib	Y772_A775dup	civic:EID1893:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	NA	37880990	37881013
ERBB2	17	Y772_A775dup	inframe_insertion	EID960	Y772_A775DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19122144' target='_blank'>Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	772	NA	Rapamycin (Sirolimus), Afatinib	Y772_A775dup	civic:EID960:ERBB2:p.Y772_A775	c.2314_2325dup	17_37880996_T_TTACGTGATGGCT	ENST00000269571	NA	37880990	37881013
ERBB2	17	G776L	missense_variant	EID1889	G776L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22325357' target='_blank'>De Grève et al., 2012, Lung Cancer</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	776	NA	Afatinib	G776L	civic:EID1889:ERBB2:p.G776	c.2326_2327delinsCT	17_37880997_GG_CT	ENST00000269571	NA	37880991	37881003
ERBB2	17	V777L	missense_variant	EID1177	V777L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	777	NA	Lapatinib, Neratinib, Trastuzumab	V777L	civic:EID1177:ERBB2:p.V777	c.2329G>T	17_37881000_G_T	ENST00000269571	NA	37880994	37881005
ERBB2	17	V777L	missense_variant	EID288	V777L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	777	NA	Neratinib	V777L	civic:EID288:ERBB2:p.V777	c.2329G>T	17_37881000_G_T	ENST00000269571	NA	37880994	37881005
ERBB2	17	G778_P780dup	inframe_insertion	EID1048	P780INS	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25899785' target='_blank'>Kris et al., 2015, Ann. Oncol.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	778	NA	Dacomitinib	P780INS	civic:EID1048:ERBB2:p.G778_P780	c.2332_2340dup	17_37881011_A_AGGCTCCCCA	ENST00000269571	NA	37881005	37881025
ERBB2	17	G778_P780dup	inframe_insertion	EID1890	G778_P780DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22325357' target='_blank'>De Grève et al., 2012, Lung Cancer</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	778	NA	Afatinib	G778_P780dup	civic:EID1890:ERBB2:p.G778_P780	c.2332_2340dup	17_37881011_A_AGGCTCCCCA	ENST00000269571	NA	37881005	37881025
ERBB2	17	G778_P780dup	inframe_insertion	EID1892	G778_P780DUP	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25899785' target='_blank'>Kris et al., 2015, Ann. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	778	NA	Dacomitinib	G778_P780dup	civic:EID1892:ERBB2:p.G778_P780	c.2332_2340dup	17_37881011_A_AGGCTCCCCA	ENST00000269571	NA	37881005	37881025
ERBB2	17	G778_P780dup	inframe_insertion	EID285	P780INS	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	778	NA	Neratinib	P780INS	civic:EID285:ERBB2:p.G778_P780	c.2332_2340dup	17_37881011_A_AGGCTCCCCA	ENST00000269571	NA	37881005	37881025
ERBB2	17	V842I	missense_variant	EID1174	V842I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	842	NA	Trastuzumab, Lapatinib, Neratinib	V842I	civic:EID1174:ERBB2:p.V842	c.2524G>A	17_37881332_G_A	ENST00000269571	NA	37881326	37881337
ERBB2	17	V842I	missense_variant	EID289	V842I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	842	NA	Neratinib	V842I	civic:EID289:ERBB2:p.V842	c.2524G>A	17_37881332_G_A	ENST00000269571	NA	37881326	37881337
ERBB2	17	N857S	missense_variant	EID1988	N857S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22046346' target='_blank'>Kancha et al., 2011, PLoS ONE</a>	Ovarian Cancer	Predictive	D: Preclinical evidence	DOID:2394	857	NA	Lapatinib	N857S	civic:EID1988:ERBB2:p.N857	c.2570A>G	17_37881378_A_G	ENST00000269571	NA	37881372	37881383
ERBB2	17	T862A	missense_variant	EID1986	T862A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22046346' target='_blank'>Kancha et al., 2011, PLoS ONE</a>	Stomach Carcinoma	Predictive	D: Preclinical evidence	DOID:5517	862	NA	Lapatinib	T862A	civic:EID1986:ERBB2:p.T862	c.2584A>G	17_37881392_A_G	ENST00000269571	NA	37881386	37881397
ERBB2	17	L866M	missense_variant	EID1178	L866M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26243863' target='_blank'>Kavuri et al., 2015, Cancer Discov</a>	Colon Cancer	Predictive	D: Preclinical evidence	DOID:219	866	NA	Neratinib, Lapatinib, Trastuzumab	L866M	civic:EID1178:ERBB2:p.L866	c.2596C>A	17_37881404_C_A	ENST00000269571	NA	37881398	37881409
ERBB2	17	H878Y	missense_variant	EID1989	H878Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22046346' target='_blank'>Kancha et al., 2011, PLoS ONE</a>	Hepatocellular Carcinoma	Predictive	D: Preclinical evidence	DOID:684	878	NA	Lapatinib	H878Y	civic:EID1989:ERBB2:p.H878	c.2632C>T	17_37881440_C_T	ENST00000269571	NA	37881434	37881445
ERBB2	17	R896C	missense_variant	EID287	R896C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23220880' target='_blank'>Bose et al., 2013, Cancer Discov</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	896	NA	Neratinib	R896C	civic:EID287:ERBB2:p.R896	c.2686C>T	17_37881616_C_T	ENST00000269571	NA	37881610	37881621
BRCA1	17	W1836X	stop_gained	EID4623	W1815X	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23415752' target='_blank'>Stordal et al., 2013, Mol Oncol</a>	Ovarian Cancer	Predictive	D: Preclinical evidence	DOID:2394	1836	NA	Olaparib	W1815X	civic:EID4623:BRCA1:p.W1836	c.5508G>A	17_41199682_C_T	ENST00000471181	NM_007300	41199676	41199687
BRCA1	17	D1713N	missense_variant&splice_region_variant	EID2876	D1692N	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	1713	NA	Rucaparib	D1692N	civic:EID2876:BRCA1:p.D1713	c.5137G>A	17_41219625_C_T	ENST00000471181	NM_007300	41219619	41219630
BRCA1	17	E1580K	missense_variant&splice_region_variant	EID2875	E1559K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	1580	NA	Rucaparib	E1559K	civic:EID2875:BRCA1:p.E1580	c.4738G>A	17_41226348_C_T	ENST00000471181	NM_007300	41226342	41226353
BRCA1	17	R1516M	missense_variant&splice_region_variant	EID2874	R1495M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	1516	NA	Rucaparib	R1495M	civic:EID2874:BRCA1:p.R1516	c.4547G>T	17_41228505_C_A	ENST00000471181	NM_007300	41228499	41228510
BRCA1	17	Q1488X	stop_gained	EID2878	Q1467*	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	1488	NA	Rucaparib	Q1467X	civic:EID2878:BRCA1:p.Q1488	c.4462C>T	17_41228590_G_A	ENST00000471181	NM_007300	41228584	41228595
BRCA1	17	R1443X	stop_gained	EID2877	R1443*	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	1443	NA	Rucaparib	R1443X	civic:EID2877:BRCA1:p.R1443	c.4327C>T	17_41234451_G_A	ENST00000471181	NM_007300	41234445	41234456
BRCA1	17	R71K	missense_variant&splice_region_variant	EID2873	R71K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	71	NA	Rucaparib	R71K	civic:EID2873:BRCA1:p.R71	c.212G>A	17_41258473_C_T	ENST00000471181	NM_007300	41258467	41258478
BRCA1	17	R71G	missense_variant&splice_region_variant	EID2872	R71G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	71	NA	Rucaparib	R71G	civic:EID2872:BRCA1:p.R71	c.211A>G	17_41258474_T_C	ENST00000471181	NM_007300	41258468	41258479
BRCA1	17	C64Y	missense_variant	EID2871	C64Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	64	NA	Rucaparib	C64Y	civic:EID2871:BRCA1:p.C64	c.191G>A	17_41258494_C_T	ENST00000471181	NM_007300	41258488	41258499
BRCA1	17	C61G	missense_variant	EID2870	C61G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	61	NA	Rucaparib	C61G	civic:EID2870:BRCA1:p.C61	c.181T>G	17_41258504_A_C	ENST00000471181	NM_007300	41258498	41258509
BRCA1	17	M1?	start_lost	EID2869	M1I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	1	NA	Rucaparib	M1I	civic:EID2869:BRCA1:p.M1?	c.3G>T	17_41276111_C_A	ENST00000471181	NM_007300	41276105	41276116
BRCA1	17	M1?	start_lost	EID2868	M1V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27908594' target='_blank'>Swisher et al., 2017, Lancet Oncol.</a>	Ovarian Cancer	Predictive	C: Case study	DOID:2394	1	NA	Rucaparib	M1V	civic:EID2868:BRCA1:p.M1?	c.1A>G	17_41276113_T_C	ENST00000471181	NM_007300	41276107	41276118
SETBP1	18	NA	NA	EID839	EXON 4 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23222956' target='_blank'>Piazza et al., 2013, Nat. Genet.</a>	Chronic Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:8552	NA	4	NA	EXON 4 MUTATION	civic:EID839:SETBP1:exon4	NA	NA	NA	NA	42531876	42531918
SETBP1	18	G870S	missense_variant	EID840	G870S	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23222956' target='_blank'>Piazza et al., 2013, Nat. Genet.</a>	Chronic Myeloid Leukemia	Prognostic	D: Preclinical evidence	DOID:8552	870	NA	NA	G870S	civic:EID840:SETBP1:p.G870	c.2608G>A	18_42531913_G_A	ENST00000282030	NM_015559	42531907	42531918
STK11	19	NA	NA	EID750	EXON 1-2 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26625312' target='_blank'>Pécuchet et al., 2015, Oncotarget</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	1	NA	EXON 1-2 MUTATION	civic:EID750:STK11:exon1	NA	NA	NA	NA	1205739	1218499
STK11	19	NA	NA	EID750	EXON 1-2 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26625312' target='_blank'>Pécuchet et al., 2015, Oncotarget</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	NA	2	NA	EXON 1-2 MUTATION	civic:EID750:STK11:exon2	NA	NA	NA	NA	1205739	1218499
GNA11	19	NA	NA	EID1212	Q209	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24938562' target='_blank'>Carvajal et al., 2014, JAMA</a>	Uveal Melanoma	Predictive	B: Clinical evidence	DOID:6039	209	NA	Selumetinib (AZD6244)	Q209	civic:EID1212:GNA11:p.Q209	NA	NA	NA	NA	3118941	3118942
CALR	19	NA	NA	EID1482	EXON 9 FRAMESHIFT	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26486786' target='_blank'>Verger et al., 2015, Blood</a>	Chronic Myeloproliferative Disease	Predictive	B: Clinical evidence	DOID:2226	NA	9	Pegylated IFN-alpha-2a	EXON 9 FRAMESHIFT	civic:EID1482:CALR:exon9	NA	NA	NA	NA	13054526	13054727
CALR	19	NA	NA	EID1649	EXON 9 FRAMESHIFT	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24496303' target='_blank'>Tefferi et al., 2014, Leukemia</a>	Myelofibrosis	Prognostic	B: Clinical evidence	DOID:4971	NA	9	NA	EXON 9 FRAMESHIFT	civic:EID1649:CALR:exon9	NA	NA	NA	NA	13054526	13054727
CALR	19	NA	NA	EID1387	EXON 9 FRAMESHIFT	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25037629' target='_blank'>Tefferi et al., 2014, Blood</a>	Myelofibrosis	Prognostic	A: Validated	DOID:4971	NA	9	NA	EXON 9 FRAMESHIFT	civic:EID1387:CALR:exon9	NA	NA	NA	NA	13054526	13054727
PIK3R2	19	N561D	missense_variant	EID4783	N561D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	561	NA	Vemurafenib	N561D	civic:EID4783:PIK3R2:p.N561	c.1681A>G, c.1681_1683delinsGAT	19_18278061_A_G, 19_18278061_AAC_GAT	ENST00000222254	NM_005027	18278055	18278068
POLD1	19	C284Y	missense_variant	EID4776	C284Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25765070' target='_blank'>Rizvi et al., 2015, Science</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	284	NA	Pembrolizumab	C284Y	civic:EID4776:POLD1:p.C284	c.851G>A, c.851_852delinsAT	19_50905879_G_A, 19_50905879_GC_AT	ENST00000440232	NM_002691&NM_001256849	50905873	50905885
POLD1	19	E374K	missense_variant	EID4777	E374K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25765070' target='_blank'>Rizvi et al., 2015, Science</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	374	NA	Pembrolizumab	E374K	civic:EID4777:POLD1:p.E374	c.1120G>A, c.1120_1122delinsAAA	19_50906459_G_A, 19_50906459_GAG_AAA	ENST00000440232	NM_002691&NM_001256849	50906453	50906466
DNMT3A	2	NA	NA	EID11	R882	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22081665' target='_blank'>LaRochelle et al., 2011, Oncotarget</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	882	NA	Daunorubicin	R882	civic:EID11:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID18	R882	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22081665' target='_blank'>LaRochelle et al., 2011, Oncotarget</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	882	NA	Idarubicin	R882	civic:EID18:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID25	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID25:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID66	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22291079' target='_blank'>Marcucci et al., 2012, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID66:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID31	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24512939' target='_blank'>El Ghannam et al., Blood Cells Mol. Dis.</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID31:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID64	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID64:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID186	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22490330' target='_blank'>Ribeiro et al., 2012, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID186:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID189	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22490330' target='_blank'>Ribeiro et al., 2012, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID189:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID112	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID112:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID65	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24512939' target='_blank'>El Ghannam et al., Blood Cells Mol. Dis.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID65:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID113	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID113:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID170	R882	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID170:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID68	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22291079' target='_blank'>Marcucci et al., 2012, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID68:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID110	R882	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID110:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID62	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID62:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID187	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22291079' target='_blank'>Marcucci et al., 2012, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID187:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID114	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID114:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID67	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22490330' target='_blank'>Ribeiro et al., 2012, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID67:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID50	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID50:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID115	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID115:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID4	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22490330' target='_blank'>Ribeiro et al., 2012, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID4:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID3	R882	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22081665' target='_blank'>LaRochelle et al., 2011, Oncotarget</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID3:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID61	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Prognostic	A: Validated	DOID:9119	882	NA	NA	R882	civic:EID61:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
DNMT3A	2	NA	NA	EID63	R882	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23632886' target='_blank'>Gaidzik et al., 2013, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	882	NA	NA	R882	civic:EID63:DNMT3A:p.R882	NA	NA	NA	NA	25457240	25457243
ALK	2	R1275Q	missense_variant	EID1270	R1275Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23598171' target='_blank'>Mossé et al., 2013, Lancet Oncol.</a>	Neuroblastoma	Predictive	C: Case study	DOID:769	1275	NA	Crizotinib	R1275Q	civic:EID1270:ALK:p.R1275	c.3824G>A	2_29432664_C_T	ENST00000389048	NM_004304	29432658	29432669
ALK	2	R1275Q	missense_variant	EID1331	R1275Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26554404' target='_blank'>Infarinato et al., 2016, Cancer Discov</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	1275	NA	Lorlatinib	R1275Q	civic:EID1331:ALK:p.R1275	c.3824G>A	2_29432664_C_T	ENST00000389048	NM_004304	29432658	29432669
ALK	2	R1275Q	missense_variant	EID143	R1275Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22072639' target='_blank'>Bresler et al., 2011, Sci Transl Med</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	1275	NA	Crizotinib	R1275Q	civic:EID143:ALK:p.R1275	c.3824G>A	2_29432664_C_T	ENST00000389048	NM_004304	29432658	29432669
ALK	2	R1275Q	missense_variant	EID39	R1275Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18923525' target='_blank'>George et al., 2008, Nature</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	1275	NA	TAE684	R1275Q	civic:EID39:ALK:p.R1275	c.3824G>A	2_29432664_C_T	ENST00000389048	NM_004304	29432658	29432669
ALK	2	R1275Q	missense_variant	EID48	R1275Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18923525' target='_blank'>George et al., 2008, Nature</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	1275	NA	TAE684	R1275Q	civic:EID48:ALK:p.R1275	c.3824G>A	2_29432664_C_T	ENST00000389048	NM_004304	29432658	29432669
ALK	2	G1269A	missense_variant	EID1342	ALK FUSION G1269A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1269	NA	Ceritinib	ALK FUSION G1269A	civic:EID1342:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	NM_004304	29432676	29432687
ALK	2	G1269A	missense_variant	EID1353	ALK FUSION G1269A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25727400' target='_blank'>Fontana et al., 2015, Cancer Med</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	1269	NA	Brigatinib	ALK FUSION G1269A	civic:EID1353:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	NM_004304	29432676	29432687
ALK	2	G1269A	missense_variant	EID1354	ALK FUSION G1269A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25727400' target='_blank'>Fontana et al., 2015, Cancer Med</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	1269	NA	Alectinib (CH5424802)	ALK FUSION G1269A	civic:EID1354:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	NM_004304	29432676	29432687
ALK	2	G1269A	missense_variant	EID1355	ALK FUSION G1269A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25727400' target='_blank'>Fontana et al., 2015, Cancer Med</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	1269	NA	Ceritinib	ALK FUSION G1269A	civic:EID1355:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	NM_004304	29432676	29432687
ALK	2	G1269A	missense_variant	EID764	EML4-ALK G1269A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22235099' target='_blank'>Doebele et al., 2012, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1269	NA	Crizotinib	EML4-ALK G1269A	civic:EID764:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	NM_004304	29432676	29432687
ALK	2	G1269A	missense_variant	EID765	EML4-ALK G1269A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23344087' target='_blank'>Kim et al., 2013, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1269	NA	Crizotinib	EML4-ALK G1269A	civic:EID765:ALK:p.G1269	c.3806G>C	2_29432682_C_G	ENST00000389048	NM_004304	29432676	29432687
ALK	2	F1245C	missense_variant	EID1330	F1245C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26554404' target='_blank'>Infarinato et al., 2016, Cancer Discov</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	1245	NA	Lorlatinib	F1245C	civic:EID1330:ALK:p.F1245	c.3734T>G	2_29436859_A_C	ENST00000389048	NM_004304	29436853	29436864
ALK	2	F1245C	missense_variant	EID1333	F1245C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23598171' target='_blank'>Mossé et al., 2013, Lancet Oncol.</a>	Neuroblastoma	Predictive	C: Case study	DOID:769	1245	NA	Crizotinib	F1245C	civic:EID1333:ALK:p.F1245	c.3734T>G	2_29436859_A_C	ENST00000389048	NM_004304	29436853	29436864
ALK	2	F1245C	missense_variant	EID1337	ALK FUSION F1245C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22034911' target='_blank'>Zhang et al., 2011, Chem Biol Drug Des</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	1245	NA	Crizotinib	ALK FUSION F1245C	civic:EID1337:ALK:p.F1245	c.3734T>G	2_29436859_A_C	ENST00000389048	NM_004304	29436853	29436864
ALK	2	F1245C	missense_variant	EID1338	ALK FUSION F1245C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26775591' target='_blank'>Kodityal et al., 2016, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1245	NA	Ceritinib	ALK FUSION F1245C	civic:EID1338:ALK:p.F1245	c.3734T>G	2_29436859_A_C	ENST00000389048	NM_004304	29436853	29436864
ALK	2	F1245C	missense_variant	EID1339	ALK FUSION F1245C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26775591' target='_blank'>Kodityal et al., 2016, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1245	NA	Crizotinib	ALK FUSION F1245C	civic:EID1339:ALK:p.F1245	c.3734T>G	2_29436859_A_C	ENST00000389048	NM_004304	29436853	29436864
ALK	2	S1206Y	missense_variant	EID1343	EML4-ALK S1206Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	1206	NA	Ceritinib	EML4-ALK S1206Y	civic:EID1343:ALK:p.S1206	c.3617C>A	2_29443600_G_T	ENST00000389048	NM_004304	29443594	29443605
ALK	2	S1206Y	missense_variant	EID443	EML4-ALK S1206Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1206	NA	Crizotinib	EML4-ALK S1206Y	civic:EID443:ALK:p.S1206	c.3617C>A	2_29443600_G_T	ENST00000389048	NM_004304	29443594	29443605
ALK	2	G1202R	missense_variant	EID1345	ALK FUSION G1202R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1202	NA	Ceritinib	ALK FUSION G1202R	civic:EID1345:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	NM_004304	29443607	29443618
ALK	2	G1202R	missense_variant	EID1350	ALK FUSION G1202R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25727400' target='_blank'>Fontana et al., 2015, Cancer Med</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	1202	NA	Alectinib (CH5424802)	ALK FUSION G1202R	civic:EID1350:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	NM_004304	29443607	29443618
ALK	2	G1202R	missense_variant	EID1351	ALK FUSION G1202R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25727400' target='_blank'>Fontana et al., 2015, Cancer Med</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	1202	NA	Brigatinib	ALK FUSION G1202R	civic:EID1351:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	NM_004304	29443607	29443618
ALK	2	G1202R	missense_variant	EID1352	ALK FUSION G1202R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1202	NA	17-AAG	ALK FUSION G1202R	civic:EID1352:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	NM_004304	29443607	29443618
ALK	2	G1202R	missense_variant	EID1357	ALK FUSION G1202R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	1202	NA	Crizotinib	ALK FUSION G1202R	civic:EID1357:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	NM_004304	29443607	29443618
ALK	2	G1202R	missense_variant	EID441	ALK FUSION G1202R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1202	NA	Crizotinib	ALK FUSION G1202R	civic:EID441:ALK:p.G1202	c.3604G>A	2_29443613_C_T	ENST00000389048	NM_004304	29443607	29443618
ALK	2	L1196M	missense_variant	EID1341	EML4-ALK L1196M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1196	NA	Ceritinib	EML4-ALK L1196M	civic:EID1341:ALK:p.L1196	c.3586C>A	2_29443631_G_T	ENST00000389048	NM_004304	29443625	29443636
ALK	2	L1196M	missense_variant	EID141	EML4-ALK L1196M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21575866' target='_blank'>Sakamoto et al., 2011, Cancer Cell</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1196	NA	Alectinib (CH5424802)	EML4-ALK L1196M	civic:EID141:ALK:p.L1196	c.3586C>A	2_29443631_G_T	ENST00000389048	NM_004304	29443625	29443636
ALK	2	L1196M	missense_variant	EID237	EML4-ALK L1196M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20979473' target='_blank'>Choi et al., 2010, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	1196	NA	Crizotinib	EML4-ALK L1196M	civic:EID237:ALK:p.L1196	c.3586C>A	2_29443631_G_T	ENST00000389048	NM_004304	29443625	29443636
ALK	2	L1196M	missense_variant	EID442	EML4-ALK L1196M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1196	NA	Crizotinib	EML4-ALK L1196M	civic:EID442:ALK:p.L1196	c.3586C>A	2_29443631_G_T	ENST00000389048	NM_004304	29443625	29443636
ALK	2	V1180L	missense_variant	EID1286	EML4-ALK  V1180L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1180	NA	Alectinib (CH5424802)	EML4-ALK  V1180L	civic:EID1286:ALK:p.V1180	c.3538G>C	2_29443679_C_G	ENST00000389048	NM_004304	29443673	29443684
ALK	2	V1180L	missense_variant	EID1288	EML4-ALK  V1180L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1180	NA	Crizotinib	EML4-ALK  V1180L	civic:EID1288:ALK:p.V1180	c.3538G>C	2_29443679_C_G	ENST00000389048	NM_004304	29443673	29443684
ALK	2	V1180L	missense_variant	EID1289	EML4-ALK  V1180L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1180	NA	Ceritinib	EML4-ALK  V1180L	civic:EID1289:ALK:p.V1180	c.3538G>C	2_29443679_C_G	ENST00000389048	NM_004304	29443673	29443684
ALK	2	V1180L	missense_variant	EID1290	EML4-ALK  V1180L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1180	NA	TAE684	EML4-ALK  V1180L	civic:EID1290:ALK:p.V1180	c.3538G>C	2_29443679_C_G	ENST00000389048	NM_004304	29443673	29443684
ALK	2	V1180L	missense_variant	EID1291	EML4-ALK  V1180L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1180	NA	Brigatinib	EML4-ALK  V1180L	civic:EID1291:ALK:p.V1180	c.3538G>C	2_29443679_C_G	ENST00000389048	NM_004304	29443673	29443684
ALK	2	F1174L	missense_variant	EID125	F1174L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22072639' target='_blank'>Bresler et al., 2011, Sci Transl Med</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	1174	NA	Crizotinib	F1174L	civic:EID125:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	NM_004304	29443689	29443700
ALK	2	F1174L	missense_variant	EID1271	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23598171' target='_blank'>Mossé et al., 2013, Lancet Oncol.</a>	Neuroblastoma	Predictive	C: Case study	DOID:769	1174	NA	Crizotinib	F1174L	civic:EID1271:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	NM_004304	29443689	29443700
ALK	2	F1174L	missense_variant	EID1327	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26786851' target='_blank'>Wang et al., 2016, Sci Rep</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	1174	NA	AZD3463	F1174L	civic:EID1327:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	NM_004304	29443689	29443700
ALK	2	F1174L	missense_variant	EID1329	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26554404' target='_blank'>Infarinato et al., 2016, Cancer Discov</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	1174	NA	Lorlatinib	F1174L	civic:EID1329:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	NM_004304	29443689	29443700
ALK	2	F1174L	missense_variant	EID142	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18923525' target='_blank'>George et al., 2008, Nature</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	1174	NA	TAE684	F1174L	civic:EID142:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	NM_004304	29443689	29443700
ALK	2	F1174L	missense_variant	EID32	F1174L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21030459' target='_blank'>Sasaki et al., 2010, Cancer Res.</a>	Inflammatory Myofibroblastic Tumor	Predictive	D: Preclinical evidence	DOID:0050905	1174	NA	Crizotinib	F1174L	civic:EID32:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	NM_004304	29443689	29443700
ALK	2	F1174L	missense_variant	EID33	F1174L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21030459' target='_blank'>Sasaki et al., 2010, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1174	NA	Crizotinib	F1174L	civic:EID33:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	NM_004304	29443689	29443700
ALK	2	F1174L	missense_variant	EID37	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21575866' target='_blank'>Sakamoto et al., 2011, Cancer Cell</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	1174	NA	Alectinib (CH5424802)	F1174L	civic:EID37:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	NM_004304	29443689	29443700
ALK	2	F1174L	missense_variant	EID38	F1174L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21948233' target='_blank'>Heuckmann et al., 2011, Clin. Cancer Res.</a>	Neuroblastoma	Predictive	D: Preclinical evidence	DOID:769	1174	NA	Crizotinib	F1174L	civic:EID38:ALK:p.F1174	c.3522C>A	2_29443695_G_T	ENST00000389048	NM_004304	29443689	29443700
ALK	2	I1171N	missense_variant	EID1483	HIP1-ALK I1171N	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25393796' target='_blank'>Ou et al., 2014, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1171	NA	Alectinib (CH5424802), Crizotinib	HIP1-ALK I1171N	civic:EID1483:ALK:p.I1171	c.3512T>A	2_29445213_A_T	ENST00000389048	NM_004304	29445207	29445218
ALK	2	I1171S	missense_variant	EID1484	EML4-ALK I1171S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25393796' target='_blank'>Ou et al., 2014, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1171	NA	Alectinib (CH5424802), Crizotinib	EML4-ALK I1171S	civic:EID1484:ALK:p.I1171	c.3512T>G	2_29445213_A_C	ENST00000389048	NM_004304	29445207	29445218
ALK	2	I1171T	missense_variant	EID1283	ALK FUSION I1171	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1171	NA	Alectinib (CH5424802)	ALK FUSION I1171	civic:EID1283:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	NM_004304	29445207	29445218
ALK	2	I1171T	missense_variant	EID1284	ALK FUSION I1171	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1171	NA	Ceritinib	ALK FUSION I1171	civic:EID1284:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	NM_004304	29445207	29445218
ALK	2	I1171T	missense_variant	EID1285	ALK FUSION I1171	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1171	NA	TAE684	ALK FUSION I1171	civic:EID1285:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	NM_004304	29445207	29445218
ALK	2	I1171T	missense_variant	EID1287	ALK FUSION I1171	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25228534' target='_blank'>Katayama et al., 2014, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1171	NA	Crizotinib	ALK FUSION I1171	civic:EID1287:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	NM_004304	29445207	29445218
ALK	2	I1171T	missense_variant	EID1344	ALK FUSION I1171	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1171	NA	Ceritinib	ALK FUSION I1171	civic:EID1344:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	NM_004304	29445207	29445218
ALK	2	I1171T	missense_variant	EID1367	ALK FUSION I1171	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25736571' target='_blank'>Ou et al., 2015, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1171	NA	Alectinib (CH5424802)	ALK FUSION I1171	civic:EID1367:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	NM_004304	29445207	29445218
ALK	2	I1171T	missense_variant	EID1368	ALK FUSION I1171	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25736571' target='_blank'>Ou et al., 2015, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1171	NA	Ceritinib	ALK FUSION I1171	civic:EID1368:ALK:p.I1171	c.3512T>C	2_29445213_A_G	ENST00000389048	NM_004304	29445207	29445218
ALK	2	C1156Y	missense_variant	EID1346	EML4-ALK C1156Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24675041' target='_blank'>Friboulet et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1156	NA	Crizotinib	EML4-ALK C1156Y	civic:EID1346:ALK:p.C1156	c.3467G>A	2_29445258_C_T	ENST00000389048	NM_004304	29445252	29445263
ALK	2	C1156Y	missense_variant	EID841	EML4-ALK C1156Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26698910' target='_blank'>Shaw et al., 2016, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1156	NA	AUY922, Ceritinib, Crizotinib	EML4-ALK C1156Y	civic:EID841:ALK:p.C1156	c.3467G>A	2_29445258_C_T	ENST00000389048	NM_004304	29445252	29445263
ALK	2	C1156Y	missense_variant	EID842	EML4-ALK C1156Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26698910' target='_blank'>Shaw et al., 2016, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1156	NA	Lorlatinib	EML4-ALK C1156Y	civic:EID842:ALK:p.C1156	c.3467G>A	2_29445258_C_T	ENST00000389048	NM_004304	29445252	29445263
ALK	2	L1152R	missense_variant	EID763	EML4-ALK L1152R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21791641' target='_blank'>Sasaki et al., 2011, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1152	NA	Crizotinib	EML4-ALK L1152R	civic:EID763:ALK:p.L1152	c.3455T>G	2_29445270_A_C	ENST00000389048	NM_004304	29445264	29445275
ALK	2	T1151dup	inframe_insertion	EID1347	EML4-ALK T1151INST	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1151	NA	Alectinib (CH5424802)	EML4-ALK T1151INST	civic:EID1347:ALK:p.T1151	c.3451_3453dup	2_29445271_G_GCGT	ENST00000389048	NM_004304	29445265	29445279
ALK	2	T1151dup	inframe_insertion	EID1348	EML4-ALK T1151INST	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1151	NA	TAE684	EML4-ALK T1151INST	civic:EID1348:ALK:p.T1151	c.3451_3453dup	2_29445271_G_GCGT	ENST00000389048	NM_004304	29445265	29445279
ALK	2	T1151dup	inframe_insertion	EID1349	EML4-ALK T1151INST	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1151	NA	17-AAG	EML4-ALK T1151INST	civic:EID1349:ALK:p.T1151	c.3451_3453dup	2_29445271_G_GCGT	ENST00000389048	NM_004304	29445265	29445279
ALK	2	T1151dup	inframe_insertion	EID444	EML4-ALK T1151INST	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22277784' target='_blank'>Katayama et al., 2012, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1151	NA	Crizotinib	EML4-ALK T1151INST	civic:EID444:ALK:p.T1151	c.3451_3453dup	2_29445271_G_GCGT	ENST00000389048	NM_004304	29445265	29445279
ACVR1	2	G328E	missense_variant	EID6091	G328E	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24705252' target='_blank'>Taylor et al., 2014, Nat. Genet.</a>	Diffuse Intrinsic Pontine Glioma	Diagnostic	C: Case study	NA	328	NA	NA	G328E	civic:EID6091:ACVR1:p.G328	c.983_984delinsAA, c.983G>A	2_158622515_CC_TT, 2_158622516_C_T	ENST00000263640	NM_001105	158622509	158622521
ACVR1	2	G328V	missense_variant	EID4846	G328V	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24705250' target='_blank'>Fontebasso et al., 2014, Nat. Genet.</a>	Diffuse Intrinsic Pontine Glioma	Diagnostic	B: Clinical evidence	NA	328	NA	NA	G328V	civic:EID4846:ACVR1:p.G328	c.983G>T	2_158622516_C_A	ENST00000263640	NM_001105	158622510	158622521
ACVR1	2	G328V	missense_variant	EID6955	G328V	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24705254' target='_blank'>Buczkowicz et al., 2014, Nat. Genet.</a>	Diffuse Intrinsic Pontine Glioma	Diagnostic	B: Clinical evidence	NA	328	NA	NA	G328V	civic:EID6955:ACVR1:p.G328	c.983G>T	2_158622516_C_A	ENST00000263640	NM_001105	158622510	158622521
SF3B1	2	K700E	missense_variant	EID1417	K700E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25424858' target='_blank'>Maguire et al., 2015, J. Pathol.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	700	NA	Spliceostatin A	K700E	civic:EID1417:SF3B1:p.K700	c.2098A>G	2_198266834_T_C	ENST00000335508	NM_012433	198266828	198266839
SF3B1	2	K666N	missense_variant	EID1418	K666N	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25424858' target='_blank'>Maguire et al., 2015, J. Pathol.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	666	NA	Spliceostatin A	K666N	civic:EID1418:SF3B1:p.K666	c.1998G>T	2_198267359_C_A	ENST00000335508	NM_012433	198267353	198267364
IDH1	2	R132H	missense_variant	EID5987	R132H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27466707' target='_blank'>Brody et al., 2016, Cancer Biol. Ther.</a>	Pancreatic Ductal Adenocarcinoma	Predictive	C: Case study	DOID:3498	132	NA	AG-120	R132H	civic:EID5987:IDH1:p.R132	c.395G>A	2_209113112_C_T	ENST00000415913	NM_001282387	209113106	209113117
IDH1	2	R132H	missense_variant	EID979	R132H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23558169' target='_blank'>Rohle et al., 2013, Science</a>	Anaplastic Oligodendroglioma	Predictive	D: Preclinical evidence	DOID:3181	132	NA	AGI-5198	R132H	civic:EID979:IDH1:p.R132	c.395G>A	2_209113112_C_T	ENST00000415913	NM_001282387	209113106	209113117
IDH1	2	R132L	missense_variant	EID2020	R132L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22199315' target='_blank'>Lv et al., 2011, Anticancer Res.</a>	Malignant Glioma	Predictive	B: Clinical evidence	DOID:3070	132	NA	Bevacizumab	R132L	civic:EID2020:IDH1:p.R132	c.395G>T	2_209113112_C_A	ENST00000415913	NM_001282387	209113106	209113117
IDH1	2	R132C	missense_variant	EID224	R132C	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20538800' target='_blank'>Abbas et al., 2010, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	132	NA	NA	R132C	civic:EID224:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	NM_001282387	209113107	209113118
IDH1	2	R132C	missense_variant	EID2327	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20975057' target='_blank'>Houillier et al., 2010, Neurology</a>	Brain Glioma	Predictive	B: Clinical evidence	DOID:0060108	132	NA	Temozolomide	R132C	civic:EID2327:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	NM_001282387	209113107	209113118
IDH1	2	R132C	missense_variant	EID2329	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23558169' target='_blank'>Rohle et al., 2013, Science</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	132	NA	AGI-5198	R132C	civic:EID2329:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	NM_001282387	209113107	209113118
IDH1	2	R132C	missense_variant	EID2330	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22199315' target='_blank'>Lv et al., 2011, Anticancer Res.</a>	Malignant Glioma	Predictive	B: Clinical evidence	DOID:3070	132	NA	Bevacizumab	R132C	civic:EID2330:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	NM_001282387	209113107	209113118
IDH1	2	R132C	missense_variant	EID2331	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25583779' target='_blank'>2015, Cancer Discov</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	132	NA	AG-120	R132C	civic:EID2331:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	NM_001282387	209113107	209113118
IDH1	2	R132C	missense_variant	EID2332	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24333121' target='_blank'>Emadi et al., 2014, Exp. Hematol.</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	132	NA	Bis-2-[5-(phenylacetamide)-1,3,4-thiadiazol-2-yl]ethyl Sulfide	R132C	civic:EID2332:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	NM_001282387	209113107	209113118
IDH1	2	R132C	missense_variant	EID4032	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22199315' target='_blank'>Lv et al., 2011, Anticancer Res.</a>	Glioblastoma Multiforme	Predictive	B: Clinical evidence	DOID:3068	132	NA	Cetuximab	R132C	civic:EID4032:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	NM_001282387	209113107	209113118
IDH1	2	R132C	missense_variant	EID732	R132C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26436839' target='_blank'>Okoye-Okafor et al., 2015, Nat. Chem. Biol.</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	132	NA	GSK321	R132C	civic:EID732:IDH1:p.R132	c.394C>T	2_209113113_G_A	ENST00000415913	NM_001282387	209113107	209113118
IDH1	2	R132S	missense_variant	EID2339	R132S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22199315' target='_blank'>Lv et al., 2011, Anticancer Res.</a>	Malignant Glioma	Predictive	B: Clinical evidence	DOID:3070	132	NA	Bevacizumab	R132S	civic:EID2339:IDH1:p.R132	c.394C>A	2_209113113_G_T	ENST00000415913	NM_001282387	209113107	209113118
IDH1	2	NA	NA	EID481	R132	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19228619' target='_blank'>Yan et al., 2009, N. Engl. J. Med.</a>	Astrocytoma	Prognostic	B: Clinical evidence	DOID:3069	132	NA	NA	R132	civic:EID481:IDH1:p.R132	NA	NA	NA	NA	209113110	209113113
IDH1	2	NA	NA	EID480	R132	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19228619' target='_blank'>Yan et al., 2009, N. Engl. J. Med.</a>	Glioblastoma Multiforme	Prognostic	B: Clinical evidence	DOID:3068	132	NA	NA	R132	civic:EID480:IDH1:p.R132	NA	NA	NA	NA	209113110	209113113
IDH1	2	NA	NA	EID374	R132	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20494930' target='_blank'>Thol et al., 2010, Haematologica</a>	Myelodysplastic Syndrome	Prognostic	B: Clinical evidence	DOID:0050908	132	NA	NA	R132	civic:EID374:IDH1:p.R132	NA	NA	NA	NA	209113110	209113113
IDH1	2	NA	NA	EID349	R132	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20127344' target='_blank'>Bleeker et al., 2010, Acta Neuropathol.</a>	Glioblastoma Multiforme	Prognostic	B: Clinical evidence	DOID:3068	132	NA	NA	R132	civic:EID349:IDH1:p.R132	NA	NA	NA	NA	209113110	209113113
IDH1	2	NA	NA	EID348	R132	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19933982' target='_blank'>Dubbink et al., 2009, Neurology</a>	Astrocytoma	Prognostic	B: Clinical evidence	DOID:3069	132	NA	NA	R132	civic:EID348:IDH1:p.R132	NA	NA	NA	NA	209113110	209113113
IDH1	2	NA	NA	EID223	R132	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20376086' target='_blank'>Ho et al., 2010, Leukemia</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	132	NA	NA	R132	civic:EID223:IDH1:p.R132	NA	NA	NA	NA	209113110	209113113
ASXL1	20	NA	NA	EID1379	EXON 12 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23018865' target='_blank'>Schnittger et al., 2013, Leukemia</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID1379:ASXL1:exon12	NA	NA	NA	NA	31021086	31021720
GNAS	20	R844C	missense_variant	EID1906	R201C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27729313' target='_blank'>Hong et al., 2016, Cancer Discov</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	844	NA	Irinotecan, Cetuximab, Vemurafenib	R201C	civic:EID1906:GNAS:p.R844	c.2530C>T	20_57484420_C_T	ENST00000371100	NM_001077490&NM_080425	57484414	57484425
GNAS	20	R844H	missense_variant	EID3045	R201H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26788326' target='_blank'>Lu et al., 2016, Endocrinol Diabetes Metab Case Rep</a>	Follicular Thyroid Carcinoma	Predictive	C: Case study	DOID:3962	844	NA	Radioactive Iodine	R201H	civic:EID3045:GNAS:p.R844	c.2531G>A, c.2531_2532inv	20_57484421_G_A, 20_57484421_GT_AC	ENST00000371100	NM_001077490&NM_080425	57484415	57484427
U2AF1	21	Q157P	missense_variant	EID217	Q157P/R	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23029227' target='_blank'>Qian et al., 2012, PLoS ONE</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	157	NA	NA	Q157P/R	civic:EID217:U2AF1:p.Q157	c.470A>C	21_44514777_T_G	ENST00000291552	NM_006758	44514771	44514782
U2AF1	21	Q157P	missense_variant	EID400	Q157P/R	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23861105' target='_blank'>Wu et al., 2013, Am. J. Hematol.</a>	Myelodysplastic Syndrome	Prognostic	B: Clinical evidence	DOID:0050908	157	NA	NA	Q157P/R	civic:EID400:U2AF1:p.Q157	c.470A>C	21_44514777_T_G	ENST00000291552	NM_006758	44514771	44514782
U2AF1	21	S34F	missense_variant	EID218	S34Y/F	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23029227' target='_blank'>Qian et al., 2012, PLoS ONE</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	34	NA	NA	S34Y/F	civic:EID218:U2AF1:p.S34	c.101C>T	21_44524456_G_A	ENST00000291552	NM_006758	44524450	44524461
U2AF1	21	S34F	missense_variant	EID401	S34Y/F	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23861105' target='_blank'>Wu et al., 2013, Am. J. Hematol.</a>	Myelodysplastic Syndrome	Prognostic	B: Clinical evidence	DOID:0050908	34	NA	NA	S34Y/F	civic:EID401:U2AF1:p.S34	c.101C>T	21_44524456_G_A	ENST00000291552	NM_006758	44524450	44524461
MAPK1	22	E322K	missense_variant&splice_region_variant	EID791	E322K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26181029' target='_blank'>Van Allen et al., 2015, JAMA Oncol</a>	Head And Neck Squamous Cell Carcinoma	Predictive	C: Case study	DOID:5520	322	NA	Erlotinib	E322K	civic:EID791:MAPK1:p.E322	c.964G>A	22_22127164_C_T	ENST00000215832	NM_002745	22127158	22127169
NF2	22	NA	NA	EID715	K159FS*16	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25878190' target='_blank'>Moulder et al., 2015, Ann. Oncol.</a>	Breast Cancer	Predictive	C: Case study	DOID:1612	159	NA	Temsirolimus	K159	civic:EID715:NF2:p.K159	NA	NA	NA	NA	30050672	30050675
NF2	22	Y177fs	frameshift_variant	EID649	Y177FS	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25798586' target='_blank'>Sheffield et al., 2015, PLoS ONE</a>	Peritoneal Mesothelioma	Predictive	C: Case study	DOID:1788	177	NA	Cisplatin, Carboplatin	Y177fs	civic:EID649:NF2:p.Y177	c.527dup	22_30051593_T_TT	ENST00000338641	NM_000268&NM_016418&NM_181832	30051587	30051599
MYD88	3	L273P	missense_variant	EID1489	L265P	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24943832' target='_blank'>Baliakas et al., 2015, Leukemia</a>	Chronic Lymphocytic Leukemia	Prognostic	B: Clinical evidence	DOID:1040	273	NA	NA	L265P	civic:EID1489:MYD88:p.L273	c.818T>C	3_38182641_T_C	ENST00000417037	NM_001172567	38182635	38182646
MYD88	3	L273P	missense_variant	EID1641	L265P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22931316' target='_blank'>Treon et al., 2012, N. Engl. J. Med.</a>	Waldenström's Macroglobulinemia	Predictive	D: Preclinical evidence	DOID:	273	NA	IMG-2005-5, IRAK-1/4 Inhibitor	L265P	civic:EID1641:MYD88:p.L273	c.818T>C	3_38182641_T_C	ENST00000417037	NM_001172567	38182635	38182646
MYD88	3	L273P	missense_variant	EID986	L265P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25853747' target='_blank'>Treon et al., 2015, N. Engl. J. Med.</a>	Waldenström's Macroglobulinemia	Predictive	B: Clinical evidence	DOID:	273	NA	Ibrutinib	L265P	civic:EID986:MYD88:p.L273	c.818T>C	3_38182641_T_C	ENST00000417037	NM_001172567	38182635	38182646
CTNNB1	3	T41A	missense_variant	EID2973	T41A	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Diagnostic	B: Clinical evidence	NA	41	NA	NA	T41A	civic:EID2973:CTNNB1:p.T41	c.121A>G	3_41266124_A_G	ENST00000349496	NM_001904	41266118	41266129
CTNNB1	3	T41A	missense_variant	EID3044	T41A	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Prognostic	B: Clinical evidence	NA	41	NA	NA	T41A	civic:EID3044:CTNNB1:p.T41	c.121A>G	3_41266124_A_G	ENST00000349496	NM_001904	41266118	41266129
CTNNB1	3	T41A	missense_variant	EID5070	T41A	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22766794' target='_blank'>Le Guellec et al., 2012, Mod. Pathol.</a>	Desmoid Fibromatosis	Diagnostic	B: Clinical evidence	NA	41	NA	NA	T41A	civic:EID5070:CTNNB1:p.T41	c.121A>G	3_41266124_A_G	ENST00000349496	NM_001904	41266118	41266129
CTNNB1	3	S45P	missense_variant	EID2975	S45P	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Diagnostic	B: Clinical evidence	NA	45	NA	NA	S45P	civic:EID2975:CTNNB1:p.S45	c.133T>C	3_41266136_T_C	ENST00000349496	NM_001904	41266130	41266141
CTNNB1	3	S45P	missense_variant	EID3043	S45P	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Prognostic	B: Clinical evidence	NA	45	NA	NA	S45P	civic:EID3043:CTNNB1:p.S45	c.133T>C	3_41266136_T_C	ENST00000349496	NM_001904	41266130	41266141
CTNNB1	3	S45P	missense_variant	EID5072	S45P	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22766794' target='_blank'>Le Guellec et al., 2012, Mod. Pathol.</a>	Desmoid Fibromatosis	Diagnostic	B: Clinical evidence	NA	45	NA	NA	S45P	civic:EID5072:CTNNB1:p.S45	c.133T>C	3_41266136_T_C	ENST00000349496	NM_001904	41266130	41266141
CTNNB1	3	S45F	missense_variant	EID2974	S45F	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Diagnostic	B: Clinical evidence	NA	45	NA	NA	S45F	civic:EID2974:CTNNB1:p.S45	c.134C>T	3_41266137_C_T	ENST00000349496	NM_001904	41266131	41266142
CTNNB1	3	S45F	missense_variant	EID2976	S45F	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18832571' target='_blank'>Lazar et al., 2008, Am. J. Pathol.</a>	Desmoid Fibromatosis	Prognostic	B: Clinical evidence	NA	45	NA	NA	S45F	civic:EID2976:CTNNB1:p.S45	c.134C>T	3_41266137_C_T	ENST00000349496	NM_001904	41266131	41266142
CTNNB1	3	S45F	missense_variant	EID6049	S45F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24788118' target='_blank'>Hamada et al., 2014, PLoS ONE</a>	Desmoid Fibromatosis	Predictive	C: Case study	NA	45	NA	Meloxicam	S45F	civic:EID6049:CTNNB1:p.S45	c.134C>T	3_41266137_C_T	ENST00000349496	NM_001904	41266131	41266142
FOXL2	3	C134W	missense_variant	EID479	C134W	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20693978' target='_blank'>Jamieson et al., 2010, Mod. Pathol.</a>	Ovarian Granulosa Cell Tumor	Diagnostic	B: Clinical evidence	DOID:2999	134	NA	NA	C134W	civic:EID479:FOXL2:p.C134	c.402C>G	3_138665163_G_C	ENST00000330315	NM_023067	138665157	138665168
FOXL2	3	C134W	missense_variant	EID6034	C134W	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26033501' target='_blank'>Goulvent et al., 2016, Histopathology</a>	Ovarian Sex Cord-stromal Tumours	Diagnostic	A: Validated	NA	134	NA	NA	C134W	civic:EID6034:FOXL2:p.C134	c.402C>G	3_138665163_G_C	ENST00000330315	NM_023067	138665157	138665168
ATR	3	NA	NA	EID690	I774FS	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19470935' target='_blank'>Zighelboim et al., 2009, J. Clin. Oncol.</a>	Endometrial Cancer	Prognostic	B: Clinical evidence	DOID:1380	774	NA	NA	I774	civic:EID690:ATR:p.I774	NA	NA	NA	NA	142274739	142274740
PIK3CA	3	D350G	missense_variant	EID4784	D350G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	350	NA	Vemurafenib	D350G	civic:EID4784:PIK3CA:p.D350	c.1049A>G	3_178921567_A_G	ENST00000263967	NM_006218	178921561	178921572
PIK3CA	3	P471L	missense_variant	EID739	P471L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26466009' target='_blank'>Shiver et al., 2015, N. Engl. J. Med.</a>	Merkel Cell Carcinoma	Predictive	C: Case study	DOID:3965	471	NA	Idelalisib	P471L	civic:EID739:PIK3CA:p.P471	c.1412C>T	3_178928226_C_T	ENST00000263967	NM_006218	178928220	178928231
PIK3CA	3	E542K	missense_variant	EID1549	E542K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26787751' target='_blank'>Dolly et al., 2016, Clin. Cancer Res.</a>	Head And Neck Squamous Cell Carcinoma	Predictive	C: Case study	DOID:5520	542	NA	Apitolisib	E542K	civic:EID1549:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	NM_006218	178936076	178936087
PIK3CA	3	E542K	missense_variant	EID1626	E542K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19706758' target='_blank'>Liu et al., 2009, Cancer Res.</a>	Thyroid Cancer	Predictive	D: Preclinical evidence	DOID:1781	542	NA	Perifosine, Temsirolimus	E542K	civic:EID1626:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	NM_006218	178936076	178936087
PIK3CA	3	E542K	missense_variant	EID256	E542K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	542	NA	Cetuximab, Panitumumab	E542K	civic:EID256:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	NM_006218	178936076	178936087
PIK3CA	3	E542K	missense_variant	EID310	E542K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21558396' target='_blank'>Tanaka et al., 2011, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	542	NA	CH5132799	E542K	civic:EID310:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	NM_006218	178936076	178936087
PIK3CA	3	E542K	missense_variant	EID311	E542K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15647370' target='_blank'>Kang et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	542	NA	Rapamycin (Sirolimus)	E542K	civic:EID311:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	NM_006218	178936076	178936087
PIK3CA	3	E542K	missense_variant	EID384	E542K	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22357840' target='_blank'>Liao et al., 2012, Clin. Cancer Res.</a>	Colorectal Cancer	Prognostic	E: Indirect evidence	DOID:9256	542	NA	NA	E542K	civic:EID384:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	NM_006218	178936076	178936087
PIK3CA	3	E542K	missense_variant	EID385	E542K	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	542	NA	NA	E542K	civic:EID385:PIK3CA:p.E542	c.1624G>A	3_178936082_G_A	ENST00000263967	NM_006218	178936076	178936087
PIK3CA	3	E545K	missense_variant	EID1171	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16906227' target='_blank'>Engelman et al., 2006, J. Clin. Invest.</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	545	NA	Gefitinib	E545K	civic:EID1171:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	NM_006218	178936085	178936096
PIK3CA	3	E545K	missense_variant	EID1453	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18829560' target='_blank'>Serra et al., 2008, Cancer Res.</a>	Her2-receptor Positive Breast Cancer	Predictive	D: Preclinical evidence	DOID:0060079	545	NA	Trastuzumab	E545K	civic:EID1453:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	NM_006218	178936085	178936096
PIK3CA	3	E545K	missense_variant	EID1550	E545K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26787751' target='_blank'>Dolly et al., 2016, Clin. Cancer Res.</a>	Cancer	Predictive	C: Case study	DOID:162	545	NA	Apitolisib	E545K	civic:EID1550:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	NM_006218	178936085	178936096
PIK3CA	3	E545K	missense_variant	EID1670	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27304188' target='_blank'>Belchis et al., 2016, Oncotarget</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	545	NA	Gefitinib, Erlotinib, Afatinib	E545K	civic:EID1670:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	NM_006218	178936085	178936096
PIK3CA	3	E545K	missense_variant	EID2034	E545K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20453058' target='_blank'>O'Brien et al., 2010, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	545	NA	Pictilisib	E545K	civic:EID2034:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	NM_006218	178936085	178936096
PIK3CA	3	E545K	missense_variant	EID2036	E545K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26920887' target='_blank'>Baselga et al., 2016, Clin. Cancer Res.</a>	Breast Cancer	Predictive	B: Clinical evidence	DOID:1612	545	NA	Ado-trastuzumab Emtansine	E545K	civic:EID2036:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	NM_006218	178936085	178936096
PIK3CA	3	E545K	missense_variant	EID2037	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	545	NA	Panitumumab, Cetuximab	E545K	civic:EID2037:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	NM_006218	178936085	178936096
PIK3CA	3	E545K	missense_variant	EID2040	E545K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19513541' target='_blank'>Zou et al., 2009, Int. J. Mol. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	545	NA	PI103	E545K	civic:EID2040:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	NM_006218	178936085	178936096
PIK3CA	3	E545K	missense_variant	EID3722	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	545	NA	Vemurafenib	E545K	civic:EID3722:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	NM_006218	178936085	178936096
PIK3CA	3	E545K	missense_variant	EID387	E545K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	545	NA	Cetuximab, Panitumumab	E545K	civic:EID387:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	NM_006218	178936085	178936096
PIK3CA	3	E545K	missense_variant	EID710	E545K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23888070' target='_blank'>Beaver et al., 2013, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	545	NA	MK-2206, Pictilisib	E545K	civic:EID710:PIK3CA:p.E545	c.1633G>A	3_178936091_G_A	ENST00000263967	NM_006218	178936085	178936096
PIK3CA	3	E545G	missense_variant	EID3724	E545G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	545	NA	Vemurafenib	E545G	civic:EID3724:PIK3CA:p.E545	c.1634A>G	3_178936092_A_G	ENST00000263967	NM_006218	178936086	178936097
PIK3CA	3	NA	NA	EID138	EXON 21 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	NA	21	Cetuximab	EXON 21 MUTATION	civic:EID138:PIK3CA:exon21	NA	NA	NA	NA	178951881	178952495
PIK3CA	3	H1047R	missense_variant	EID1361	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25855885' target='_blank'>Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg</a>	Head And Neck Cancer	Predictive	D: Preclinical evidence	DOID:11934	1047	NA	BEZ235 (NVP-BEZ235, Dactolisib)	H1047R	civic:EID1361:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID1362	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23619167' target='_blank'>Lui et al., 2013, Cancer Discov</a>	Head And Neck Cancer	Predictive	D: Preclinical evidence	DOID:11934	1047	NA	BEZ235 (NVP-BEZ235, Dactolisib)	H1047R	civic:EID1362:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID1363	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23619167' target='_blank'>Lui et al., 2013, Cancer Discov</a>	Head And Neck Cancer	Predictive	D: Preclinical evidence	DOID:11934	1047	NA	Cetuximab, BEZ235 (NVP-BEZ235, Dactolisib)	H1047R	civic:EID1363:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID1401	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25550549' target='_blank'>Keam et al., 2015, Anticancer Res.</a>	Head And Neck Cancer	Predictive	D: Preclinical evidence	DOID:11934	1047	NA	BYL719 (Alpelisib)	H1047R	civic:EID1401:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID1447	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19029981' target='_blank'>Engelman et al., 2008, Nat. Med.</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	1047	NA	BEZ235 (NVP-BEZ235, Dactolisib)	H1047R	civic:EID1447:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID1465	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26589432' target='_blank'>Zumsteg et al., 2016, Clin. Cancer Res.</a>	Head And Neck Squamous Cell Carcinoma	Predictive	D: Preclinical evidence	DOID:5520	1047	NA	Taselisib (GDC-0032)	H1047R	civic:EID1465:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID1505	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22294718' target='_blank'>Davies et al., 2012, Mol. Cancer Ther.</a>	Her2-receptor Positive Breast Cancer	Predictive	D: Preclinical evidence	DOID:0060079	1047	NA	AZD5363, Trastuzumab	H1047R	civic:EID1505:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID1506	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22294718' target='_blank'>Davies et al., 2012, Mol. Cancer Ther.</a>	Her2-receptor Positive Breast Cancer	Predictive	D: Preclinical evidence	DOID:0060079	1047	NA	AZD5363, Lapatinib	H1047R	civic:EID1506:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID1623	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27445490' target='_blank'>Sun et al., 2016, Onco Targets Ther</a>	Her2-receptor Positive Breast Cancer	Predictive	C: Case study	DOID:0060079	1047	NA	Everolimus, Fulvestrant	H1047R	civic:EID1623:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID1625	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19706758' target='_blank'>Liu et al., 2009, Cancer Res.</a>	Thyroid Cancer	Predictive	D: Preclinical evidence	DOID:1781	1047	NA	Perifosine, Temsirolimus	H1047R	civic:EID1625:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID2100	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17202311' target='_blank'>Maruyama et al., 2007, Clin. Cancer Res.</a>	Breast Cancer	Predictive	B: Clinical evidence	DOID:1612	1047	NA	Trastuzumab	H1047R	civic:EID2100:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID2102	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20453058' target='_blank'>O'Brien et al., 2010, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	1047	NA	Trastuzumab	H1047R	civic:EID2102:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID2103	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26920887' target='_blank'>Baselga et al., 2016, Clin. Cancer Res.</a>	Breast Cancer	Predictive	B: Clinical evidence	DOID:1612	1047	NA	Ado-trastuzumab Emtansine	H1047R	civic:EID2103:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID2105	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17590872' target='_blank'>Kato et al., 2007, Int. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	1047	NA	Panitumumab	H1047R	civic:EID2105:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID2106	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19903786' target='_blank'>He et al., 2009, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	1047	NA	Panitumumab	H1047R	civic:EID2106:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID2110	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19513541' target='_blank'>Zou et al., 2009, Int. J. Mol. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	1047	NA	PI103	H1047R	civic:EID2110:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID258	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	1047	NA	Cetuximab, Panitumumab	H1047R	civic:EID258:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID314	H1047R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21558396' target='_blank'>Tanaka et al., 2011, Clin. Cancer Res.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	1047	NA	CH5132799	H1047R	civic:EID314:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
PIK3CA	3	H1047R	missense_variant	EID388	H1047R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19223544' target='_blank'>Sartore-Bianchi et al., 2009, Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	1047	NA	Cetuximab, Panitumumab	H1047R	civic:EID388:PIK3CA:p.H1047	c.3140A>G	3_178952085_A_G	ENST00000263967	NM_006218	178952079	178952090
FGFR3	4	S249C	missense_variant	EID1603	S249C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25766722' target='_blank'>Palma et al., 2015, Eur. Urol.</a>	Urothelial Carcinoma	Predictive	C: Case study	DOID:2671	249	NA	Pazopanib	S249C	civic:EID1603:FGFR3:p.S249	c.746C>G	4_1803568_C_G	ENST00000340107	NM_001163213	1803562	1803573
FGFR3	4	Y375C	missense_variant	EID477	Y375C	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20542753' target='_blank'>Bodoor et al., 2010, Cancer Epidemiol</a>	Bladder Carcinoma	Diagnostic	B: Clinical evidence	DOID:4007	375	NA	NA	Y375C	civic:EID477:FGFR3:p.Y375	c.1124A>G	4_1806099_A_G	ENST00000340107	NM_001163213	1806093	1806104
PDGFRA	4	V561A	missense_variant	EID652	V561A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12949711' target='_blank'>Hirota et al., 2003, Gastroenterology</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	561	NA	Imatinib	V561A	civic:EID652:PDGFRA:p.V561	c.1682T>C	4_55141036_T_C	ENST00000257290	NM_006206	55141030	55141041
PDGFRA	4	V561D	missense_variant	EID2454	V561D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	561	NA	Imatinib	V561D	civic:EID2454:PDGFRA:p.V561	c.1682T>A	4_55141036_T_A	ENST00000257290	NM_006206	55141030	55141041
PDGFRA	4	V561D	missense_variant	EID2474	V561D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955451' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	561	NA	Imatinib	V561D	civic:EID2474:PDGFRA:p.V561	c.1682T>A	4_55141036_T_A	ENST00000257290	NM_006206	55141030	55141041
PDGFRA	4	V561D	missense_variant	EID4056	V561D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955458' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	561	NA	Sunitinib	V561D	civic:EID4056:PDGFRA:p.V561	c.1682T>A	4_55141036_T_A	ENST00000257290	NM_006206	55141030	55141041
PDGFRA	4	V561D	missense_variant	EID5347	V561D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955458' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	561	NA	Imatinib Mesylate	V561D	civic:EID5347:PDGFRA:p.V561	c.1682T>A	4_55141036_T_A	ENST00000257290	NM_006206	55141030	55141041
PDGFRA	4	P577S	missense_variant	EID1974	P577S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24132921' target='_blank'>Dai et al., 2013, Clin. Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	577	NA	Imatinib, Crenolanib	P577S	civic:EID1974:PDGFRA:p.P577	c.1729C>T	4_55141083_C_T	ENST00000257290	NM_006206	55141077	55141088
PDGFRA	4	T674I	missense_variant	EID1446	FIP1L1-PDGFRA T674I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12660384' target='_blank'>Cools et al., 2003, N. Engl. J. Med.</a>	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Predictive	C: Case study	DOID:0080164	674	NA	Imatinib	FIP1L1-PDGFRA T674I	civic:EID1446:PDGFRA:p.T674	c.2021C>T	4_55144547_C_T	ENST00000257290	NM_006206	55144541	55144552
PDGFRA	4	T674I	missense_variant	EID1779	FIP1L1-PDGFRA T674I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24407160' target='_blank'>Sadovnik et al., 2014, Exp. Hematol.</a>	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Predictive	D: Preclinical evidence	DOID:0080164	674	NA	Ponatinib	FIP1L1-PDGFRA T674I	civic:EID1779:PDGFRA:p.T674	c.2021C>T	4_55144547_C_T	ENST00000257290	NM_006206	55144541	55144552
PDGFRA	4	T674I	missense_variant	EID7020	FIP1L1-PDGFRA T674I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21818111' target='_blank'>Metzgeroth et al., 2012, Leukemia</a>	Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1	Predictive	C: Case study	DOID:0080164	674	NA	Imatinib	FIP1L1-PDGFRA T674I	civic:EID7020:PDGFRA:p.T674	c.2021C>T	4_55144547_C_T	ENST00000257290	NM_006206	55144541	55144552
PDGFRA	4	D842Y	missense_variant	EID45	D842Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22745105' target='_blank'>Heinrich et al., 2012, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	842	NA	Crenolanib	D842Y	civic:EID45:PDGFRA:p.D842	c.2524G>T	4_55152092_G_T	ENST00000257290	NM_006206	55152086	55152097
PDGFRA	4	D842I	missense_variant	EID43	D842I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22745105' target='_blank'>Heinrich et al., 2012, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	842	NA	Crenolanib	D842I	civic:EID43:PDGFRA:p.D842	c.2524_2525delinsAT	4_55152092_GA_AT	ENST00000257290	NM_006206	55152086	55152098
PDGFRA	4	D842V	missense_variant	EID15	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15928335' target='_blank'>Corless et al., 2005, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	842	NA	Imatinib	D842V	civic:EID15:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	NM_006206	55152087	55152098
PDGFRA	4	D842V	missense_variant	EID16	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	842	NA	Imatinib	D842V	civic:EID16:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	NM_006206	55152087	55152098
PDGFRA	4	D842V	missense_variant	EID2	D842V	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15146165' target='_blank'>Lasota et al., 2004, Lab. Invest.</a>	Gastrointestinal Stromal Tumor	Diagnostic	B: Clinical evidence	DOID:9253	842	NA	NA	D842V	civic:EID2:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	NM_006206	55152087	55152098
PDGFRA	4	D842V	missense_variant	EID2463	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	842	NA	Imatinib	D842V	civic:EID2463:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	NM_006206	55152087	55152098
PDGFRA	4	D842V	missense_variant	EID2478	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	842	NA	Imatinib	D842V	civic:EID2478:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	NM_006206	55152087	55152098
PDGFRA	4	D842V	missense_variant	EID4060	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955458' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	842	NA	Sunitinib	D842V	civic:EID4060:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	NM_006206	55152087	55152098
PDGFRA	4	D842V	missense_variant	EID44	D842V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22745105' target='_blank'>Heinrich et al., 2012, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	842	NA	Crenolanib	D842V	civic:EID44:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	NM_006206	55152087	55152098
PDGFRA	4	D842V	missense_variant	EID5346	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955458' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	842	NA	Imatinib Mesylate	D842V	civic:EID5346:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	NM_006206	55152087	55152098
PDGFRA	4	D842V	missense_variant	EID651	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12949711' target='_blank'>Hirota et al., 2003, Gastroenterology</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	842	NA	Imatinib	D842V	civic:EID651:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	NM_006206	55152087	55152098
PDGFRA	4	D842V	missense_variant	EID738	D842V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26130666' target='_blank'>Yoo et al., 2016, Cancer Res Treat</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	842	NA	Imatinib	D842V	civic:EID738:PDGFRA:p.D842	c.2525A>T	4_55152093_A_T	ENST00000257290	NM_006206	55152087	55152098
PDGFRA	4	D842_I843delinsVM	missense_variant	EID47	DI842-843VM	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22745105' target='_blank'>Heinrich et al., 2012, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	842	NA	Crenolanib	DI842-843VM	civic:EID47:PDGFRA:p.D842_I843	c.2525_2529delinsTCATG	4_55152093_ACATC_TCATG	ENST00000257290	NM_006206	55152087	55152102
PDGFRA	4	H845Y	missense_variant	EID1976	H845Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24132921' target='_blank'>Dai et al., 2013, Clin. Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	845	NA	Imatinib, Crenolanib	H845Y	civic:EID1976:PDGFRA:p.H845	c.2533C>T	4_55152101_C_T	ENST00000257290	NM_006206	55152095	55152106
PDGFRA	4	G853D	missense_variant	EID1977	G853D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24132921' target='_blank'>Dai et al., 2013, Clin. Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	853	NA	Imatinib, Crenolanib	G853D	civic:EID1977:PDGFRA:p.G853	c.2558G>A	4_55152126_G_A	ENST00000257290	NM_006206	55152120	55152131
KIT	4	NA	NA	EID4139	EXON 9 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22614970' target='_blank'>George et al., 2012, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	9	Regorafenib	EXON 9 MUTATION	civic:EID4139:KIT:exon9	NA	NA	NA	NA	55592022	55592216
KIT	4	NA	NA	EID4104	EXON 9 MUTATION	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27371698' target='_blank'>Ben-Ami et al., 2016, Ann. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	NA	9	Regorafenib	EXON 9 MUTATION	civic:EID4104:KIT:exon9	NA	NA	NA	NA	55592022	55592216
KIT	4	NA	NA	EID4628	EXON 9 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23177515' target='_blank'>Demetri et al., 2013, Lancet</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	9	Regorafenib	EXON 9 MUTATION	civic:EID4628:KIT:exon9	NA	NA	NA	NA	55592022	55592216
KIT	4	NA	NA	EID2466	EXON 9 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	9	Imatinib	EXON 9 MUTATION	civic:EID2466:KIT:exon9	NA	NA	NA	NA	55592022	55592216
KIT	4	NA	NA	EID2477	EXON 9 MUTATION	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955451' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	9	Imatinib	EXON 9 MUTATION	civic:EID2477:KIT:exon9	NA	NA	NA	NA	55592022	55592216
KIT	4	NA	NA	EID1424	EXON 9 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955458' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	9	Sunitinib	EXON 9 MUTATION	civic:EID1424:KIT:exon9	NA	NA	NA	NA	55592022	55592216
KIT	4	NA	NA	EID1221	EXON 9 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16624552' target='_blank'>Debiec-Rychter et al., 2006, Eur. J. Cancer</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	9	Imatinib	EXON 9 MUTATION	civic:EID1221:KIT:exon9	NA	NA	NA	NA	55592022	55592216
KIT	4	NA	NA	EID1223	EXON 9 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22439647' target='_blank'>Rutkowski et al., 2012, BMC Cancer</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	9	Sunitinib	EXON 9 MUTATION	civic:EID1223:KIT:exon9	NA	NA	NA	NA	55592022	55592216
KIT	4	A502_Y503insAY	inframe_insertion	EID4100	A502_Y503insAY	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955458' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	502	NA	Sunitinib	A502_Y503insAY	civic:EID4100:KIT:p.A502_Y503	c.1506_1507insGCCTAT	4_55592182_C_CGCCTAT	ENST00000288135	NM_000222&NM_001093772	55592176	55592193
KIT	4	A502_Y503dup	inframe_insertion	EID2484	Y503_F504insAY	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	502	NA	Imatinib	Y503_F504insAY	civic:EID2484:KIT:p.A502_Y503	c.1504_1509dup	4_55592185_T_TGCCTAT	ENST00000288135	NM_000222&NM_001093772	55592179	55592196
KIT	4	M541L	missense_variant	EID1423	M541L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25015329' target='_blank'>Iurlo et al., 2014, Oncotarget</a>	Chronic Leukemia	Predictive	C: Case study	DOID:1036	541	NA	Imatinib	M541L	civic:EID1423:KIT:p.M541	c.1621A>C	4_55593464_A_C	ENST00000288135	NM_000222&NM_001093772	55593458	55593469
KIT	4	M541L	missense_variant	EID485	M541L	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16307017' target='_blank'>Krüger et al., 2006, Leukemia</a>	Chronic Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:8552	541	NA	NA	M541L	civic:EID485:KIT:p.M541	c.1621A>C	4_55593464_A_C	ENST00000288135	NM_000222&NM_001093772	55593458	55593469
KIT	4	NA	NA	EID4629	EXON 11 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22614970' target='_blank'>George et al., 2012, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	11	Regorafenib	EXON 11 MUTATION	civic:EID4629:KIT:exon11	NA	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID6377	EXON 11 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27371698' target='_blank'>Ben-Ami et al., 2016, Ann. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	11	Regorafenib	EXON 11 MUTATION	civic:EID6377:KIT:exon11	NA	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID4599	EXON 11 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23177515' target='_blank'>Demetri et al., 2013, Lancet</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	11	Regorafenib	EXON 11 MUTATION	civic:EID4599:KIT:exon11	NA	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID654	EXON 11 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	11	Imatinib	EXON 11 MUTATION	civic:EID654:KIT:exon11	NA	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID2471	EXON 11 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955451' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	NA	11	Imatinib	EXON 11 MUTATION	civic:EID2471:KIT:exon11	NA	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID58	EXON 11 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23775962' target='_blank'>Hodi et al., 2013, J. Clin. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	NA	11	Imatinib	EXON 11 MUTATION	civic:EID58:KIT:exon11	NA	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID1224	EXON 11 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22261812' target='_blank'>Minor et al., 2012, Clin. Cancer Res.</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	11	Sunitinib	EXON 11 MUTATION	civic:EID1224:KIT:exon11	NA	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID376	EXON 11 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/10485475' target='_blank'>Taniguchi et al., 1999, Cancer Res.</a>	Gastrointestinal Stromal Tumor	Prognostic	B: Clinical evidence	DOID:9253	NA	11	NA	EXON 11 MUTATION	civic:EID376:KIT:exon11	NA	NA	NA	NA	55593581	55593708
KIT	4	NA	NA	EID225	EXON 11 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/10485475' target='_blank'>Taniguchi et al., 1999, Cancer Res.</a>	Gastrointestinal Stromal Tumor	Diagnostic	B: Clinical evidence	DOID:9253	NA	11	NA	EXON 11 MUTATION	civic:EID225:KIT:exon11	NA	NA	NA	NA	55593581	55593708
KIT	4	V559D	missense_variant	EID3028	V559D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22114577' target='_blank'>Cameron et al., 2011, Case Rep Oncol</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	559	NA	Imatinib	V559D	civic:EID3028:KIT:p.V559	c.1676T>A	4_55593610_T_A	ENST00000288135	NM_000222&NM_001093772	55593604	55593615
KIT	4	V559D	missense_variant	EID3029	V559D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16046538' target='_blank'>Carter et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	559	NA	SU11248, MLN518, PD-180970, BMS-354825, Imatinib	V559D	civic:EID3029:KIT:p.V559	c.1676T>A	4_55593610_T_A	ENST00000288135	NM_000222&NM_001093772	55593604	55593615
KIT	4	V560D	missense_variant	EID4077	V560D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955458' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	560	NA	Sunitinib	V560D	civic:EID4077:KIT:p.V560	c.1679T>A	4_55593613_T_A	ENST00000288135	NM_000222&NM_001093772	55593607	55593618
KIT	4	V560D	missense_variant	EID5348	V560D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18955458' target='_blank'>Heinrich et al., 2008, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	560	NA	Imatinib Mesylate	V560D	civic:EID5348:KIT:p.V560	c.1679T>A	4_55593613_T_A	ENST00000288135	NM_000222&NM_001093772	55593607	55593618
KIT	4	V560G	missense_variant	EID2469	V560G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	560	NA	Imatinib	V560G	civic:EID2469:KIT:p.V560	c.1679T>G	4_55593613_T_G	ENST00000288135	NM_000222&NM_001093772	55593607	55593618
KIT	4	L576P	missense_variant	EID303	L576P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17372901' target='_blank'>Antonescu et al., 2007, Int. J. Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	576	NA	Nilotinib, Imatinib, Dasatinib	L576P	civic:EID303:KIT:p.L576	c.1727T>C	4_55593661_T_C	ENST00000288135	NM_000222&NM_001093772	55593655	55593666
KIT	4	L576P	missense_variant	EID34	L576P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19671763' target='_blank'>Woodman et al., 2009, Mol. Cancer Ther.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	576	NA	Sorafenib, Nilotinib, Imatinib	L576P	civic:EID34:KIT:p.L576	c.1727T>C	4_55593661_T_C	ENST00000288135	NM_000222&NM_001093772	55593655	55593666
KIT	4	L576P	missense_variant	EID42	L576P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19671763' target='_blank'>Woodman et al., 2009, Mol. Cancer Ther.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	576	NA	Dasatinib	L576P	civic:EID42:KIT:p.L576	c.1727T>C	4_55593661_T_C	ENST00000288135	NM_000222&NM_001093772	55593655	55593666
KIT	4	K642E	missense_variant	EID2472	K642E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	642	NA	Imatinib	K642E	civic:EID2472:KIT:p.K642	c.1924A>G	4_55594221_A_G	ENST00000288135	NM_000222&NM_001093772	55594215	55594226
KIT	4	K642E	missense_variant	EID2889	K642E	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18510589' target='_blank'>Lutzky et al., 2008, Pigment Cell Melanoma Res</a>	Melanoma	Prognostic	C: Case study	DOID:1909	642	NA	NA	K642E	civic:EID2889:KIT:p.K642	c.1924A>G	4_55594221_A_G	ENST00000288135	NM_000222&NM_001093772	55594215	55594226
KIT	4	V654A	missense_variant	EID249	V654A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	D: Preclinical evidence	DOID:9253	654	NA	Imatinib	V654A	civic:EID249:KIT:p.V654	c.1961T>C	4_55594258_T_C	ENST00000288135	NM_000222&NM_001093772	55594252	55594263
KIT	4	V654A	missense_variant	EID304	V654A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16638875' target='_blank'>Prenen et al., 2006, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Predictive	B: Clinical evidence	DOID:9253	654	NA	Sunitinib	V654A	civic:EID304:KIT:p.V654	c.1961T>C	4_55594258_T_C	ENST00000288135	NM_000222&NM_001093772	55594252	55594263
KIT	4	NA	NA	EID70	EXON 14 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16551858' target='_blank'>Wardelmann et al., 2006, Clin. Cancer Res.</a>	Gastrointestinal Stromal Tumor	Prognostic	B: Clinical evidence	DOID:9253	NA	14	NA	EXON 14 MUTATION	civic:EID70:KIT:exon14	NA	NA	NA	NA	55595500	55595651
KIT	4	T670I	missense_variant	EID2924	T670I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	670	NA	Imatinib	T670I	civic:EID2924:KIT:p.T670	c.2009C>T	4_55595519_C_T	ENST00000288135	NM_000222&NM_001093772	55595513	55595524
KIT	4	C809G	missense_variant	EID2920	C809G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	809	NA	Imatinib	C809G	civic:EID2920:KIT:p.C809	c.2425T>G	4_55599299_T_G	ENST00000288135	NM_000222&NM_001093772	55599293	55599304
KIT	4	D816H	missense_variant	EID2923	D816H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	816	NA	Imatinib	D816H	civic:EID2923:KIT:p.D816	c.2446G>C	4_55599320_G_C	ENST00000288135	NM_000222&NM_001093772	55599314	55599325
KIT	4	D816V	missense_variant	EID1725	D816V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27355533' target='_blank'>Gotlib et al., 2016, N. Engl. J. Med.</a>	Systemic Mastocytosis	Predictive	B: Clinical evidence	DOID:349	816	NA	Midostaurin	D816V	civic:EID1725:KIT:p.D816	c.2447A>T	4_55599321_A_T	ENST00000288135	NM_000222&NM_001093772	55599315	55599326
KIT	4	D816V	missense_variant	EID1726	D816V	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26464169' target='_blank'>Jawhar et al., 2016, Leukemia</a>	Systemic Mastocytosis	Prognostic	B: Clinical evidence	DOID:349	816	NA	NA	D816V	civic:EID1726:KIT:p.D816	c.2447A>T	4_55599321_A_T	ENST00000288135	NM_000222&NM_001093772	55599315	55599326
KIT	4	D816V	missense_variant	EID2451	D816V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	816	NA	Imatinib	D816V	civic:EID2451:KIT:p.D816	c.2447A>T	4_55599321_A_T	ENST00000288135	NM_000222&NM_001093772	55599315	55599326
KIT	4	D816V	missense_variant	EID26	D816V	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16384925' target='_blank'>Cairoli et al., 2006, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	816	NA	NA	D816V	civic:EID26:KIT:p.D816	c.2447A>T	4_55599321_A_T	ENST00000288135	NM_000222&NM_001093772	55599315	55599326
KIT	4	D820Y	missense_variant	EID2886	D820Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21642685' target='_blank'>Carvajal et al., 2011, JAMA</a>	Melanoma	Predictive	C: Case study	DOID:1909	820	NA	Imatinib	D820Y	civic:EID2886:KIT:p.D820	c.2458G>T	4_55599332_G_T	ENST00000288135	NM_000222&NM_001093772	55599326	55599337
KIT	4	D820Y	missense_variant	EID4589	D820Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22614970' target='_blank'>George et al., 2012, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	820	NA	Regorafenib	D820Y	civic:EID4589:KIT:p.D820	c.2458G>T	4_55599332_G_T	ENST00000288135	NM_000222&NM_001093772	55599326	55599337
KIT	4	D820A	missense_variant	EID2921	D820A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	820	NA	Imatinib	D820A	civic:EID2921:KIT:p.D820	c.2459A>C	4_55599333_A_C	ENST00000288135	NM_000222&NM_001093772	55599327	55599338
KIT	4	D820G	missense_variant	EID2922	D820G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	820	NA	Imatinib	D820G	civic:EID2922:KIT:p.D820	c.2459A>G	4_55599333_A_G	ENST00000288135	NM_000222&NM_001093772	55599327	55599338
KIT	4	N822H	missense_variant	EID2445	N822H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	822	NA	Imatinib	N822H	civic:EID2445:KIT:p.N822	c.2464A>C	4_55599338_A_C	ENST00000288135	NM_000222&NM_001093772	55599332	55599343
KIT	4	N822K	missense_variant	EID2448	N822K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/14645423' target='_blank'>Heinrich et al., 2003, J. Clin. Oncol.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	822	NA	Imatinib	N822K	civic:EID2448:KIT:p.N822	c.2466T>A	4_55599340_T_A	ENST00000288135	NM_000222&NM_001093772	55599334	55599345
KIT	4	N822K	missense_variant	EID2918	N822K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	822	NA	Imatinib	N822K	civic:EID2918:KIT:p.N822	c.2466T>A	4_55599340_T_A	ENST00000288135	NM_000222&NM_001093772	55599334	55599345
KIT	4	N822K	missense_variant	EID4595	N822K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22614970' target='_blank'>George et al., 2012, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	822	NA	Regorafenib	N822K	civic:EID4595:KIT:p.N822	c.2466T>G	4_55599340_T_G	ENST00000288135	NM_000222&NM_001093772	55599334	55599345
KIT	4	Y823D	missense_variant	EID2919	Y823D	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16954519' target='_blank'>Heinrich et al., 2006, J. Clin. Oncol.</a>	Gastrointestinal Stromal Tumor	Predictive	C: Case study	DOID:9253	823	NA	Imatinib	Y823D	civic:EID2919:KIT:p.Y823	c.2467T>G	4_55599341_T_G	ENST00000288135	NM_000222&NM_001093772	55599335	55599346
KDR	4	A1065T	missense_variant&splice_region_variant	EID1106	A1065T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19723655' target='_blank'>Antonescu et al., 2009, Cancer Res.</a>	Angiosarcoma	Predictive	D: Preclinical evidence	DOID:0001816	1065	NA	Sorafenib, Sunitinib	A1065T	civic:EID1106:KDR:p.A1065	c.3193G>A	4_55955969_C_T	ENST00000263923	NM_002253	55955963	55955974
KDR	4	R961W	missense_variant	EID1191	R961W	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27004155' target='_blank'>Loaiza-Bonilla et al., 2016, Cureus</a>	Colorectal Adenocarcinoma	Predictive	C: Case study	DOID:0050861	961	NA	Regorafenib	R961W	civic:EID1191:KDR:p.R961	c.2881C>T	4_55961059_G_A	ENST00000263923	NM_002253	55961053	55961064
KDR	4	D717V	missense_variant	EID1107	D717V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19723655' target='_blank'>Antonescu et al., 2009, Cancer Res.</a>	Angiosarcoma	Predictive	D: Preclinical evidence	DOID:0001816	717	NA	Sorafenib, Sunitinib	D717V	civic:EID1107:KDR:p.D717	c.2150A>T	4_55968180_T_A	ENST00000263923	NM_002253	55968174	55968185
TERT	5	.	upstream_gene_variant	EID1646	C228T	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25121551' target='_blank'>Liu et al., 2014, Endocr. Relat. Cancer</a>	Thyroid Cancer	Diagnostic	B: Clinical evidence	DOID:1781	NA	NA	NA	C228T	TERT:upstream_gene_variant_C228T	NA	5_1295228_G_A	NA	NA	1295222	1295233
TERT	5	.	upstream_gene_variant	EID655	C228T	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25024077' target='_blank'>Xing et al., 2014, J. Clin. Oncol.</a>	Papillary Thyroid Carcinoma	Prognostic	B: Clinical evidence	DOID:3969	NA	NA	NA	C228T	TERT:upstream_gene_variant_C228T	NA	5_1295228_G_A	NA	NA	1295222	1295233
RAD50	5	L1237F	missense_variant	EID5829	L1237F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24934408' target='_blank'>Al-Ahmadie et al., 2014, Cancer Discov</a>	Ureter Small Cell Carcinoma	Predictive	C: Case study	DOID:6886	1237	NA	Irinotecan, AZD7762	L1237F	civic:EID5829:RAD50:p.L1237	c.3709C>T, c.3709_3711delinsTTC	5_131976454_C_T, 5_131976454_CTT_TTC	ENST00000265335	NA	131976448	131976461
NPM1	5	NA	NA	EID147	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22417203' target='_blank'>Patel et al., 2012, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	12	Daunorubicin	EXON 12 MUTATION	civic:EID147:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID148	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24797300' target='_blank'>Tassara et al., 2014, Blood</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	12	Valproic Acid	EXON 12 MUTATION	civic:EID148:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID149	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21719597' target='_blank'>Balusu et al., 2011, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	NA	12	NSC348884, All-trans Retinoic Acid	EXON 12 MUTATION	civic:EID149:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID151	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24927407' target='_blank'>Ehninger et al., 2014, Blood Cancer J</a>	Acute Myeloid Leukemia	Predictive	E: Indirect evidence	DOID:9119	NA	12	Anti-CD33	EXON 12 MUTATION	civic:EID151:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID150	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24927407' target='_blank'>Ehninger et al., 2014, Blood Cancer J</a>	Acute Myeloid Leukemia	Predictive	E: Indirect evidence	DOID:9119	NA	12	Anti-CD33, Anti-CD123	EXON 12 MUTATION	civic:EID150:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID137	EXON 12 MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19965647' target='_blank'>Burnett et al., 2010, Blood</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	12	All-trans Retinoic Acid	EXON 12 MUTATION	civic:EID137:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID146	EXON 12 MUTATION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19059939' target='_blank'>Schlenk et al., 2009, Haematologica</a>	Acute Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:9119	NA	12	All-trans Retinoic Acid	EXON 12 MUTATION	civic:EID146:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID120	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19059939' target='_blank'>Schlenk et al., 2009, Haematologica</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID120:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID119	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16455956' target='_blank'>Thiede et al., 2006, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID119:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID1369	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16046528' target='_blank'>Boissel et al., 2005, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID1369:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID196	EXON 12 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19587375' target='_blank'>Schnittger et al., 2009, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID196:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID177	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15659725' target='_blank'>Falini et al., 2005, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID177:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID182	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22430270' target='_blank'>Gaidzik et al., 2012, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID182:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID181	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24855211' target='_blank'>Linch et al., 2014, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID181:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID108	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16455956' target='_blank'>Thiede et al., 2006, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID108:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID1102	EXON 12 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26789727' target='_blank'>Ivey et al., 2016, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID1102:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID184	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20026798' target='_blank'>Becker et al., 2010, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID184:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID179	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22417203' target='_blank'>Patel et al., 2012, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID179:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID175	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16455956' target='_blank'>Thiede et al., 2006, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID175:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID180	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19047294' target='_blank'>Büchner et al., 2009, J. Clin. Oncol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID180:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID117	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17957027' target='_blank'>Gale et al., 2008, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID117:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID185	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16051734' target='_blank'>Döhner et al., 2005, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID185:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID116	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19357394' target='_blank'>Vardiman et al., 2009, Blood</a>	Acute Myeloid Leukemia	Diagnostic	A: Validated	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID116:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID174	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19059939' target='_blank'>Schlenk et al., 2009, Haematologica</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID174:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID111	EXON 12 MUTATION	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16076867' target='_blank'>Schnittger et al., 2005, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID111:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID199	EXON 12 MUTATION	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24859829' target='_blank'>Tian et al., 2014, Int. J. Hematol.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID199:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID176	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16076867' target='_blank'>Schnittger et al., 2005, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID176:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID173	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17957027' target='_blank'>Gale et al., 2008, Blood</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID173:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID183	EXON 12 MUTATION	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18450602' target='_blank'>Schlenk et al., 2008, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Prognostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID183:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	NA	NA	EID118	EXON 12 MUTATION	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16076867' target='_blank'>Schnittger et al., 2005, Blood</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	NA	12	NA	EXON 12 MUTATION	civic:EID118:NPM1:exon12	NA	NA	NA	NA	170837530	170837569
NPM1	5	W288fs	frameshift_variant	EID109	W288FS	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	288	NA	NA	W288fs	civic:EID109:NPM1:p.W288	c.860_863dup	5_170837547_G_GTCTG	ENST00000296930	NM_002520	170837541	170837556
NPM1	5	W288fs	frameshift_variant	EID121	W288FS	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21067377' target='_blank'>Ley et al., 2010, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:9119	288	NA	NA	W288fs	civic:EID121:NPM1:p.W288	c.860_863dup	5_170837547_G_GTCTG	ENST00000296930	NM_002520	170837541	170837556
NPM1	5	W288fs	frameshift_variant	EID152	W288FS	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21719597' target='_blank'>Balusu et al., 2011, Blood</a>	Acute Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:9119	288	NA	NSC348884	W288fs	civic:EID152:NPM1:p.W288	c.860_863dup	5_170837547_G_GTCTG	ENST00000296930	NM_002520	170837541	170837556
NPM1	5	W288fs	frameshift_variant	EID153	W288FS	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15659725' target='_blank'>Falini et al., 2005, N. Engl. J. Med.</a>	Acute Myeloid Leukemia	Predictive	E: Indirect evidence	DOID:9119	288	NA	Induction Therapy	W288fs	civic:EID153:NPM1:p.W288	c.860_863dup	5_170837547_G_GTCTG	ENST00000296930	NM_002520	170837541	170837556
ROS1	6	L2155S	missense_variant	EID1256	CD74-ROS1 L2155S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2155	NA	TAE684, Foretinib, Crizotinib	CD74-ROS1 L2155S	civic:EID1256:ROS1:p.L2155	c.6464T>C	6_117630062_A_G	ENST00000368508	NM_002944	117630056	117630067
ROS1	6	G2101A	missense_variant	EID1259	CD74-ROS1 G2101A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2101	NA	Crizotinib	CD74-ROS1 G2101A	civic:EID1259:ROS1:p.G2101	c.6302G>C	6_117631376_C_G	ENST00000368508	NM_002944	117631370	117631381
ROS1	6	G2101A	missense_variant	EID1260	CD74-ROS1 G2101A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2101	NA	Foretinib	CD74-ROS1 G2101A	civic:EID1260:ROS1:p.G2101	c.6302G>C	6_117631376_C_G	ENST00000368508	NM_002944	117631370	117631381
ROS1	6	G2032R	missense_variant	EID1100	CD74-ROS1 G2032R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23724914' target='_blank'>Awad et al., 2013, N. Engl. J. Med.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	2032	NA	Crizotinib	CD74-ROS1 G2032R	civic:EID1100:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	NM_002944	117638341	117638352
ROS1	6	G2032R	missense_variant	EID1101	CD74-ROS1 G2032R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25351743' target='_blank'>Katayama et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2032	NA	Cabozantinib	CD74-ROS1 G2032R	civic:EID1101:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	NM_002944	117638341	117638352
ROS1	6	G2032R	missense_variant	EID1249	CD74-ROS1 G2032R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26372962' target='_blank'>Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2032	NA	Cabozantinib, Foretinib	CD74-ROS1 G2032R	civic:EID1249:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	NM_002944	117638341	117638352
ROS1	6	G2032R	missense_variant	EID1250	CD74-ROS1 G2032R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26372962' target='_blank'>Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2032	NA	AZD3463, Ceritinib, Brigatinib, Crizotinib	CD74-ROS1 G2032R	civic:EID1250:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	NM_002944	117638341	117638352
ROS1	6	G2032R	missense_variant	EID1251	CD74-ROS1 G2032R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25733882' target='_blank'>Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2032	NA	Lorlatinib	CD74-ROS1 G2032R	civic:EID1251:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	NM_002944	117638341	117638352
ROS1	6	G2032R	missense_variant	EID1254	CD74-ROS1 G2032R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	2032	NA	Crizotinib	CD74-ROS1 G2032R	civic:EID1254:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	NM_002944	117638341	117638352
ROS1	6	G2032R	missense_variant	EID1255	CD74-ROS1 G2032R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2032	NA	Foretinib	CD74-ROS1 G2032R	civic:EID1255:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	NM_002944	117638341	117638352
ROS1	6	G2032R	missense_variant	EID2934	G2032R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23724914' target='_blank'>Awad et al., 2013, N. Engl. J. Med.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	2032	NA	Crizotinib	G2032R	civic:EID2934:ROS1:p.G2032	c.6094G>A	6_117638347_C_T	ENST00000368508	NM_002944	117638341	117638352
ROS1	6	L2026M	missense_variant	EID1252	CD74-ROS1 L2026M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25733882' target='_blank'>Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2026	NA	Crizotinib	CD74-ROS1 L2026M	civic:EID1252:ROS1:p.L2026	c.6076C>A	6_117638365_G_T	ENST00000368508	NM_002944	117638359	117638370
ROS1	6	L2026M	missense_variant	EID1253	CD74-ROS1 L2026M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25733882' target='_blank'>Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2026	NA	Lorlatinib	CD74-ROS1 L2026M	civic:EID1253:ROS1:p.L2026	c.6076C>A	6_117638365_G_T	ENST00000368508	NM_002944	117638359	117638370
ROS1	6	L2026M	missense_variant	EID1257	CD74-ROS1 L2026M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2026	NA	Crizotinib	CD74-ROS1 L2026M	civic:EID1257:ROS1:p.L2026	c.6076C>A	6_117638365_G_T	ENST00000368508	NM_002944	117638359	117638370
ROS1	6	L2026M	missense_variant	EID1258	CD74-ROS1 L2026M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25688157' target='_blank'>Song et al., 2015, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	2026	NA	Foretinib	CD74-ROS1 L2026M	civic:EID1258:ROS1:p.L2026	c.6076C>A	6_117638365_G_T	ENST00000368508	NM_002944	117638359	117638370
ESR1	6	S463P	missense_variant	EID1727	S463P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Estrogen-receptor Positive Breast Cancer	Predictive	D: Preclinical evidence	DOID:0060075	463	NA	Aromatase Inhibitor	S463P	civic:EID1727:ESR1:p.S463	c.1387T>C	6_152415537_T_C	ENST00000440973	NM_001122742	152415531	152415542
ESR1	6	L536Q	missense_variant	EID242	L536Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	536	NA	Hormone Therapy	L536Q	civic:EID242:ESR1:p.L536	c.1607_1608delinsAG	6_152419920_TC_AG	ENST00000440973	NM_001122742	152419914	152419926
ESR1	6	L536Q	missense_variant	EID290	L536Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185510' target='_blank'>Robinson et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	536	NA	Fulvestrant, Tamoxifen	L536Q	civic:EID290:ESR1:p.L536	c.1607_1608delinsAG	6_152419920_TC_AG	ENST00000440973	NM_001122742	152419914	152419926
ESR1	6	Y537N	missense_variant	EID245	Y537N	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	537	NA	Hormone Therapy	Y537N	civic:EID245:ESR1:p.Y537	c.1609T>A	6_152419922_T_A	ENST00000440973	NM_001122742	152419916	152419927
ESR1	6	Y537N	missense_variant	EID293	Y537N	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185510' target='_blank'>Robinson et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	537	NA	Fulvestrant, Tamoxifen	Y537N	civic:EID293:ESR1:p.Y537	c.1609T>A	6_152419922_T_A	ENST00000440973	NM_001122742	152419916	152419927
ESR1	6	Y537C	missense_variant	EID244	Y537C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	537	NA	Hormone Therapy	Y537C	civic:EID244:ESR1:p.Y537	c.1610A>G	6_152419923_A_G	ENST00000440973	NM_001122742	152419917	152419928
ESR1	6	Y537C	missense_variant	EID292	Y537C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185510' target='_blank'>Robinson et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	537	NA	Fulvestrant, Tamoxifen	Y537C	civic:EID292:ESR1:p.Y537	c.1610A>G	6_152419923_A_G	ENST00000440973	NM_001122742	152419917	152419928
ESR1	6	Y537S	missense_variant	EID246	Y537S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	537	NA	Hormone Therapy	Y537S	civic:EID246:ESR1:p.Y537	c.1610A>C	6_152419923_A_C	ENST00000440973	NM_001122742	152419917	152419928
ESR1	6	Y537S	missense_variant	EID294	Y537S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185510' target='_blank'>Robinson et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	537	NA	Fulvestrant, Tamoxifen	Y537S	civic:EID294:ESR1:p.Y537	c.1610A>C	6_152419923_A_C	ENST00000440973	NM_001122742	152419917	152419928
ESR1	6	D538G	missense_variant	EID243	D538G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185512' target='_blank'>Toy et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	538	NA	Hormone Therapy	D538G	civic:EID243:ESR1:p.D538	c.1613A>G	6_152419926_A_G	ENST00000440973	NM_001122742	152419920	152419931
ESR1	6	D538G	missense_variant	EID291	D538G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24185510' target='_blank'>Robinson et al., 2013, Nat. Genet.</a>	Breast Cancer	Predictive	D: Preclinical evidence	DOID:1612	538	NA	Fulvestrant, Tamoxifen	D538G	civic:EID291:ESR1:p.D538	c.1613A>G	6_152419926_A_G	ENST00000440973	NM_001122742	152419920	152419931
ESR1	6	D538G	missense_variant	EID4814	D538G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27556863' target='_blank'>Gyanchandani et al., 2016, Oncotarget</a>	Breast Cancer	Predictive	B: Clinical evidence	DOID:1612	538	NA	Letrozole, Palbociclib	D538G	civic:EID4814:ESR1:p.D538	c.1613A>G	6_152419926_A_G	ENST00000440973	NM_001122742	152419920	152419931
RAC1	7	P29S	missense_variant	EID873	P29S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25056119' target='_blank'>Watson et al., 2014, Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	29	NA	Dabrafenib, Vemurafenib	P29S	civic:EID873:RAC1:p.P29	c.85C>T	7_6426892_C_T	ENST00000356142	NM_018890	6426886	6426897
EGFR	7	R108K	missense_variant	EID4186	R108K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17177598' target='_blank'>Lee et al., 2006, PLoS Med.</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	108	NA	Erlotinib	R108K	civic:EID4186:EGFR:p.R108	c.323G>A, c.323_324delinsAG	7_55211080_G_A, 7_55211080_GA_AG	ENST00000275493	NM_005228	55211074	55211086
EGFR	7	NA	NA	EID662	EXON 4 DELETION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23764753' target='_blank'>Zhang et al., 2013, Carcinogenesis</a>	Epithelial Ovarian Cancer	Predictive	D: Preclinical evidence	DOID:2152	NA	4	Cisplatin	EXON 4 DELETION	civic:EID662:EGFR:exon4	NA	NA	NA	NA	55214298	55214433
EGFR	7	T263P	missense_variant	EID4187	T263P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17177598' target='_blank'>Lee et al., 2006, PLoS Med.</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	263	NA	Erlotinib	T263P	civic:EID4187:EGFR:p.T263	c.787A>C, c.787_789delinsCCA, c.787_789delinsCCG, c.787_789delinsCCT	7_55221743_A_C, 7_55221743_ACC_CCA, 7_55221743_ACC_CCG, 7_55221743_ACC_CCT	ENST00000275493	NM_005228	55221737	55221750
EGFR	7	A289V	missense_variant	EID4188	A289V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17177598' target='_blank'>Lee et al., 2006, PLoS Med.</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	289	NA	Erlotinib	A289V	civic:EID4188:EGFR:p.A289	c.866C>T	7_55221822_C_T	ENST00000275493	NM_005228	55221816	55221827
EGFR	7	R451C	missense_variant	EID1081	R451C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	451	NA	Sym004, Panitumumab, Cetuximab	R451C	civic:EID1081:EGFR:p.R451	c.1351C>T	7_55227884_C_T	ENST00000275493	NM_005228	55227878	55227889
EGFR	7	G465R	missense_variant	EID1057	G465R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	465	NA	Sym004	G465R	civic:EID1057:EGFR:p.G465	c.1393G>A	7_55227926_G_A	ENST00000275493	NM_005228	55227920	55227931
EGFR	7	G465R	missense_variant	EID1058	G465R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	465	NA	Panitumumab, Cetuximab	G465R	civic:EID1058:EGFR:p.G465	c.1393G>A	7_55227926_G_A	ENST00000275493	NM_005228	55227920	55227931
EGFR	7	K467T	missense_variant	EID1082	K467T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	467	NA	Sym004, Panitumumab	K467T	civic:EID1082:EGFR:p.K467	c.1400A>C	7_55227933_A_C	ENST00000275493	NM_005228	55227927	55227938
EGFR	7	K467T	missense_variant	EID1083	K467T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	467	NA	Cetuximab	K467T	civic:EID1083:EGFR:p.K467	c.1400A>C	7_55227933_A_C	ENST00000275493	NM_005228	55227927	55227938
EGFR	7	S492R	missense_variant	EID1078	S492R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22270724' target='_blank'>Montagut et al., 2012, Nat. Med.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	492	NA	Panitumumab	S492R	civic:EID1078:EGFR:p.S492	c.1476C>A	7_55228009_C_A	ENST00000275493	NM_005228	55228003	55228014
EGFR	7	S492R	missense_variant	EID1079	S492R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	492	NA	Panitumumab, Sym004	S492R	civic:EID1079:EGFR:p.S492	c.1476C>A	7_55228009_C_A	ENST00000275493	NM_005228	55228003	55228014
EGFR	7	S492R	missense_variant	EID1080	S492R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26888827' target='_blank'>Sánchez-Martín et al., 2016, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	492	NA	Cetuximab	S492R	civic:EID1080:EGFR:p.S492	c.1476C>A	7_55228009_C_A	ENST00000275493	NM_005228	55228003	55228014
EGFR	7	S492R	missense_variant	EID717	S492R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22270724' target='_blank'>Montagut et al., 2012, Nat. Med.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	492	NA	Cetuximab	S492R	civic:EID717:EGFR:p.S492	c.1476C>A	7_55228009_C_A	ENST00000275493	NM_005228	55228003	55228014
EGFR	7	R705K	missense_variant	EID6182	R705K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23749122' target='_blank'>Locatelli-Sanchez et al., 2013, Lung</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	705	NA	Gefitinib, Erlotinib	R705K	civic:EID6182:EGFR:p.R705	c.2114G>A, c.2114_2115delinsAA	7_55241666_G_A, 7_55241666_GG_AA	ENST00000275493	NM_005228	55241660	55241672
EGFR	7	G719S	missense_variant	EID1736	G719S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26124334' target='_blank'>Otsuka et al., 2015, Anticancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	719	NA	Erlotinib, Gefitinib	G719S	civic:EID1736:EGFR:p.G719	c.2155G>A	7_55241707_G_A	ENST00000275493	NM_005228	55241701	55241712
EGFR	7	G719S	missense_variant	EID274	G719S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15118125' target='_blank'>Paez et al., 2004, Science</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	719	NA	Gefitinib	G719S	civic:EID274:EGFR:p.G719	c.2155G>A	7_55241707_G_A	ENST00000275493	NM_005228	55241701	55241712
EGFR	7	G719S	missense_variant	EID4190	G719S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	719	NA	Erlotinib	G719S	civic:EID4190:EGFR:p.G719	c.2155G>A	7_55241707_G_A	ENST00000275493	NM_005228	55241701	55241712
EGFR	7	G719S	missense_variant	EID787	G719S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24894453' target='_blank'>Cho et al., 2014, Mol. Cancer</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	719	NA	Cetuximab	G719S	civic:EID787:EGFR:p.G719	c.2155G>A	7_55241707_G_A	ENST00000275493	NM_005228	55241701	55241712
EGFR	7	G719A	missense_variant	EID2508	G719A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20038723' target='_blank'>Douillard et al., 2010, J. Clin. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	719	NA	Gefitinib	G719A	civic:EID2508:EGFR:p.G719	c.2156G>C	7_55241708_G_C	ENST00000275493	NM_005228	55241702	55241713
EGFR	7	G719A	missense_variant	EID6181	G719A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23749122' target='_blank'>Locatelli-Sanchez et al., 2013, Lung</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	719	NA	Gefitinib, Erlotinib	G719A	civic:EID6181:EGFR:p.G719	c.2156G>C	7_55241708_G_C	ENST00000275493	NM_005228	55241702	55241713
EGFR	7	G719D	missense_variant	EID4210	G719D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	719	NA	Gefitinib, Erlotinib	G719D	civic:EID4210:EGFR:p.G719	c.2156G>A, c.2156_2157delinsAT	7_55241708_G_A, 7_55241708_GC_AT	ENST00000275493	NM_005228	55241702	55241714
EGFR	7	NA	NA	EID1780	G719	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26773740' target='_blank'>Klughammer et al., 2016, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	719	NA	Erlotinib	G719	civic:EID1780:EGFR:p.G719	NA	NA	NA	NA	55241706	55241708
EGFR	7	NA	NA	EID4189	G719	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	719	NA	Gefitinib, Erlotinib	G719	civic:EID4189:EGFR:p.G719	NA	NA	NA	NA	55241706	55241708
EGFR	7	NA	NA	EID1782	S720	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26773740' target='_blank'>Klughammer et al., 2016, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	720	NA	Erlotinib	S720	civic:EID1782:EGFR:p.S720	NA	NA	NA	NA	55241709	55241711
EGFR	7	G724S	missense_variant	EID786	G724S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24894453' target='_blank'>Cho et al., 2014, Mol. Cancer</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	724	NA	Cetuximab	G724S	civic:EID786:EGFR:p.G724	c.2170G>A	7_55241722_G_A	ENST00000275493	NM_005228	55241716	55241727
EGFR	7	NA	NA	EID273	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16730237' target='_blank'>Ji et al., 2006, Cancer Cell</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	19	Gefitinib	EXON 19 DELETION	civic:EID273:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID413	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16818686' target='_blank'>Jackman et al., 2006, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	19	Gefitinib, Erlotinib	EXON 19 DELETION	civic:EID413:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID880	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23816960' target='_blank'>Sequist et al., 2013, J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	19	Afatinib	EXON 19 DELETION	civic:EID880:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID881	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25862853' target='_blank'>Banno et al., 2015, Anticancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	19	Afatinib	EXON 19 DELETION	civic:EID881:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID882	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22452895' target='_blank'>Yang et al., 2012, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	19	Afatinib	EXON 19 DELETION	civic:EID882:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID884	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22285168' target='_blank'>Rosell et al., 2012, Lancet Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	19	Erlotinib	EXON 19 DELETION	civic:EID884:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID969	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26515464' target='_blank'>Hirano et al., 2015, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	NA	19	Afatinib	EXON 19 DELETION	civic:EID969:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID981	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24439929' target='_blank'>Wu et al., 2014, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	19	Afatinib	EXON 19 DELETION	civic:EID981:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID983	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25589191' target='_blank'>Yang et al., 2015, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	19	Afatinib	EXON 19 DELETION	civic:EID983:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID1666	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18509184' target='_blank'>Yang et al., 2008, J. Clin. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	19	Gefitinib	EXON 19 DELETION	civic:EID1666:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID2519	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22370314' target='_blank'>Han et al., 2012, J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	19	Gefitinib	EXON 19 DELETION	civic:EID2519:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID2995	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24868098' target='_blank'>Khozin et al., 2014, Oncologist</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	NA	19	Erlotinib	EXON 19 DELETION	civic:EID2995:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID2996	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23982599' target='_blank'>Dungo et al., 2013, Drugs</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	NA	19	Afatinib	EXON 19 DELETION	civic:EID2996:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID4766	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27566387' target='_blank'>Kanemaru et al., 2016, Respir Investig</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	19	Erlotinib	EXON 19 DELETION	civic:EID4766:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID4859	EXON 19 DELETION	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26768165' target='_blank'>Ramalingam et al., 2016, Ann. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	NA	19	Dacomitinib, Erlotinib	EXON 19 DELETION	civic:EID4859:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	NA	NA	EID6184	EXON 19 DELETION	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27022112' target='_blank'>Urata et al., 2016, J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	19	Gefitinib	EXON 19 DELETION	civic:EID6184:EGFR:exon19	NA	NA	NA	NA	55242414	55242513
EGFR	7	W731L	missense_variant	EID4655	W731L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	731	NA	Erlotinib	W731L	civic:EID4655:EGFR:p.W731	c.2191_2192delinsCT, c.2191_2193delinsCTA, c.2191_2193delinsCTC, c.2191_2193delinsCTT, c.2192G>T, c.2192_2193delinsTA	7_55242421_TG_CT, 7_55242421_TGG_CTA, 7_55242421_TGG_CTC, 7_55242421_TGG_CTT, 7_55242422_G_T, 7_55242422_GG_TA	ENST00000275493	NM_005228	55242415	55242428
EGFR	7	E734Q	missense_variant	EID4656	E734Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	734	NA	Erlotinib	E734Q	civic:EID4656:EGFR:p.E734	c.2200G>C, c.2200_2202delinsCAG	7_55242430_G_C, 7_55242430_GAA_CAG	ENST00000275493	NM_005228	55242424	55242437
EGFR	7	V742A	missense_variant	EID4197	V742A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	742	NA	Erlotinib	V742A	civic:EID4197:EGFR:p.V742	c.2225T>C, c.2225_2226delinsCA, c.2225_2226delinsCG, c.2225_2226delinsCT	7_55242455_T_C, 7_55242455_TC_CA, 7_55242455_TC_CG, 7_55242455_TC_CT	ENST00000275493	NM_005228	55242449	55242461
EGFR	7	E746G	missense_variant	EID1787	E746G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26773740' target='_blank'>Klughammer et al., 2016, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	746	NA	Erlotinib	E746G	civic:EID1787:EGFR:p.E746	c.2237A>G	7_55242467_A_G	ENST00000275493	NM_005228	55242461	55242472
EGFR	7	L747P	missense_variant	EID4220	L747P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	747	NA	Erlotinib	L747P	civic:EID4220:EGFR:p.L747	c.2239_2240delinsCC, c.2239_2241delinsCCC, c.2239_2241delinsCCG, c.2239_2241delinsCCT	7_55242469_TT_CC, 7_55242469_TTA_CCC, 7_55242469_TTA_CCG, 7_55242469_TTA_CCT	ENST00000275493	NM_005228	55242463	55242476
EGFR	7	P753S	missense_variant	EID1089	P753S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24934779' target='_blank'>Ganesan et al., 2016, J. Clin. Oncol.</a>	Skin Squamous Cell Carcinoma	Predictive	C: Case study	DOID:3151	753	NA	Rapamycin (Sirolimus), Cetuximab	P753S	civic:EID1089:EGFR:p.P753	c.2257C>T	7_55242487_C_T	ENST00000275493	NM_005228	55242481	55242492
EGFR	7	K757R	missense_variant	EID1786	K757R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26773740' target='_blank'>Klughammer et al., 2016, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	757	NA	Erlotinib	K757R	civic:EID1786:EGFR:p.K757	c.2270A>G	7_55242500_A_G	ENST00000275493	NM_005228	55242494	55242505
EGFR	7	D761Y	missense_variant&splice_region_variant	EID1763	D761Y	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17085664' target='_blank'>Balak et al., 2006, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	761	NA	Erlotinib, Gefitinib	D761Y	civic:EID1763:EGFR:p.D761	c.2281G>T	7_55242511_G_T	ENST00000275493	NM_005228	55242505	55242516
EGFR	7	A763_Y764insFQEA	inframe_insertion	EID4497	A763_Y764insFQEA	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	763	NA	Erlotinib	A763_Y764insFQEA	civic:EID4497:EGFR:p.A763_Y764	c.2284-5_2290dup	7_55248992_T_TTCCAGGAAGCCT	ENST00000275493	NM_005228	55248986	55249009
EGFR	7	NA	NA	EID4650	EXON 20 INSERTION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22895145' target='_blank'>Lund-Iversen et al., 2012, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	NA	20	Erlotinib	EXON 20 INSERTION	civic:EID4650:EGFR:exon20	NA	NA	NA	NA	55248990	55249022
EGFR	7	NA	NA	EID1809	EXON 20 INSERTION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26051236' target='_blank'>Yang et al., 2015, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	NA	20	Afatinib	EXON 20 INSERTION	civic:EID1809:EGFR:exon20	NA	NA	NA	NA	55248990	55249022
EGFR	7	A767_V769dup	inframe_insertion	EID4665	A767_V769dupASV	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	767	NA	Erlotinib	A767_V769dupASV	civic:EID4665:EGFR:p.A767_V769	c.2300_2308dup	7_55249000_G_GGCCAGCGTG	ENST00000275493	NM_005228	55248994	55249014
EGFR	7	S768I	missense_variant	EID1394	S768I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25521405' target='_blank'>Hellmann et al., 2014, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	768	NA	Erlotinib	S768I	civic:EID1394:EGFR:p.S768	c.2303G>T	7_55249005_G_T	ENST00000275493	NM_005228	55248999	55249010
EGFR	7	S768I	missense_variant	EID1395	S768I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20522446' target='_blank'>Masago et al., 2010, Jpn. J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	768	NA	Gefitinib	S768I	civic:EID1395:EGFR:p.S768	c.2303G>T	7_55249005_G_T	ENST00000275493	NM_005228	55248999	55249010
EGFR	7	S768I	missense_variant	EID2906	S768I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27211795' target='_blank'>Leventakos et al., 2016, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	768	NA	Erlotinib	S768I	civic:EID2906:EGFR:p.S768	c.2303G>T	7_55249005_G_T	ENST00000275493	NM_005228	55248999	55249010
EGFR	7	S768I	missense_variant	EID4273	S768I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22895145' target='_blank'>Lund-Iversen et al., 2012, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	768	NA	Erlotinib	S768I	civic:EID4273:EGFR:p.S768	c.2303G>T	7_55249005_G_T	ENST00000275493	NM_005228	55248999	55249010
EGFR	7	S768I	missense_variant	EID4274	S768I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	768	NA	Erlotinib	S768I	civic:EID4274:EGFR:p.S768	c.2303G>T	7_55249005_G_T	ENST00000275493	NM_005228	55248999	55249010
EGFR	7	A767_V769dup	inframe_insertion	EID1799	V769_770insASV	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26773740' target='_blank'>Klughammer et al., 2016, J Thorac Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	767	NA	Erlotinib	V769_770insASV	civic:EID1799:EGFR:p.A767_V769	c.2300_2308dup	7_55249009_G_GGCCAGCGTG	ENST00000275493	NM_005228	55249003	55249023
EGFR	7	D770_N771insGL	inframe_insertion	EID4494	D770_N771insGL	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	770	NA	Erlotinib	D770_N771insGL	civic:EID4494:EGFR:p.D770_N771	c.2310_2311insGGGTTA	7_55249012_C_CGGGTTA	ENST00000275493	NM_005228	55249006	55249023
EGFR	7	D770_N771insGT	inframe_insertion	EID4643	D770_N771insGT	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23371856' target='_blank'>Arcila et al., 2013, Mol. Cancer Ther.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	770	NA	Erlotinib	D770_N771insGT	civic:EID4643:EGFR:p.D770_N771	c.2310_2311insGGCACA	7_55249012_C_CGGCACA	ENST00000275493	NM_005228	55249006	55249023
EGFR	7	N771_H773dup	inframe_insertion	EID4493	H773_V774insNPH	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	771	NA	Erlotinib	H773_V774insNPH	civic:EID4493:EGFR:p.N771_H773	c.2311_2319dup	7_55249012_C_CAACCCCCAC	ENST00000275493	NM_005228	55249006	55249026
EGFR	7	S768_D770dup	inframe_insertion	EID4275	D770_N771insSVD	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	768	NA	Erlotinib	D770_N771insSVD	civic:EID4275:EGFR:p.S768_D770	c.2303_2311dup	7_55249013_A_AGCGTGGACA	ENST00000275493	NM_005228	55249007	55249027
EGFR	7	V774M	missense_variant	EID4231	V774M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	774	NA	Erlotinib	V774M	civic:EID4231:EGFR:p.V774	c.2320G>A	7_55249022_G_A	ENST00000275493	NM_005228	55249016	55249027
EGFR	7	V774A	missense_variant	EID4226	V774A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	774	NA	Gefitinib	V774A	civic:EID4226:EGFR:p.V774	c.2321T>C, c.2321_2322inv, c.2321_2322delinsCC, c.2321_2322delinsCT	7_55249023_T_C, 7_55249023_TG_CA, 7_55249023_TG_CC, 7_55249023_TG_CT	ENST00000275493	NM_005228	55249017	55249029
EGFR	7	R776C	missense_variant	EID4468	R776C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	776	NA	Erlotinib	R776C	civic:EID4468:EGFR:p.R776	c.2326C>T, c.2326_2328delinsTGT	7_55249028_C_T, 7_55249028_CGC_TGT	ENST00000275493	NM_005228	55249022	55249035
EGFR	7	T785A	missense_variant	EID4657	T785A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	785	NA	Erlotinib	T785A	civic:EID4657:EGFR:p.T785	c.2353A>G, c.2353_2355delinsGCA, c.2353_2355delinsGCG, c.2353_2355delinsGCT	7_55249055_A_G, 7_55249055_ACC_GCA, 7_55249055_ACC_GCG, 7_55249055_ACC_GCT	ENST00000275493	NM_005228	55249049	55249062
EGFR	7	T790M	missense_variant	EID1391	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23470965' target='_blank'>Yu et al., 2013, Clin. Cancer Res.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	790	NA	Gefitinib, Erlotinib	T790M	civic:EID1391:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID1397	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26181354' target='_blank'>Yu et al., 2015, JAMA Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	790	NA	Osimertinib	T790M	civic:EID1397:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID1592	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26729184' target='_blank'>Greig, 2016, Drugs</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	790	NA	Osimertinib	T790M	civic:EID1592:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID1667	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27304188' target='_blank'>Belchis et al., 2016, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	790	NA	Gefitinib, Erlotinib, Afatinib	T790M	civic:EID1667:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID1863	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24035188' target='_blank'>Sun et al., 2013, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	790	NA	Afatinib	T790M	civic:EID1863:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID1867	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27959700' target='_blank'>Mok et al., 2016, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	790	NA	Osimertinib	T790M	civic:EID1867:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID2157	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26269204' target='_blank'>Planchard et al., 2015, Ann. Oncol.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	790	NA	Osimertinib	T790M	civic:EID2157:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID2158	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15737014' target='_blank'>Pao et al., 2005, PLoS Med.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	790	NA	Gefitinib	T790M	civic:EID2158:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID2159	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17020982' target='_blank'>Kosaka et al., 2006, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	790	NA	Gefitinib	T790M	civic:EID2159:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID2160	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	790	NA	Lapatinib	T790M	civic:EID2160:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID2161	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18089823' target='_blank'>Engelman et al., 2007, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	790	NA	PF 00299804	T790M	civic:EID2161:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID2162	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16818618' target='_blank'>Shimamura et al., 2006, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	790	NA	Neratinib	T790M	civic:EID2162:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID2163	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	790	NA	Afatinib	T790M	civic:EID2163:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID2164	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21732342' target='_blank'>Cha et al., 2012, Int. J. Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	790	NA	Afatinib	T790M	civic:EID2164:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID2165	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	790	NA	Canertinib	T790M	civic:EID2165:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID238	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25668228' target='_blank'>Denis et al., 2015, Clin. Chim. Acta</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	790	NA	Erlotinib	T790M	civic:EID238:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID239	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15728811' target='_blank'>Kobayashi et al., 2005, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	790	NA	Gefitinib	T790M	civic:EID239:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID240	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21430269' target='_blank'>Sequist et al., 2011, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	790	NA	Dacomitinib	T790M	civic:EID240:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID277	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24636847' target='_blank'>Li et al., 2014, Lung Cancer</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	790	NA	Erlotinib, Pemetrexed	T790M	civic:EID277:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID278	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24658966' target='_blank'>Ai et al., 2014, Amino Acids</a>	Non-small Cell Lung Carcinoma	Predictive	E: Indirect evidence	DOID:3908	790	NA	Staurosporine	T790M	civic:EID278:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID369	T790M	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24623981' target='_blank'>Ding et al., 2014, Onco Targets Ther</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	790	NA	NA	T790M	civic:EID369:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID370	T790M	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24729716' target='_blank'>Li et al., 2014, Onco Targets Ther</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	790	NA	NA	T790M	civic:EID370:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID642	T790M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18227510' target='_blank'>Yun et al., 2008, Proc. Natl. Acad. Sci. U.S.A.</a>	Lung Cancer	Predictive	D: Preclinical evidence	DOID:1324	790	NA	Gefitinib, AEE788	T790M	civic:EID642:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID646	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25923550' target='_blank'>Sequist et al., 2015, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	790	NA	Rociletinib	T790M	civic:EID646:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID762	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24065731' target='_blank'>Walter et al., 2013, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	790	NA	Rociletinib	T790M	civic:EID762:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID963	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24893891' target='_blank'>Cross et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	790	NA	Osimertinib	T790M	civic:EID963:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID965	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25923549' target='_blank'>Jänne et al., 2015, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	790	NA	Osimertinib	T790M	civic:EID965:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID966	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26720284' target='_blank'>Sequist et al., 2016, JAMA Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	790	NA	Osimertinib	T790M	civic:EID966:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	T790M	missense_variant	EID967	T790M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26515464' target='_blank'>Hirano et al., 2015, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	790	NA	Osimertinib, Rociletinib	T790M	civic:EID967:EGFR:p.T790	c.2369C>T	7_55249071_C_T	ENST00000275493	NM_005228	55249065	55249076
EGFR	7	L792P	missense_variant	EID4220	L747P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	792	NA	Erlotinib	L747P	civic:EID4220:EGFR:p.L792	c.2375T>C, c.2375_2376delinsCA, c.2375_2376delinsCG, c.2375_2376delinsCT	7_55249077_T_C, 7_55249077_TC_CA, 7_55249077_TC_CG, 7_55249077_TC_CT	ENST00000275493	NM_005228	55249071	55249083
EGFR	7	C797S	missense_variant	EID1396	C797S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26181354' target='_blank'>Yu et al., 2015, JAMA Oncol</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	797	NA	Osimertinib	C797S	civic:EID1396:EGFR:p.C797	c.2389T>A	7_55249091_T_A	ENST00000275493	NM_005228	55249085	55249096
EGFR	7	C797S	missense_variant	EID964	C797S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25939061' target='_blank'>Thress et al., 2015, Nat. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	797	NA	Osimertinib	C797S	civic:EID964:EGFR:p.C797	c.2389T>A	7_55249091_T_A	ENST00000275493	NM_005228	55249085	55249096
EGFR	7	C797Y	missense_variant	EID4658	C797Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	797	NA	Erlotinib	C797Y	civic:EID4658:EGFR:p.C797	c.2390G>A	7_55249092_G_A	ENST00000275493	NM_005228	55249086	55249097
EGFR	7	Y801H	missense_variant	EID4659	Y801H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	801	NA	Erlotinib	Y801H	civic:EID4659:EGFR:p.Y801	c.2401T>C, c.2401_2403delinsCAC	7_55249103_T_C, 7_55249103_TAT_CAC	ENST00000275493	NM_005228	55249097	55249110
EGFR	7	K806E	missense_variant	EID4239	K806E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	806	NA	Gefitinib	K806E	civic:EID4239:EGFR:p.K806	c.2416A>G	7_55249118_A_G	ENST00000275493	NM_005228	55249112	55249123
EGFR	7	V819M	missense_variant	EID4231	V774M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	819	NA	Erlotinib	V774M	civic:EID4231:EGFR:p.V819	c.2455G>A	7_55249157_G_A	ENST00000275493	NM_005228	55249151	55249162
EGFR	7	V819A	missense_variant	EID4226	V774A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	819	NA	Gefitinib	V774A	civic:EID4226:EGFR:p.V819	c.2456T>C, c.2456_2457inv, c.2456_2457delinsCT, c.2456_2457delinsCC	7_55249158_T_C, 7_55249158_TG_CA, 7_55249158_TG_CT, 7_55249158_TG_CC	ENST00000275493	NM_005228	55249152	55249164
EGFR	7	N826S	missense_variant	EID4496	N826S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	826	NA	Erlotinib	N826S	civic:EID4496:EGFR:p.N826	c.2476_2477delinsTC, c.2476_2478delinsTCA, c.2476_2478delinsTCG, c.2476_2478delinsTCT, c.2477A>G, c.2477_2478inv	7_55259418_AA_TC, 7_55259418_AAC_TCA, 7_55259418_AAC_TCG, 7_55259418_AAC_TCT, 7_55259419_A_G, 7_55259419_AC_GT	ENST00000275493	NM_005228	55259412	55259425
EGFR	7	N826Y	missense_variant	EID4244	N826Y	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	826	NA	Erlotinib	N826Y	civic:EID4244:EGFR:p.N826	c.2476A>T, c.2476_2478delinsTAT	7_55259418_A_T, 7_55259418_AAC_TAT	ENST00000275493	NM_005228	55259412	55259425
EGFR	7	R831H	missense_variant	EID4279	R831H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	831	NA	Erlotinib	R831H	civic:EID4279:EGFR:p.R831	c.2492G>A	7_55259434_G_A	ENST00000275493	NM_005228	55259428	55259439
EGFR	7	V834I	missense_variant	EID4248	V834I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	834	NA	Gefitinib	V834I	civic:EID4248:EGFR:p.V834	c.2500_2502delinsATA, c.2500_2502delinsATC, c.2500_2502delinsATT	7_55259442_GTG_ATA, 7_55259442_GTG_ATC, 7_55259442_GTG_ATT	ENST00000275493	NM_005228	55259436	55259449
EGFR	7	L838V	missense_variant	EID4280	L838V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	838	NA	Erlotinib	L838V	civic:EID4280:EGFR:p.L838	c.2512C>G, c.2512_2514delinsGTC, c.2512_2514delinsGTA, c.2512_2514delinsGTT	7_55259454_C_G, 7_55259454_CTG_GTC, 7_55259454_CTG_GTA, 7_55259454_CTG_GTT	ENST00000275493	NM_005228	55259448	55259461
EGFR	7	L838P	missense_variant	EID4252	L838P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	838	NA	Gefitinib	L838P	civic:EID4252:EGFR:p.L838	c.2513T>C, c.2513_2514delinsCC, c.2513_2514inv, c.2513_2514delinsCT	7_55259455_T_C, 7_55259455_TG_CC, 7_55259455_TG_CA, 7_55259455_TG_CT	ENST00000275493	NM_005228	55259449	55259461
EGFR	7	N842S	missense_variant	EID4256	N842S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	842	NA	Gefitinib	N842S	civic:EID4256:EGFR:p.N842	c.2524_2525delinsTC, c.2524_2526delinsTCG, c.2524_2526delinsTCT, c.2524_2526delinsTCA, c.2525A>G, c.2525_2526inv	7_55259466_AA_TC, 7_55259466_AAC_TCG, 7_55259466_AAC_TCT, 7_55259466_AAC_TCA, 7_55259467_A_G, 7_55259467_AC_GT	ENST00000275493	NM_005228	55259460	55259473
EGFR	7	T847I	missense_variant	EID4260	T847I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	847	NA	Gefitinib	T847I	civic:EID4260:EGFR:p.T847	c.2540C>T, c.2540_2541delinsTT, c.2540_2541delinsTC	7_55259482_C_T, 7_55259482_CA_TT, 7_55259482_CA_TC	ENST00000275493	NM_005228	55259476	55259488
EGFR	7	V851I	missense_variant	EID4264	V851I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	851	NA	Erlotinib	V851I	civic:EID4264:EGFR:p.V851	c.2551G>A, c.2551_2553delinsATA, c.2551_2553delinsATT	7_55259493_G_A, 7_55259493_GTC_ATA, 7_55259493_GTC_ATT	ENST00000275493	NM_005228	55259487	55259500
EGFR	7	L858R	missense_variant	EID1665	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18509184' target='_blank'>Yang et al., 2008, J. Clin. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	858	NA	Gefitinib	L858R	civic:EID1665:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID229	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24736073' target='_blank'>Lim et al., 2014, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	858	NA	Gefitinib, Erlotinib	L858R	civic:EID229:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2621	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20038723' target='_blank'>Douillard et al., 2010, J. Clin. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	858	NA	Gefitinib	L858R	civic:EID2621:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2624	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15329413' target='_blank'>Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	858	NA	Gefitinib	L858R	civic:EID2624:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2625	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24893891' target='_blank'>Cross et al., 2014, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	Gefitinib	L858R	civic:EID2625:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2626	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	Lapatinib	L858R	civic:EID2626:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2627	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18089823' target='_blank'>Engelman et al., 2007, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	PF 00299804	L858R	civic:EID2627:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2628	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16818618' target='_blank'>Shimamura et al., 2006, Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	Neratinib	L858R	civic:EID2628:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2629	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	Afatinib	L858R	civic:EID2629:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2631	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	Canertinib	L858R	civic:EID2631:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2632	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15329413' target='_blank'>Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	858	NA	Erlotinib	L858R	civic:EID2632:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2634	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22370314' target='_blank'>Han et al., 2012, J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	858	NA	Gefitinib	L858R	civic:EID2634:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID275	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24457318' target='_blank'>Fukihara et al., 2014, Oncology</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	858	NA	Gefitinib, Erlotinib	L858R	civic:EID275:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID276	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15118125' target='_blank'>Paez et al., 2004, Science</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	Gefitinib	L858R	civic:EID276:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2994	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24868098' target='_blank'>Khozin et al., 2014, Oncologist</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	858	NA	Erlotinib	L858R	civic:EID2994:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID2997	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23982599' target='_blank'>Dungo et al., 2013, Drugs</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	858	NA	Afatinib	L858R	civic:EID2997:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID347	L858R	Better Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24662454' target='_blank'>Douillard et al., 2014, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	858	NA	NA	L858R	civic:EID347:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID3811	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	858	NA	Gefitinib, Erlotinib, AEE788	L858R	civic:EID3811:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID4265	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17877814' target='_blank'>de Gunst et al., 2007, Mol. Cancer</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	858	NA	Erlotinib	L858R	civic:EID4265:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID4284	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18408761' target='_blank'>Li et al., 2008, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	Erlotinib	L858R	civic:EID4284:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID4285	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21132006' target='_blank'>Harada et al., 2011, Oncogene</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	Erlotinib	L858R	civic:EID4285:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID4286	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24353160' target='_blank'>Yasuda et al., 2013, Sci Transl Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	Erlotinib	L858R	civic:EID4286:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID4287	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27612423' target='_blank'>Ray et al., 2016, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	Erlotinib	L858R	civic:EID4287:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID4288	L858R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22235099' target='_blank'>Doebele et al., 2012, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	858	NA	Crizotinib	L858R	civic:EID4288:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID4290	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27032107' target='_blank'>De Grève et al., 2016, PLoS ONE</a>	Lung Adenocarcinoma	Predictive	C: Case study	DOID:3910	858	NA	Erlotinib	L858R	civic:EID4290:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID4291	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27102076' target='_blank'>Konduri et al., 2016, Cancer Discov</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	858	NA	Erlotinib	L858R	civic:EID4291:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID4292	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27102076' target='_blank'>Konduri et al., 2016, Cancer Discov</a>	Lung Adenocarcinoma	Predictive	D: Preclinical evidence	DOID:3910	858	NA	Cetuximab	L858R	civic:EID4292:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID4295	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17177598' target='_blank'>Lee et al., 2006, PLoS Med.</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	858	NA	Erlotinib	L858R	civic:EID4295:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID4860	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26768165' target='_blank'>Ramalingam et al., 2016, Ann. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	858	NA	Dacomitinib	L858R	civic:EID4860:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID6183	L858R	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27022112' target='_blank'>Urata et al., 2016, J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	858	NA	Gefitinib	L858R	civic:EID6183:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID879	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23816960' target='_blank'>Sequist et al., 2013, J. Clin. Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	858	NA	Afatinib	L858R	civic:EID879:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID883	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22452895' target='_blank'>Yang et al., 2012, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	858	NA	Afatinib	L858R	civic:EID883:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID885	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22285168' target='_blank'>Rosell et al., 2012, Lancet Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	858	NA	Erlotinib	L858R	civic:EID885:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID968	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26515464' target='_blank'>Hirano et al., 2015, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	858	NA	Afatinib	L858R	civic:EID968:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L858R	missense_variant	EID982	L858R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24439929' target='_blank'>Wu et al., 2014, Lancet Oncol.</a>	Lung Adenocarcinoma	Predictive	B: Clinical evidence	DOID:3910	858	NA	Afatinib	L858R	civic:EID982:EGFR:p.L858	c.2573T>G	7_55259515_T_G	ENST00000275493	NM_005228	55259509	55259520
EGFR	7	L861R	missense_variant	EID4669	L861R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	861	NA	Gefitinib	L861R	civic:EID4669:EGFR:p.L861	c.2581_2582inv, c.2581_2583delinsAGA, c.2582T>G, c.2582_2583delinsGA, c.2582_2583delinsGT, c.2582_2583delinsGC	7_55259523_CT_AG, 7_55259523_CTG_AGA, 7_55259524_T_G, 7_55259524_TG_GA, 7_55259524_TG_GT, 7_55259524_TG_GC	ENST00000275493	NM_005228	55259517	55259530
EGFR	7	L861Q	missense_variant	EID3802	L861Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	861	NA	Gefitinib	L861Q	civic:EID3802:EGFR:p.L861	c.2582T>A, c.2582_2583delinsAA	7_55259524_T_A, 7_55259524_TG_AA	ENST00000275493	NM_005228	55259518	55259530
EGFR	7	L861Q	missense_variant	EID4299	L861Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17177598' target='_blank'>Lee et al., 2006, PLoS Med.</a>	Malignant Glioma	Predictive	D: Preclinical evidence	DOID:3070	861	NA	Erlotinib	L861Q	civic:EID4299:EGFR:p.L861	c.2582T>A, c.2582_2583delinsAA	7_55259524_T_A, 7_55259524_TG_AA	ENST00000275493	NM_005228	55259518	55259530
EGFR	7	A864T	missense_variant	EID4495	A864T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	864	NA	Erlotinib	A864T	civic:EID4495:EGFR:p.A864	c.2590G>A	7_55259532_G_A	ENST00000275493	NM_005228	55259526	55259537
EGFR	7	E868G	missense_variant	EID4301	E868G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20942962' target='_blank'>Foster et al., 2010, World J Surg Oncol</a>	Malignant Mesothelioma	Predictive	D: Preclinical evidence	DOID:1790	868	NA	Erlotinib	E868G	civic:EID4301:EGFR:p.E868	c.2603A>G, c.2603_2604delinsGT, c.2603_2604delinsGG, c.2603_2604delinsGC	7_55259545_A_G, 7_55259545_AA_GT, 7_55259545_AA_GG, 7_55259545_AA_GC	ENST00000275493	NM_005228	55259539	55259551
EGFR	7	L883P	missense_variant	EID4252	L838P	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	883	NA	Gefitinib	L838P	civic:EID4252:EGFR:p.L883	c.2647_2648delinsCC, c.2647_2649delinsCCT, c.2647_2649delinsCCA, c.2647_2649delinsCCC	7_55260480_TT_CC, 7_55260480_TTG_CCT, 7_55260480_TTG_CCA, 7_55260480_TTG_CCC	ENST00000275493	NM_005228	55260474	55260487
EGFR	7	L883V	missense_variant	EID4280	L838V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19147750' target='_blank'>Kancha et al., 2009, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	883	NA	Erlotinib	L838V	civic:EID4280:EGFR:p.L883	c.2647T>G, c.2647_2649delinsGTT, c.2647_2649delinsGTA, c.2647_2649delinsGTC	7_55260480_T_G, 7_55260480_TTG_GTT, 7_55260480_TTG_GTA, 7_55260480_TTG_GTC	ENST00000275493	NM_005228	55260474	55260487
EGFR	7	T892I	missense_variant	EID4260	T847I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	892	NA	Gefitinib	T847I	civic:EID4260:EGFR:p.T892	c.2675C>T, c.2675_2676delinsTA, c.2675_2676delinsTT	7_55260508_C_T, 7_55260508_CC_TA, 7_55260508_CC_TT	ENST00000275493	NM_005228	55260502	55260514
EGFR	7	V904I	missense_variant	EID4264	V851I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21531810' target='_blank'>Wu et al., 2011, Clin. Cancer Res.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	904	NA	Erlotinib	V851I	civic:EID4264:EGFR:p.V904	c.2710G>A, c.2710_2712delinsATA, c.2710_2712delinsATC	7_55266418_G_A, 7_55266418_GTT_ATA, 7_55266418_GTT_ATC	ENST00000275493	NM_005228	55266412	55266425
MET	7	D1246N	missense_variant	EID1652	D1228N	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27343442' target='_blank'>Heist et al., 2016, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1246	NA	Crizotinib	D1228N	civic:EID1652:MET:p.D1246	c.3736G>A	7_116423407_G_A	ENST00000318493	NA	116423401	116423412
MET	7	D1246V	missense_variant	EID1864	D1228V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27694386' target='_blank'>Bahcall et al., 2016, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1246	NA	Cabozantinib	D1228V	civic:EID1864:MET:p.D1246	c.3737A>T	7_116423408_A_T	ENST00000318493	NA	116423402	116423413
MET	7	D1246V	missense_variant	EID1865	D1228V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27694386' target='_blank'>Bahcall et al., 2016, Cancer Discov</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	1246	NA	Savolitinib	D1228V	civic:EID1865:MET:p.D1246	c.3737A>T	7_116423408_A_T	ENST00000318493	NA	116423402	116423413
SMO	7	L412F	missense_variant	EID4653	L412F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25759020' target='_blank'>Atwood et al., 2015, Cancer Cell</a>	Basal Cell Carcinoma	Predictive	D: Preclinical evidence	DOID:2513	412	NA	Vismodegib	L412F	civic:EID4653:SMO:p.L412	c.1234C>T	7_128846398_C_T	ENST00000249373	NM_005631	128846392	128846403
SMO	7	L412F	missense_variant	EID4654	L412F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26822128' target='_blank'>Khamaysi et al., 2016, Br. J. Dermatol.</a>	Basal Cell Carcinoma	Predictive	C: Case study	DOID:2513	412	NA	Vismodegib	L412F	civic:EID4654:SMO:p.L412	c.1234C>T	7_128846398_C_T	ENST00000249373	NM_005631	128846392	128846403
SMO	7	D473H	missense_variant	EID1099	D473H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22550175' target='_blank'>Lee et al., 2012, Proc. Natl. Acad. Sci. U.S.A.</a>	Brain Medulloblastoma	Predictive	D: Preclinical evidence	DOID:0060105	473	NA	Saridegib	D473H	civic:EID1099:SMO:p.D473	c.1417G>C	7_128849189_G_C	ENST00000249373	NM_005631	128849183	128849194
SMO	7	D473H	missense_variant	EID745	D473H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19726788' target='_blank'>Yauch et al., 2009, Science</a>	Brain Medulloblastoma	Predictive	C: Case study	DOID:0060105	473	NA	Vismodegib	D473H	civic:EID745:SMO:p.D473	c.1417G>C	7_128849189_G_C	ENST00000249373	NM_005631	128849183	128849194
SMO	7	D473H	missense_variant	EID755	D473H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25759020' target='_blank'>Atwood et al., 2015, Cancer Cell</a>	Basal Cell Carcinoma	Predictive	D: Preclinical evidence	DOID:2513	473	NA	Vismodegib	D473H	civic:EID755:SMO:p.D473	c.1417G>C	7_128849189_G_C	ENST00000249373	NM_005631	128849183	128849194
BRAF	7	P731T	missense_variant	EID5972	P731T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	731	NA	Vemurafenib	P731T	civic:EID5972:BRAF:p.P731	c.2191C>A	7_140434507_G_T	ENST00000288602	NM_004333	140434501	140434512
BRAF	7	G606E	missense_variant	EID5970	G606E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	606	NA	Vemurafenib	G606E	civic:EID5970:BRAF:p.G606	c.1817G>A	7_140453118_C_T	ENST00000288602	NM_004333	140453112	140453123
BRAF	7	K601E	missense_variant	EID1462	K601E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22798288' target='_blank'>Dahlman et al., 2012, Cancer Discov</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	601	NA	Trametinib, Vemurafenib	K601E	civic:EID1462:BRAF:p.K601	c.1801A>G	7_140453134_T_C	ENST00000288602	NM_004333	140453128	140453139
BRAF	7	V600D	missense_variant	EID4488	V600D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18287029' target='_blank'>Tsai et al., 2008, Proc. Natl. Acad. Sci. U.S.A.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	600	NA	Vemurafenib	V600D	civic:EID4488:BRAF:p.V600	c.1799_1800delinsAT	7_140453135_CA_AT	ENST00000288602	NM_004333	140453129	140453141
BRAF	7	V600D	missense_variant	EID4489	V600D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20551065' target='_blank'>Yang et al., 2010, Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	600	NA	Vemurafenib	V600D	civic:EID4489:BRAF:p.V600	c.1799_1800delinsAT	7_140453135_CA_AT	ENST00000288602	NM_004333	140453129	140453141
BRAF	7	V600D	missense_variant	EID94	V600D	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23463675' target='_blank'>Ponti et al., 2013, J. Clin. Pathol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Dabrafenib	V600D	civic:EID94:BRAF:p.V600	c.1799_1800delinsAT	7_140453135_CA_AT	ENST00000288602	NM_004333	140453129	140453141
BRAF	7	V600E	missense_variant	EID6262	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Dabrafenib, Vemurafenib	V600E	civic:EID6262:BRAF:p.V600	c.1799_1800delinsAA, c.1799T>A	7_140453135_CA_TT, 7_140453136_A_T	ENST00000288602	NM_004333	140453129	140453141
BRAF	7	V600K	missense_variant	EID6262B	V600K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Dabrafenib, Vemurafenib	V600K	civic:EID6262B:BRAF:p.V600	c.1798_1800delinsAAA, c.1798_1799delinsAA	7_140453135_CAC_TTT, 7_140453136_AC_TT	ENST00000288602	NM_004333	140453129	140453142
BRAF	7	V600E	missense_variant	EID1005	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26678033' target='_blank'>Penna et al., 2016, Oncotarget</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	600	NA	BEZ235 (NVP-BEZ235, Dactolisib), Selumetinib (AZD6244)	V600E	civic:EID1005:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID102	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24354346' target='_blank'>Walczyk et al., 2014, Clin. Endocrinol. (Oxf)</a>	Papillary Thyroid Carcinoma	Prognostic	B: Clinical evidence	DOID:3969	600	NA	NA	V600E	civic:EID102:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID103	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24594804' target='_blank'>Chen et al., 2014, PLoS ONE</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	600	NA	NA	V600E	civic:EID103:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID104	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24388723' target='_blank'>Nagore et al., 2014, J. Am. Acad. Dermatol.</a>	Melanoma	Prognostic	B: Clinical evidence	DOID:1909	600	NA	NA	V600E	civic:EID104:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID105	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21594703' target='_blank'>Howell et al., 2011, Ann. Surg. Oncol.</a>	Papillary Thyroid Carcinoma	Prognostic	B: Clinical evidence	DOID:3969	600	NA	NA	V600E	civic:EID105:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID106	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24396464' target='_blank'>He et al., 2014, Oncol Lett</a>	Papillary Thyroid Carcinoma	Prognostic	B: Clinical evidence	DOID:3969	600	NA	NA	V600E	civic:EID106:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID107	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21594703' target='_blank'>Howell et al., 2011, Ann. Surg. Oncol.</a>	Papillary Thyroid Carcinoma	Prognostic	B: Clinical evidence	DOID:3969	600	NA	NA	V600E	civic:EID107:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1127	V600E	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21663470' target='_blank'>Tiacci et al., 2011, N. Engl. J. Med.</a>	Hairy Cell Leukemia	Diagnostic	B: Clinical evidence	DOID:285	600	NA	NA	V600E	civic:EID1127:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1141	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23934108' target='_blank'>Hatzivassiliou et al., 2013, Nature</a>	Cancer	Predictive	D: Preclinical evidence	DOID:162	600	NA	Cobimetinib	V600E	civic:EID1141:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID126	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20619739' target='_blank'>De Roock et al., 2010, Lancet Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Cetuximab	V600E	civic:EID126:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1398	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24508103' target='_blank'>McArthur et al., 2014, Lancet Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Vemurafenib	V600E	civic:EID1398:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1405	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26460303' target='_blank'>Kopetz et al., 2015, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Vemurafenib	V600E	civic:EID1405:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1406	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22608338' target='_blank'>Falchook et al., 2012, Lancet</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Dabrafenib	V600E	civic:EID1406:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1408	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22281684' target='_blank'>Prahallad et al., 2012, Nature</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	600	NA	Cetuximab, Gefitinib, Vemurafenib	V600E	civic:EID1408:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1409	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21639808' target='_blank'>Chapman et al., 2011, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	A: Validated	DOID:8923	600	NA	Vemurafenib	V600E	civic:EID1409:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1410	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22356324' target='_blank'>Sosman et al., 2012, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	B: Clinical evidence	DOID:8923	600	NA	Vemurafenib	V600E	civic:EID1410:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1413	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25589621' target='_blank'>Yaeger et al., 2015, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Panitumumab, Vemurafenib	V600E	civic:EID1413:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1414	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24987354' target='_blank'>Ali et al., 2014, Case Rep Oncol</a>	Papillary Thyroid Carcinoma	Predictive	C: Case study	DOID:3969	600	NA	Vemurafenib	V600E	civic:EID1414:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1421	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25265494' target='_blank'>Larkin et al., 2014, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Cobimetinib, Vemurafenib	V600E	civic:EID1421:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1428	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23549875' target='_blank'>Coffee et al., 2013, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	600	NA	GDC-0879, BEZ235 (NVP-BEZ235, Dactolisib)	V600E	civic:EID1428:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1430	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27048246' target='_blank'>Klempner et al., 2016, Cancer Discov</a>	Gastrointestinal Neuroendocrine Tumor	Predictive	C: Case study	DOID:0050626	600	NA	Vemurafenib, Trametinib, Dabrafenib	V600E	civic:EID1430:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1552	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27404270' target='_blank'>Amaki-Takao et al., 2016, Oncology</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	600	NA	NA	V600E	civic:EID1552:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1579	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26352686' target='_blank'>Tiacci et al., 2015, N. Engl. J. Med.</a>	Hairy Cell Leukemia	Predictive	B: Clinical evidence	DOID:285	600	NA	Vemurafenib	V600E	civic:EID1579:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1589	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27325282' target='_blank'>Pietrantonio et al., 2016, Cancer Discov</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	600	NA	Panitumumab, Vemurafenib	V600E	civic:EID1589:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1591	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27460442' target='_blank'>Brose et al., 2016, Lancet Oncol.</a>	Papillary Thyroid Carcinoma	Predictive	B: Clinical evidence	DOID:3969	600	NA	Vemurafenib	V600E	civic:EID1591:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1698	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24997557' target='_blank'>Sharman et al., 2014, Clin Lymphoma Myeloma Leuk</a>	Multiple Myeloma	Predictive	C: Case study	DOID:9538	600	NA	Vemurafenib	V600E	civic:EID1698:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1699	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24997557' target='_blank'>Sharman et al., 2014, Clin Lymphoma Myeloma Leuk</a>	Multiple Myeloma	Predictive	C: Case study	DOID:9538	600	NA	Vemurafenib	V600E	civic:EID1699:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1749	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20818844' target='_blank'>Flaherty et al., 2010, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Vemurafenib	V600E	civic:EID1749:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1902	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27729313' target='_blank'>Hong et al., 2016, Cancer Discov</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Irinotecan, Cetuximab, Vemurafenib	V600E	civic:EID1902:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID1940	V600E	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27302369' target='_blank'>Schell et al., 2016, Nat Commun</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	600	NA	NA	V600E	civic:EID1940:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID2115	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19001320' target='_blank'>Di Nicolantonio et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Cetuximab, Panitumumab	V600E	civic:EID2115:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID2117	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Oxaliplatin	V600E	civic:EID2117:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID2118	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Irinotecan	V600E	civic:EID2118:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID2121	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19571295' target='_blank'>Tol et al., 2009, N. Engl. J. Med.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Bevacizumab	V600E	civic:EID2121:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID2135	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22663011' target='_blank'>Flaherty et al., 2012, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Trametinib	V600E	civic:EID2135:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID2137	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18682506' target='_blank'>Elisei et al., 2008, J. Clin. Endocrinol. Metab.</a>	Papillary Thyroid Carcinoma	Prognostic	B: Clinical evidence	DOID:3969	600	NA	NA	V600E	civic:EID2137:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID2503	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21882184' target='_blank'>Kim et al., 2012, Cancer</a>	Papillary Thyroid Carcinoma	Prognostic	B: Clinical evidence	DOID:3969	600	NA	NA	V600E	civic:EID2503:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID3017	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27283860' target='_blank'>Planchard et al., 2016, Lancet Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	A: Validated	DOID:3908	600	NA	Trametinib, Dabrafenib	V600E	civic:EID3017:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID3739	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25666295' target='_blank'>Kaczirek et al., 2015, Clin Colorectal Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Cetuximab	V600E	civic:EID3739:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID3750	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23569304' target='_blank'>Trunzer et al., 2013, J. Clin. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Vemurafenib	V600E	civic:EID3750:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID3755	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26557775' target='_blank'>Rutkowski et al., 2015, Contemp Oncol (Pozn)</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Vemurafenib	V600E	civic:EID3755:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID3757	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25524477' target='_blank'>Ugurel et al., 2015, Ann. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Vemurafenib	V600E	civic:EID3757:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID3758	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25399551' target='_blank'>Robert et al., 2015, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	B: Clinical evidence	DOID:8923	600	NA	Trametinib, Dabrafenib	V600E	civic:EID3758:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID3777	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25524464' target='_blank'>del Bufalo et al., 2014, J Transl Med</a>	Ganglioglioma	Predictive	C: Case study	DOID:5078	600	NA	Vemurafenib	V600E	civic:EID3777:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID3787	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26490654' target='_blank'>Combe et al., 2015, Invest New Drugs</a>	Ovarian Cystadenocarcinoma	Predictive	C: Case study	DOID:3605	600	NA	Vemurafenib	V600E	civic:EID3787:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID463	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23612012' target='_blank'>Andrulis et al., 2013, Cancer Discov</a>	Myeloma	Prognostic	B: Clinical evidence	DOID:0070004	600	NA	NA	V600E	civic:EID463:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID5902	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28480077' target='_blank'>Kocsis et al., 2017, J Gastrointest Oncol</a>	Cholangiocarcinoma	Predictive	C: Case study	DOID:4947	600	NA	Trametinib DMSO, Dabrafenib	V600E	civic:EID5902:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID5903	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28078132' target='_blank'>Lavingia et al., 2016, J Gastrointest Oncol</a>	Cholangiocarcinoma	Predictive	C: Case study	DOID:4947	600	NA	Trametinib DMSO, Dabrafenib	V600E	civic:EID5903:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID5904	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25435907' target='_blank'>Loaiza-Bonilla et al., 2014, Ecancermedicalscience</a>	Cholangiocarcinoma	Predictive	C: Case study	DOID:4947	600	NA	Trametinib DMSO, Dabrafenib	V600E	civic:EID5904:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID5906	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26687137' target='_blank'>Silkin et al., 2016, J Gastrointest Cancer</a>	Cholangiocarcinoma	Predictive	C: Case study	DOID:4947	600	NA	Irinotecan, Panitumumab, Vemurafenib	V600E	civic:EID5906:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID5958	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	600	NA	Vemurafenib	V600E	civic:EID5958:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID5959	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Ovarian Cancer	Predictive	B: Clinical evidence	DOID:2394	600	NA	Vemurafenib	V600E	civic:EID5959:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID5960	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	600	NA	Vemurafenib	V600E	civic:EID5960:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID5961	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Anaplastic Thyroid Carcinoma	Predictive	C: Case study	NA	600	NA	Pertuzumab, Vemurafenib	V600E	civic:EID5961:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID5962	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Laryngeal Squamous Cell Carcinoma	Predictive	C: Case study	DOID:2876	600	NA	Vemurafenib	V600E	civic:EID5962:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID6045	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Anaplastic Thyroid Carcinoma	Predictive	B: Clinical evidence	NA	600	NA	Vemurafenib	V600E	civic:EID6045:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID6123	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29431699' target='_blank'>Corcoran et al., 2018, Cancer Discov</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Trametinib, Panitumumab, Dabrafenib	V600E	civic:EID6123:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID6124	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29431699' target='_blank'>Corcoran et al., 2018, Cancer Discov</a>	Colorectal Adenocarcinoma	Predictive	B: Clinical evidence	DOID:0050861	600	NA	Panitumumab, Trametinib	V600E	civic:EID6124:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID6178	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28891408' target='_blank'>Long et al., 2017, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Trametinib, Dabrafenib	V600E	civic:EID6178:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID656	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25024077' target='_blank'>Xing et al., 2014, J. Clin. Oncol.</a>	Papillary Thyroid Carcinoma	Prognostic	B: Clinical evidence	DOID:3969	600	NA	NA	V600E	civic:EID656:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID6938	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25265492' target='_blank'>Long et al., 2014, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Trametinib, Dabrafenib	V600E	civic:EID6938:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID6940	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23020132' target='_blank'>Flaherty et al., 2012, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Trametinib, Dabrafenib	V600E	civic:EID6940:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID6975	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29072975' target='_blank'>Subbiah et al., 2018, J. Clin. Oncol.</a>	Anaplastic Thyroid Carcinoma	Predictive	B: Clinical evidence	NA	600	NA	Trametinib, Dabrafenib	V600E	civic:EID6975:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID7156	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20008640' target='_blank'>Roth et al., 2010, J. Clin. Oncol.</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	600	NA	NA	V600E	civic:EID7156:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID7157	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21502544' target='_blank'>Van Cutsem et al., 2011, J. Clin. Oncol.</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	600	NA	NA	V600E	civic:EID7157:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID757	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25370471' target='_blank'>Sarker et al., 2015, Clin. Cancer Res.</a>	Melanoma	Predictive	C: Case study	DOID:1909	600	NA	Pictilisib	V600E	civic:EID757:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID79	V600E	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21594703' target='_blank'>Howell et al., 2011, Ann. Surg. Oncol.</a>	Thyroid Cancer	Diagnostic	B: Clinical evidence	DOID:1781	600	NA	NA	V600E	civic:EID79:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID80	V600E	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24570209' target='_blank'>Crescenzi et al., 2014, Horm. Metab. Res.</a>	Papillary Thyroid Carcinoma	Diagnostic	B: Clinical evidence	DOID:3969	600	NA	NA	V600E	civic:EID80:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID816	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25989278' target='_blank'>Rowland et al., 2015, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Panitumumab, Cetuximab	V600E	civic:EID816:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID82	V600E	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24586605' target='_blank'>Meckbach et al., 2014, PLoS ONE</a>	Melanoma	Prognostic	B: Clinical evidence	DOID:1909	600	NA	NA	V600E	civic:EID82:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID86	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24576830' target='_blank'>Nissan et al., 2014, Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	600	NA	PD0325901, Trametinib	V600E	civic:EID86:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID89	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19001320' target='_blank'>Di Nicolantonio et al., 2008, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	600	NA	Panitumumab, Sorafenib	V600E	civic:EID89:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID90	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24576830' target='_blank'>Nissan et al., 2014, Cancer Res.</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	600	NA	Vemurafenib	V600E	civic:EID90:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID91	V600E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23524406' target='_blank'>Rudin et al., 2013, J Thorac Oncol</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	600	NA	Dabrafenib	V600E	civic:EID91:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID95	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24583796' target='_blank'>Menzies et al., 2014, Clin. Cancer Res.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Trametinib, Dabrafenib	V600E	civic:EID95:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID96	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23845441' target='_blank'>Rad et al., 2013, Cancer Cell</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	600	NA	GDC0941, PLX4720	V600E	civic:EID96:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID97	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23812671' target='_blank'>Ji et al., 2013, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	600	NA	Nutlin-3, PLX4720	V600E	civic:EID97:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID98	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22180495' target='_blank'>Yang et al., 2012, Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	600	NA	Bevacizumab, Vemurafenib, Capecitabine	V600E	civic:EID98:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600E	missense_variant	EID99	V600E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22180495' target='_blank'>Yang et al., 2012, Cancer Res.</a>	Colorectal Cancer	Predictive	D: Preclinical evidence	DOID:9256	600	NA	Vemurafenib	V600E	civic:EID99:BRAF:p.V600	c.1799T>A	7_140453136_A_T	ENST00000288602	NM_004333	140453130	140453141
BRAF	7	V600K	missense_variant	EID1399	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24508103' target='_blank'>McArthur et al., 2014, Lancet Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Vemurafenib	V600K	civic:EID1399:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	NM_004333	140453130	140453142
BRAF	7	V600K	missense_variant	EID1400	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26989536' target='_blank'>Sahadudheen et al., 2016, Case Rep Oncol Med</a>	Melanoma	Predictive	C: Case study	DOID:1909	600	NA	Vemurafenib	V600K	civic:EID1400:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	NM_004333	140453130	140453142
BRAF	7	V600K	missense_variant	EID2505	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21343559' target='_blank'>Long et al., 2011, J. Clin. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Dabrafenib	V600K	civic:EID2505:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	NM_004333	140453130	140453142
BRAF	7	V600K	missense_variant	EID2506	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22663011' target='_blank'>Flaherty et al., 2012, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Trametinib	V600K	civic:EID2506:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	NM_004333	140453130	140453142
BRAF	7	V600K	missense_variant	EID4180	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25524477' target='_blank'>Ugurel et al., 2015, Ann. Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Vemurafenib	V600K	civic:EID4180:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	NM_004333	140453130	140453142
BRAF	7	V600K	missense_variant	EID4181	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25399551' target='_blank'>Robert et al., 2015, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	B: Clinical evidence	DOID:8923	600	NA	Trametinib, Dabrafenib	V600K	civic:EID4181:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	NM_004333	140453130	140453142
BRAF	7	V600K	missense_variant	EID6179	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28891408' target='_blank'>Long et al., 2017, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Dabrafenib, Trametinib	V600K	civic:EID6179:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	NM_004333	140453130	140453142
BRAF	7	V600K	missense_variant	EID6965	V600K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25265494' target='_blank'>Larkin et al., 2014, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Dabrafenib, Trametinib	V600K	civic:EID6965:BRAF:p.V600	c.1798_1799delinsAA	7_140453136_AC_TT	ENST00000288602	NM_004333	140453130	140453142
BRAF	7	NA	NA	EID88	V600	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23325582' target='_blank'>Peeters et al., 2013, Clin. Cancer Res.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Panitumumab	V600	civic:EID88:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID93	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23020132' target='_blank'>Flaherty et al., 2012, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Dabrafenib, Trametinib	V600	civic:EID93:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID994	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24947927' target='_blank'>Zimmer et al., 2014, Clin. Cancer Res.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	RO4987655	V600	civic:EID994:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1407	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22608338' target='_blank'>Falchook et al., 2012, Lancet</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Dabrafenib	V600	civic:EID1407:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1411	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25399551' target='_blank'>Robert et al., 2015, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	A: Validated	DOID:8923	600	NA	Trametinib, Dabrafenib	V600	civic:EID1411:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1415	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26392102' target='_blank'>Corcoran et al., 2015, J. Clin. Oncol.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Dabrafenib, Trametinib	V600	civic:EID1415:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1422	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25265494' target='_blank'>Larkin et al., 2014, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Vemurafenib, Cobimetinib	V600	civic:EID1422:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1000	V600	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23434733' target='_blank'>Weekes et al., 2013, Clin. Cancer Res.</a>	Melanoma	Predictive	C: Case study	DOID:1909	600	NA	BAY 86-9766	V600	civic:EID1000:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1574	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Non-small Cell Lung Carcinoma	Predictive	B: Clinical evidence	DOID:3908	600	NA	Vemurafenib	V600	civic:EID1574:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1575	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Langerhans-Cell Histiocytosis	Predictive	B: Clinical evidence	DOID:2571	600	NA	Vemurafenib	V600	civic:EID1575:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1576	V600	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Vemurafenib	V600	civic:EID1576:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1598	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Cetuximab, Vemurafenib	V600	civic:EID1598:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID1750	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22663011' target='_blank'>Flaherty et al., 2012, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Trametinib	V600	civic:EID1750:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID5905	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26287849' target='_blank'>Hyman et al., 2015, N. Engl. J. Med.</a>	Cholangiocarcinoma	Predictive	B: Clinical evidence	DOID:4947	600	NA	Vemurafenib	V600	civic:EID5905:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID6044	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27480103' target='_blank'>Ascierto et al., 2016, Lancet Oncol.</a>	Melanoma	Predictive	A: Validated	DOID:1909	600	NA	Cobimetinib, Vemurafenib	V600	civic:EID6044:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID6046	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28363909' target='_blank'>van Geel et al., 2017, Cancer Discov</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Encorafenib, Cetuximab	V600	civic:EID6046:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID6047	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28363909' target='_blank'>van Geel et al., 2017, Cancer Discov</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	600	NA	Encorafenib, Cetuximab, Alpelisib	V600	civic:EID6047:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID6180	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/28891408' target='_blank'>Long et al., 2017, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Trametinib, Dabrafenib	V600	civic:EID6180:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID6937	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25265492' target='_blank'>Long et al., 2014, N. Engl. J. Med.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Dabrafenib, Trametinib	V600	civic:EID6937:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID6966	V600	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25037139' target='_blank'>Ribas et al., 2014, Lancet Oncol.</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	600	NA	Vemurafenib, Cobimetinib	V600	civic:EID6966:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	NA	NA	EID30	V600	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21166657' target='_blank'>Lee et al., 2011, Br. J. Dermatol.</a>	Melanoma	Diagnostic	B: Clinical evidence	DOID:1909	600	NA	NA	V600	civic:EID30:BRAF:p.V600	NA	NA	NA	NA	140453135	140453137
BRAF	7	L597Q	missense_variant	EID1461	L597Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22798288' target='_blank'>Dahlman et al., 2012, Cancer Discov</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	597	NA	Trametinib, Vemurafenib	L597Q	civic:EID1461:BRAF:p.L597	c.1790T>A	7_140453145_A_T	ENST00000288602	NM_004333	140453139	140453150
BRAF	7	L597Q	missense_variant	EID4905	L597Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24933606' target='_blank'>Bowyer et al., 2014, Melanoma Res.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	597	NA	Trametinib	L597Q	civic:EID4905:BRAF:p.L597	c.1790T>A	7_140453145_A_T	ENST00000288602	NM_004333	140453139	140453150
BRAF	7	L597Q	missense_variant	EID5971	L597Q	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	597	NA	Vemurafenib	L597Q	civic:EID5971:BRAF:p.L597	c.1790T>A	7_140453145_A_T	ENST00000288602	NM_004333	140453139	140453150
BRAF	7	L597R	missense_variant	EID1458	L597R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22798288' target='_blank'>Dahlman et al., 2012, Cancer Discov</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	597	NA	Trametinib, Vemurafenib	L597R	civic:EID1458:BRAF:p.L597	c.1790T>G	7_140453145_A_C	ENST00000288602	NM_004333	140453139	140453150
BRAF	7	L597R	missense_variant	EID728	L597R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23715574' target='_blank'>Bahadoran et al., 2013, J. Clin. Oncol.</a>	Melanoma	Predictive	C: Case study	DOID:1909	597	NA	Vemurafenib	L597R	civic:EID728:BRAF:p.L597	c.1790T>G	7_140453145_A_C	ENST00000288602	NM_004333	140453139	140453150
BRAF	7	L597S	missense_variant	EID1459	L597S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22798288' target='_blank'>Dahlman et al., 2012, Cancer Discov</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	597	NA	Trametinib, Vemurafenib	L597S	civic:EID1459:BRAF:p.L597	c.1789_1790delinsTC	7_140453145_AG_GA	ENST00000288602	NM_004333	140453139	140453151
BRAF	7	L597S	missense_variant	EID1460	L597S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22798288' target='_blank'>Dahlman et al., 2012, Cancer Discov</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	597	NA	TAK-733	L597S	civic:EID1460:BRAF:p.L597	c.1789_1790delinsTC	7_140453145_AG_GA	ENST00000288602	NM_004333	140453139	140453151
BRAF	7	L597V	missense_variant	EID1463	L597V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22805292' target='_blank'>Falchook et al., 2012, Lancet Oncol.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	597	NA	Trametinib	L597V	civic:EID1463:BRAF:p.L597	c.1789C>G	7_140453146_G_C	ENST00000288602	NM_004333	140453140	140453151
BRAF	7	G596C	missense_variant	EID1738	G596C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27577079' target='_blank'>Noeparast et al., 2016, Oncotarget</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	596	NA	Trametinib, Dabrafenib	G596C	civic:EID1738:BRAF:p.G596	c.1786G>T	7_140453149_C_A	ENST00000288602	NM_004333	140453143	140453154
BRAF	7	G596R	missense_variant	EID5969	G596R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	596	NA	Vemurafenib	G596R	civic:EID5969:BRAF:p.G596	c.1786G>C	7_140453149_C_G	ENST00000288602	NM_004333	140453143	140453154
BRAF	7	D594K	missense_variant	EID6402	D594K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	594	NA	Irinotecan	D594K	civic:EID6402:BRAF:p.D594	c.1780_1782delinsAAG, c.1780_1782delinsAAA	7_140453153_ATC_CTT, 7_140453153_ATC_TTT	ENST00000288602	NM_004333	140453147	140453160
BRAF	7	D594K	missense_variant	EID6403	D594K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19603024' target='_blank'>Souglakos et al., 2009, Br. J. Cancer</a>	Colorectal Cancer	Predictive	B: Clinical evidence	DOID:9256	594	NA	Oxaliplatin	D594K	civic:EID6403:BRAF:p.D594	c.1780_1782delinsAAG, c.1780_1782delinsAAA	7_140453153_ATC_CTT, 7_140453153_ATC_TTT	ENST00000288602	NM_004333	140453147	140453160
BRAF	7	D594A	missense_variant	EID1454	D594A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20141835' target='_blank'>Heidorn et al., 2010, Cell</a>	Skin Melanoma	Predictive	E: Indirect evidence	DOID:8923	594	NA	MEK Inhibitor, Sorafenib	D594A	civic:EID1454:BRAF:p.D594	c.1781A>C	7_140453154_T_G	ENST00000288602	NM_004333	140453148	140453159
BRAF	7	D594G	missense_variant	EID1551	D594G	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27404270' target='_blank'>Amaki-Takao et al., 2016, Oncology</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	594	NA	NA	D594G	civic:EID1551:BRAF:p.D594	c.1781A>G	7_140453154_T_C	ENST00000288602	NM_004333	140453148	140453159
BRAF	7	D594G	missense_variant	EID1553	D594G	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27404270' target='_blank'>Amaki-Takao et al., 2016, Oncology</a>	Colorectal Cancer	Prognostic	B: Clinical evidence	DOID:9256	594	NA	NA	D594G	civic:EID1553:BRAF:p.D594	c.1781A>G	7_140453154_T_C	ENST00000288602	NM_004333	140453148	140453159
BRAF	7	D594G	missense_variant	EID1554	D594G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27404270' target='_blank'>Amaki-Takao et al., 2016, Oncology</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	594	NA	Cetuximab, Panitumumab	D594G	civic:EID1554:BRAF:p.D594	c.1781A>G	7_140453154_T_C	ENST00000288602	NM_004333	140453148	140453159
BRAF	7	D594G	missense_variant	EID4472	D594G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26989027' target='_blank'>Hsu et al., 2016, Oncotarget</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	594	NA	Cetuximab	D594G	civic:EID4472:BRAF:p.D594	c.1781A>G	7_140453154_T_C	ENST00000288602	NM_004333	140453148	140453159
BRAF	7	D594G	missense_variant	EID6001	D594G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18794803' target='_blank'>Smalley et al., 2009, Oncogene</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	594	NA	Sorafenib	D594G	civic:EID6001:BRAF:p.D594	c.1781A>G	7_140453154_T_C	ENST00000288602	NM_004333	140453148	140453159
BRAF	7	D594V	missense_variant	EID1456	D594V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20141835' target='_blank'>Heidorn et al., 2010, Cell</a>	Skin Melanoma	Predictive	E: Indirect evidence	DOID:8923	594	NA	Trametinib, Sorafenib	D594V	civic:EID1456:BRAF:p.D594	c.1781A>T	7_140453154_T_A	ENST00000288602	NM_004333	140453148	140453159
BRAF	7	N581S	missense_variant&splice_region_variant	EID5967	N581S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	581	NA	Vemurafenib	N581S	civic:EID5967:BRAF:p.N581	c.1742A>G	7_140453193_T_C	ENST00000288602	NM_004333	140453187	140453198
BRAF	7	L505H	missense_variant	EID1668	L505H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24112705' target='_blank'>Wagenaar et al., 2014, Pigment Cell Melanoma Res</a>	Melanoma	Predictive	D: Preclinical evidence	DOID:1909	505	NA	Vemurafenib	L505H	civic:EID1668:BRAF:p.L505	c.1514T>A	7_140477794_A_T	ENST00000288602	NM_004333	140477788	140477799
BRAF	7	L505H	missense_variant	EID1669	L505H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25515853' target='_blank'>Hoogstraat et al., 2015, Pigment Cell Melanoma Res</a>	Melanoma	Predictive	B: Clinical evidence	DOID:1909	505	NA	Vemurafenib	L505H	civic:EID1669:BRAF:p.L505	c.1514T>A	7_140477794_A_T	ENST00000288602	NM_004333	140477788	140477799
BRAF	7	K483M	missense_variant	EID1457	K483M	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20141835' target='_blank'>Heidorn et al., 2010, Cell</a>	Skin Melanoma	Predictive	E: Indirect evidence	DOID:8923	483	NA	MEK Inhibitor, Sorafenib	K483M	civic:EID1457:BRAF:p.K483	c.1448_1449delinsTG	7_140477859_TT_CA	ENST00000288602	NM_004333	140477853	140477865
BRAF	7	G469A	missense_variant	EID5965	G469A	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	469	NA	Vemurafenib	G469A	civic:EID5965:BRAF:p.G469	c.1406G>C	7_140481402_C_G	ENST00000288602	NM_004333	140481396	140481407
BRAF	7	G469E	missense_variant	EID6003	G469E	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18794803' target='_blank'>Smalley et al., 2009, Oncogene</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	469	NA	Sorafenib	G469E	civic:EID6003:BRAF:p.G469	c.1406G>A	7_140481402_C_T	ENST00000288602	NM_004333	140481396	140481407
BRAF	7	G466V	missense_variant	EID5968	G466V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	466	NA	Vemurafenib	G466V	civic:EID5968:BRAF:p.G466	c.1397G>T	7_140481411_C_A	ENST00000288602	NM_004333	140481405	140481416
BRAF	7	G464V	missense_variant	EID5964	G464V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/29320312' target='_blank'>Hainsworth et al., 2018, J. Clin. Oncol.</a>	Cancer	Predictive	C: Case study	DOID:162	464	NA	Vemurafenib	G464V	civic:EID5964:BRAF:p.G464	c.1391G>T	7_140481417_C_A	ENST00000288602	NM_004333	140481411	140481422
EZH2	7	NA	NA	EID1494	Y646	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26304929' target='_blank'>Tiffen et al., 2015, Oncotarget</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	646	NA	GSK126	Y646	civic:EID1494:EZH2:p.Y646	NA	NA	NA	NA	148508725	148508728
EZH2	7	NA	NA	EID433	Y646	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20081860' target='_blank'>Morin et al., 2010, Nat. Genet.</a>	Follicular Lymphoma	Diagnostic	B: Clinical evidence	DOID:0050873	646	NA	NA	Y646	civic:EID433:EZH2:p.Y646	NA	NA	NA	NA	148508725	148508728
EZH2	7	NA	NA	EID432	Y646	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20081860' target='_blank'>Morin et al., 2010, Nat. Genet.</a>	Diffuse Large B-cell Lymphoma	Diagnostic	B: Clinical evidence	DOID:0050745	646	NA	NA	Y646	civic:EID432:EZH2:p.Y646	NA	NA	NA	NA	148508725	148508728
FGFR1	8	N577K	missense_variant	EID1246	N546K	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26179511' target='_blank'>Agelopoulos et al., 2015, Clin. Cancer Res.</a>	Bone Ewing's Sarcoma	Predictive	E: Indirect evidence	DOID:3368	577	NA	Ponatinib	N546K	civic:EID1246:FGFR1:p.N577	c.1731C>A	8_38274849_G_T	ENST00000425967	NM_001174067	38274843	38274854
PREX2	8	R172I	missense_variant	EID6268	R172I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24265155' target='_blank'>Shi et al., 2014, Cancer Discov</a>	Melanoma	Predictive	C: Case study	DOID:1909	172	NA	Vemurafenib	R172I	civic:EID6268:PREX2:p.R172	c.515G>T, c.515_516delinsTT, c.515_516inv	8_68939530_G_T, 8_68939530_GA_TT, 8_68939530_GA_TC	ENST00000288368	NM_024870&NM_025170	68939524	68939536
JAK2	9	.	splice_donor_variant	EID1568	Exon 12 splice site insertion	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27433843' target='_blank'>Zaretsky et al., 2016, N. Engl. J. Med.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	NA	NA	Pembrolizumab	Exon 12 splice site insertion	civic:EID1568:JAK2:c.1641+1dup	c.1641+1dup	9_5070053_G_GG	ENST00000381652	NM_004972	5070047	5070059
JAK2	9	.	splice_donor_variant	EID4825	F547 SPLICE SITE MUTATION	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27433843' target='_blank'>Zaretsky et al., 2016, N. Engl. J. Med.</a>	Melanoma	Predictive	C: Case study	DOID:1909	NA	NA	Pembrolizumab	F547 SPLICE SITE MUTATION	civic:EID4825:JAK2:c.1641+2T>G	c.1641+2T>G	9_5070054_T_G	ENST00000381652	NM_004972	5070048	5070059
JAK2	9	V617F	missense_variant	EID1	V617F	Negative	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16081687' target='_blank'>Levine et al., 2005, Blood</a>	Lymphoid Leukemia	Diagnostic	B: Clinical evidence	DOID:10747	617	NA	NA	V617F	civic:EID1:JAK2:p.V617	c.1849G>T	9_5073770_G_T	ENST00000381652	NM_004972	5073764	5073775
JAK2	9	V617F	missense_variant	EID19	V617F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16709929' target='_blank'>Kiladjian et al., 2006, Blood</a>	Polycythemia Vera	Predictive	B: Clinical evidence	DOID:8997	617	NA	Pegylated IFN-alpha-2a	V617F	civic:EID19:JAK2:p.V617	c.1849G>T	9_5073770_G_T	ENST00000381652	NM_004972	5073764	5073775
JAK2	9	V617F	missense_variant	EID20	V617F	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18394554' target='_blank'>Wernig et al., 2008, Cancer Cell</a>	Polycythemia Vera	Predictive	D: Preclinical evidence	DOID:8997	617	NA	TG101348	V617F	civic:EID20:JAK2:p.V617	c.1849G>T	9_5073770_G_T	ENST00000381652	NM_004972	5073764	5073775
JAK2	9	V617F	missense_variant	EID5	V617F	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16081687' target='_blank'>Levine et al., 2005, Blood</a>	Chronic Myeloid Leukemia	Diagnostic	B: Clinical evidence	DOID:8552	617	NA	NA	V617F	civic:EID5:JAK2:p.V617	c.1849G>T	9_5073770_G_T	ENST00000381652	NM_004972	5073764	5073775
JAK2	9	V617F	missense_variant	EID7	V617F	Positive	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19287384' target='_blank'>Kilpivaara et al., 2009, Nat. Genet.</a>	Bone Marrow Cancer	Diagnostic	B: Clinical evidence	DOID:4960	617	NA	NA	V617F	civic:EID7:JAK2:p.V617	c.1849G>T	9_5073770_G_T	ENST00000381652	NM_004972	5073764	5073775
CDKN2A	9	.	upstream_gene_variant	EID1635	RS3814960	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27414035' target='_blank'>Li et al., 2016, PLoS ONE</a>	Esophagus Squamous Cell Carcinoma	Prognostic	B: Clinical evidence	DOID:3748	NA	NA	NA	RS3814960	CDKN2A:upstream_gene_variant_CA12951936	NA	9_21975017_C_T	NA	NA	21975011	21975022
GNAQ	9	Q209P	missense_variant	EID1533	Q209P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24504448' target='_blank'>Turajlic et al., 2014, Ann. Oncol.</a>	Skin Melanoma	Predictive	C: Case study	DOID:8923	209	NA	Vemurafenib	Q209P	civic:EID1533:GNAQ:p.Q209	c.626A>C	9_80409488_T_G	ENST00000286548	NM_002072	80409482	80409493
GNAQ	9	Q209P	missense_variant	EID1537	Q209P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24504448' target='_blank'>Turajlic et al., 2014, Ann. Oncol.</a>	Skin Melanoma	Predictive	D: Preclinical evidence	DOID:8923	209	NA	PLX4720	Q209P	civic:EID1537:GNAQ:p.Q209	c.626A>C	9_80409488_T_G	ENST00000286548	NM_002072	80409482	80409493
GNAQ	9	NA	NA	EID1213	Q209	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24938562' target='_blank'>Carvajal et al., 2014, JAMA</a>	Uveal Melanoma	Predictive	B: Clinical evidence	DOID:6039	209	NA	Selumetinib (AZD6244)	Q209	civic:EID1213:GNAQ:p.Q209	NA	NA	NA	NA	80409486	80409489
GNAQ	9	NA	NA	EID1233	Q209	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23434733' target='_blank'>Weekes et al., 2013, Clin. Cancer Res.</a>	Uveal Melanoma	Predictive	C: Case study	DOID:6039	209	NA	BAY 86-9766	Q209	civic:EID1233:GNAQ:p.Q209	NA	NA	NA	NA	80409486	80409489
ABL1	9	M244V	missense_variant	EID2638	BCR-ABL M244V	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	244	NA	Imatinib	BCR-ABL M244V	civic:EID2638:ABL1:p.M244	c.730A>G	9_133738330_A_G	ENST00000318560	NM_005157	133738324	133738335
ABL1	9	M244V	missense_variant	EID4302	BCR-ABL M244V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	244	NA	Dasatinib	BCR-ABL M244V	civic:EID4302:ABL1:p.M244	c.730A>G	9_133738330_A_G	ENST00000318560	NM_005157	133738324	133738335
ABL1	9	M244V	missense_variant	EID4307	BCR-ABL M244V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	244	NA	Bosutinib	BCR-ABL M244V	civic:EID4307:ABL1:p.M244	c.730A>G	9_133738330_A_G	ENST00000318560	NM_005157	133738324	133738335
ABL1	9	M244V	missense_variant	EID4308	BCR-ABL M244V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	244	NA	Bosutinib	BCR-ABL M244V	civic:EID4308:ABL1:p.M244	c.730A>G	9_133738330_A_G	ENST00000318560	NM_005157	133738324	133738335
ABL1	9	M244V	missense_variant	EID6242	BCR-ABL M244V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	244	NA	Imatinib Mesylate	BCR-ABL M244V	civic:EID6242:ABL1:p.M244	c.730A>G	9_133738330_A_G	ENST00000318560	NM_005157	133738324	133738335
ABL1	9	M244V	missense_variant	EID6994	BCR-ABL M244V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	244	NA	Imatinib Mesylate	BCR-ABL M244V	civic:EID6994:ABL1:p.M244	c.730A>G	9_133738330_A_G	ENST00000318560	NM_005157	133738324	133738335
ABL1	9	M244V	missense_variant	EID7042	BCR-ABL M244V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	244	NA	Imatinib Mesylate	BCR-ABL M244V	civic:EID7042:ABL1:p.M244	c.730A>G	9_133738330_A_G	ENST00000318560	NM_005157	133738324	133738335
ABL1	9	L248V	missense_variant	EID2641	BCR-ABL L248V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	248	NA	Imatinib	BCR-ABL L248V	civic:EID2641:ABL1:p.L248	c.742C>G	9_133738342_C_G	ENST00000318560	NM_005157	133738336	133738347
ABL1	9	L248V	missense_variant	EID2644	BCR-ABL L248V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	248	NA	Imatinib Mesylate, Dasatinib, Nilotinib	BCR-ABL L248V	civic:EID2644:ABL1:p.L248	c.742C>G	9_133738342_C_G	ENST00000318560	NM_005157	133738336	133738347
ABL1	9	L248V	missense_variant	EID4310	BCR-ABL L248V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	248	NA	Bosutinib	BCR-ABL L248V	civic:EID4310:ABL1:p.L248	c.742C>G	9_133738342_C_G	ENST00000318560	NM_005157	133738336	133738347
ABL1	9	L248V	missense_variant	EID6236	BCR-ABL L248V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	248	NA	Imatinib Mesylate, Nilotinib	BCR-ABL L248V	civic:EID6236:ABL1:p.L248	c.742C>G	9_133738342_C_G	ENST00000318560	NM_005157	133738336	133738347
ABL1	9	L248V	missense_variant	EID6308	BCR-ABL L248V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	248	NA	Dasatinib	BCR-ABL L248V	civic:EID6308:ABL1:p.L248	c.742C>G	9_133738342_C_G	ENST00000318560	NM_005157	133738336	133738347
ABL1	9	L248V	missense_variant	EID7044	BCR-ABL L248V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	248	NA	Imatinib Mesylate	BCR-ABL L248V	civic:EID7044:ABL1:p.L248	c.742C>G	9_133738342_C_G	ENST00000318560	NM_005157	133738336	133738347
ABL1	9	L248R	missense_variant	EID6210	BCR-ABL L248R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	248	NA	Imatinib Mesylate, Dasatinib	BCR-ABL L248R	civic:EID6210:ABL1:p.L248	c.743T>G	9_133738343_T_G	ENST00000318560	NM_005157	133738337	133738348
ABL1	9	L248R	missense_variant	EID6243	BCR-ABL L248R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	248	NA	Imatinib Mesylate	BCR-ABL L248R	civic:EID6243:ABL1:p.L248	c.743T>G	9_133738343_T_G	ENST00000318560	NM_005157	133738337	133738348
ABL1	9	G250E	missense_variant	EID2645	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	250	NA	Imatinib	BCR-ABL G250E	civic:EID2645:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	NM_005157	133738343	133738354
ABL1	9	G250E	missense_variant	EID2647	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	250	NA	Imatinib	BCR-ABL G250E	civic:EID2647:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	NM_005157	133738343	133738354
ABL1	9	G250E	missense_variant	EID2648	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	250	NA	Nilotinib	BCR-ABL G250E	civic:EID2648:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	NM_005157	133738343	133738354
ABL1	9	G250E	missense_variant	EID4313	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	250	NA	Bosutinib	BCR-ABL G250E	civic:EID4313:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	NM_005157	133738343	133738354
ABL1	9	G250E	missense_variant	EID4314	BCR-ABL G250E	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	250	NA	Bosutinib	BCR-ABL G250E	civic:EID4314:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	NM_005157	133738343	133738354
ABL1	9	G250E	missense_variant	EID4316	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	250	NA	Dasatinib	BCR-ABL G250E	civic:EID4316:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	NM_005157	133738343	133738354
ABL1	9	G250E	missense_variant	EID4318	BCR-ABL G250E	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	250	NA	Dasatinib	BCR-ABL G250E	civic:EID4318:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	NM_005157	133738343	133738354
ABL1	9	G250E	missense_variant	EID6244	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	250	NA	Imatinib Mesylate	BCR-ABL G250E	civic:EID6244:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	NM_005157	133738343	133738354
ABL1	9	G250E	missense_variant	EID6267	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	250	NA	Nilotinib	BCR-ABL G250E	civic:EID6267:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	NM_005157	133738343	133738354
ABL1	9	G250E	missense_variant	EID6993	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	250	NA	Imatinib	BCR-ABL G250E	civic:EID6993:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	NM_005157	133738343	133738354
ABL1	9	G250E	missense_variant	EID7041	BCR-ABL G250E	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	250	NA	Imatinib Mesylate	BCR-ABL G250E	civic:EID7041:ABL1:p.G250	c.749G>A	9_133738349_G_A	ENST00000318560	NM_005157	133738343	133738354
ABL1	9	Q252H	missense_variant	EID2650	Q252H	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	252	NA	Imatinib	Q252H	civic:EID2650:ABL1:p.Q252	c.756G>C	9_133738356_G_C	ENST00000318560	NM_005157	133738350	133738361
ABL1	9	Q252H	missense_variant	EID4327	Q252H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	252	NA	Dasatinib	Q252H	civic:EID4327:ABL1:p.Q252	c.756G>C	9_133738356_G_C	ENST00000318560	NM_005157	133738350	133738361
ABL1	9	Q252H	missense_variant	EID6219	Q252H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	252	NA	Dasatinib	Q252H	civic:EID6219:ABL1:p.Q252	c.756G>C	9_133738356_G_C	ENST00000318560	NM_005157	133738350	133738361
ABL1	9	Q252H	missense_variant	EID6245	Q252H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	252	NA	Imatinib Mesylate	Q252H	civic:EID6245:ABL1:p.Q252	c.756G>C	9_133738356_G_C	ENST00000318560	NM_005157	133738350	133738361
ABL1	9	Q252H	missense_variant	EID6274	Q252H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	252	NA	Dasatinib	Q252H	civic:EID6274:ABL1:p.Q252	c.756G>C	9_133738356_G_C	ENST00000318560	NM_005157	133738350	133738361
ABL1	9	Y253H	missense_variant	EID2654	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	253	NA	Nilotinib, Imatinib Mesylate	BCR-ABL Y253H	civic:EID2654:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	NM_005157	133738351	133738362
ABL1	9	Y253H	missense_variant	EID4331	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	253	NA	Bosutinib	BCR-ABL Y253H	civic:EID4331:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	NM_005157	133738351	133738362
ABL1	9	Y253H	missense_variant	EID4332	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	253	NA	Bosutinib	BCR-ABL Y253H	civic:EID4332:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	NM_005157	133738351	133738362
ABL1	9	Y253H	missense_variant	EID4335	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	253	NA	Dasatinib	BCR-ABL Y253H	civic:EID4335:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	NM_005157	133738351	133738362
ABL1	9	Y253H	missense_variant	EID6200	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19652056' target='_blank'>Hughes et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	253	NA	Nilotinib, Imatinib Mesylate	BCR-ABL Y253H	civic:EID6200:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	NM_005157	133738351	133738362
ABL1	9	Y253H	missense_variant	EID6237	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	253	NA	Imatinib Mesylate, Nilotinib	BCR-ABL Y253H	civic:EID6237:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	NM_005157	133738351	133738362
ABL1	9	Y253H	missense_variant	EID6992	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	253	NA	Imatinib Mesylate	BCR-ABL Y253H	civic:EID6992:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	NM_005157	133738351	133738362
ABL1	9	Y253H	missense_variant	EID7040	BCR-ABL Y253H	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	253	NA	Imatinib Mesylate	BCR-ABL Y253H	civic:EID7040:ABL1:p.Y253	c.757T>C	9_133738357_T_C	ENST00000318560	NM_005157	133738351	133738362
ABL1	9	Y253F	missense_variant	EID2655	Y253F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	253	NA	Imatinib	Y253F	civic:EID2655:ABL1:p.Y253	c.758A>T	9_133738358_A_T	ENST00000318560	NM_005157	133738352	133738363
ABL1	9	Y253F	missense_variant	EID2657	Y253F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	253	NA	Imatinib	Y253F	civic:EID2657:ABL1:p.Y253	c.758A>T	9_133738358_A_T	ENST00000318560	NM_005157	133738352	133738363
ABL1	9	Y253F	missense_variant	EID4340	Y253F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	253	NA	Bosutinib	Y253F	civic:EID4340:ABL1:p.Y253	c.758A>T	9_133738358_A_T	ENST00000318560	NM_005157	133738352	133738363
ABL1	9	E255K	missense_variant	EID233	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15194504' target='_blank'>Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	255	NA	Imatinib	BCR-ABL E255K	civic:EID233:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID2659	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	255	NA	Imatinib	BCR-ABL E255K	civic:EID2659:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID2661	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	255	NA	Imatinib	BCR-ABL E255K	civic:EID2661:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID2662	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	255	NA	Nilotinib	BCR-ABL E255K	civic:EID2662:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID4347	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	255	NA	Bosutinib	BCR-ABL E255K	civic:EID4347:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID4348	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	255	NA	Bosutinib	BCR-ABL E255K	civic:EID4348:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID4350	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	255	NA	Dasatinib	BCR-ABL E255K	civic:EID4350:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID4352	BCR-ABL E255K	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	255	NA	Dasatinib	BCR-ABL E255K	civic:EID4352:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID6193	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	255	NA	Imatinib Mesylate, Dasatinib	BCR-ABL E255K	civic:EID6193:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID6194	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	255	NA	Nilotinib	BCR-ABL E255K	civic:EID6194:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID6214	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	255	NA	Dasatinib, Imatinib Mesylate	BCR-ABL E255K	civic:EID6214:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID6232	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19652056' target='_blank'>Hughes et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	255	NA	Nilotinib, Imatinib Mesylate	BCR-ABL E255K	civic:EID6232:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID6282	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	255	NA	Imatinib Mesylate	BCR-ABL E255K	civic:EID6282:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID6991	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	255	NA	Imatinib Mesylate	BCR-ABL E255K	civic:EID6991:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255K	missense_variant	EID7039	BCR-ABL E255K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	255	NA	Imatinib Mesylate	BCR-ABL E255K	civic:EID7039:ABL1:p.E255	c.763G>A	9_133738363_G_A	ENST00000318560	NM_005157	133738357	133738368
ABL1	9	E255V	missense_variant	EID2850	BCR-ABL E255V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	255	NA	Nilotinib	BCR-ABL E255V	civic:EID2850:ABL1:p.E255	c.764A>T	9_133738364_A_T	ENST00000318560	NM_005157	133738358	133738369
ABL1	9	E255V	missense_variant	EID2851	BCR-ABL E255V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	255	NA	Nilotinib, Imatinib Mesylate	BCR-ABL E255V	civic:EID2851:ABL1:p.E255	c.764A>T	9_133738364_A_T	ENST00000318560	NM_005157	133738358	133738369
ABL1	9	E255V	missense_variant	EID4443	BCR-ABL E255V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	255	NA	Bosutinib	BCR-ABL E255V	civic:EID4443:ABL1:p.E255	c.764A>T	9_133738364_A_T	ENST00000318560	NM_005157	133738358	133738369
ABL1	9	E255V	missense_variant	EID4444	BCR-ABL E255V	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	255	NA	Bosutinib	BCR-ABL E255V	civic:EID4444:ABL1:p.E255	c.764A>T	9_133738364_A_T	ENST00000318560	NM_005157	133738358	133738369
ABL1	9	E255V	missense_variant	EID4447	BCR-ABL E255V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	255	NA	Dasatinib	BCR-ABL E255V	civic:EID4447:ABL1:p.E255	c.764A>T	9_133738364_A_T	ENST00000318560	NM_005157	133738358	133738369
ABL1	9	E255V	missense_variant	EID6971	BCR-ABL E255V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19652056' target='_blank'>Hughes et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	255	NA	Nilotinib, Imatinib Mesylate	BCR-ABL E255V	civic:EID6971:ABL1:p.E255	c.764A>T	9_133738364_A_T	ENST00000318560	NM_005157	133738358	133738369
ABL1	9	E255V	missense_variant	EID6986	BCR-ABL E255V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	255	NA	Imatinib Mesylate	BCR-ABL E255V	civic:EID6986:ABL1:p.E255	c.764A>T	9_133738364_A_T	ENST00000318560	NM_005157	133738358	133738369
ABL1	9	D276G	missense_variant	EID2663	BCR-ABL D276G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	276	NA	Imatinib	BCR-ABL D276G	civic:EID2663:ABL1:p.D276	c.827A>G	9_133747520_A_G	ENST00000318560	NM_005157	133747514	133747525
ABL1	9	D276G	missense_variant	EID2666	BCR-ABL D276G	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	276	NA	Nilotinib	BCR-ABL D276G	civic:EID2666:ABL1:p.D276	c.827A>G	9_133747520_A_G	ENST00000318560	NM_005157	133747514	133747525
ABL1	9	D276G	missense_variant	EID4357	BCR-ABL D276G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	276	NA	Bosutinib	BCR-ABL D276G	civic:EID4357:ABL1:p.D276	c.827A>G	9_133747520_A_G	ENST00000318560	NM_005157	133747514	133747525
ABL1	9	D276G	missense_variant	EID4359	BCR-ABL D276G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	276	NA	Dasatinib	BCR-ABL D276G	civic:EID4359:ABL1:p.D276	c.827A>G	9_133747520_A_G	ENST00000318560	NM_005157	133747514	133747525
ABL1	9	D276G	missense_variant	EID6246	BCR-ABL D276G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	276	NA	Imatinib Mesylate	BCR-ABL D276G	civic:EID6246:ABL1:p.D276	c.827A>G	9_133747520_A_G	ENST00000318560	NM_005157	133747514	133747525
ABL1	9	E279K	missense_variant	EID4543	E279K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	279	NA	Dasatinib	E279K	civic:EID4543:ABL1:p.E279	c.835G>A	9_133747528_G_A	ENST00000318560	NM_005157	133747522	133747533
ABL1	9	E292V	missense_variant	EID2853	E292V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	292	NA	Nilotinib	E292V	civic:EID2853:ABL1:p.E292	c.875A>T	9_133747568_A_T	ENST00000318560	NM_005157	133747562	133747573
ABL1	9	L298V	missense_variant	EID4475	L298V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	298	NA	Bosutinib	L298V	civic:EID4475:ABL1:p.L298	c.892C>G	9_133747585_C_G	ENST00000318560	NM_005157	133747579	133747590
ABL1	9	V299L	missense_variant	EID2862	BCR-ABL V299L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	299	NA	Nilotinib	BCR-ABL V299L	civic:EID2862:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	NM_005157	133747582	133747593
ABL1	9	V299L	missense_variant	EID4538	BCR-ABL V299L	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	299	NA	Bosutinib	BCR-ABL V299L	civic:EID4538:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	NM_005157	133747582	133747593
ABL1	9	V299L	missense_variant	EID4540	BCR-ABL V299L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	299	NA	Dasatinib	BCR-ABL V299L	civic:EID4540:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	NM_005157	133747582	133747593
ABL1	9	V299L	missense_variant	EID6216	BCR-ABL V299L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	299	NA	Dasatinib	BCR-ABL V299L	civic:EID6216:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	NM_005157	133747582	133747593
ABL1	9	V299L	missense_variant	EID6241	BCR-ABL V299L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	299	NA	Dasatinib, Imatinib Mesylate	BCR-ABL V299L	civic:EID6241:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	NM_005157	133747582	133747593
ABL1	9	V299L	missense_variant	EID6247	BCR-ABL V299L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	299	NA	Dasatinib	BCR-ABL V299L	civic:EID6247:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	NM_005157	133747582	133747593
ABL1	9	V299L	missense_variant	EID6982	BCR-ABL V299L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	299	NA	Imatinib Mesylate	BCR-ABL V299L	civic:EID6982:ABL1:p.V299	c.895G>C	9_133747588_G_C	ENST00000318560	NM_005157	133747582	133747593
ABL1	9	Q300R	missense_variant	EID4545	Q300R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	300	NA	Bosutinib	Q300R	civic:EID4545:ABL1:p.Q300	c.899A>G	9_133747592_A_G	ENST00000318560	NM_005157	133747586	133747597
ABL1	9	Q300R	missense_variant	EID6983	Q300R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	300	NA	Imatinib Mesylate	Q300R	civic:EID6983:ABL1:p.Q300	c.899A>G	9_133747592_A_G	ENST00000318560	NM_005157	133747586	133747597
ABL1	9	F311I	missense_variant	EID4478	BCR-ABL F311I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	311	NA	Bosutinib	BCR-ABL F311I	civic:EID4478:ABL1:p.F311	c.931T>A	9_133748270_T_A	ENST00000318560	NM_005157	133748264	133748275
ABL1	9	F311L	missense_variant	EID4546	BCR-ABL F311L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	311	NA	Bosutinib	BCR-ABL F311L	civic:EID4546:ABL1:p.F311	c.931T>C	9_133748270_T_C	ENST00000318560	NM_005157	133748264	133748275
ABL1	9	F311L	missense_variant	EID6238	BCR-ABL F311L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	311	NA	Nilotinib, Imatinib Mesylate	BCR-ABL F311L	civic:EID6238:ABL1:p.F311	c.931T>C	9_133748270_T_C	ENST00000318560	NM_005157	133748264	133748275
ABL1	9	T315A	missense_variant	EID6190	BCR-ABL T315A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	315	NA	Dasatinib	BCR-ABL T315A	civic:EID6190:ABL1:p.T315	c.943A>G	9_133748282_A_G	ENST00000318560	NM_005157	133748276	133748287
ABL1	9	T315I	missense_variant	EID1390	BCR-ABL T315I	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23190221' target='_blank'>Cortes et al., 2012, N. Engl. J. Med.</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	315	NA	Ponatinib	BCR-ABL T315I	civic:EID1390:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID234	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20537386' target='_blank'>An et al., 2010, Leuk. Res.</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	315	NA	Imatinib	BCR-ABL T315I	civic:EID234:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID235	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15194504' target='_blank'>Yamamoto et al., 2004, Biochem. Biophys. Res. Commun.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	315	NA	Imatinib	BCR-ABL T315I	civic:EID235:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID2667	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	315	NA	Imatinib	BCR-ABL T315I	civic:EID2667:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID2669	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	315	NA	Imatinib	BCR-ABL T315I	civic:EID2669:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID2670	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	315	NA	Nilotinib	BCR-ABL T315I	civic:EID2670:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID4362	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	315	NA	Bosutinib	BCR-ABL T315I	civic:EID4362:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID4364	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	315	NA	Bosutinib	BCR-ABL T315I	civic:EID4364:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID4365	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	315	NA	Dasatinib	BCR-ABL T315I	civic:EID4365:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID4376	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Acute Lymphocytic Leukemia	Predictive	C: Case study	DOID:9952	315	NA	Dasatinib	BCR-ABL T315I	civic:EID4376:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID6192	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	315	NA	Dasatinib, Imatinib Mesylate	BCR-ABL T315I	civic:EID6192:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID6196	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	315	NA	Imatinib Mesylate, Nilotinib	BCR-ABL T315I	civic:EID6196:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID6234	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	315	NA	Imatinib Mesylate, Dasatinib	BCR-ABL T315I	civic:EID6234:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID6235	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	315	NA	Nilotinib, Dasatinib	BCR-ABL T315I	civic:EID6235:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID6285	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	315	NA	Imatinib Mesylate, Nilotinib, Dasatinib	BCR-ABL T315I	civic:EID6285:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID6990	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	315	NA	Imatinib Mesylate	BCR-ABL T315I	civic:EID6990:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	T315I	missense_variant	EID7038	BCR-ABL T315I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	315	NA	Imatinib Mesylate	BCR-ABL T315I	civic:EID7038:ABL1:p.T315	c.944C>T	9_133748283_C_T	ENST00000318560	NM_005157	133748277	133748288
ABL1	9	F317I	missense_variant	EID6217	BCR-ABL F317I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	317	NA	Dasatinib	BCR-ABL F317I	civic:EID6217:ABL1:p.F317	c.949T>A	9_133748288_T_A	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317I	missense_variant	EID6251	BCR-ABL F317I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	317	NA	Dasatinib	BCR-ABL F317I	civic:EID6251:ABL1:p.F317	c.949T>A	9_133748288_T_A	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID2674	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	317	NA	Imatinib	BCR-ABL F317L	civic:EID2674:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID2676	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	317	NA	Imatinib	BCR-ABL F317L	civic:EID2676:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID2680	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	317	NA	Imatinib	BCR-ABL F317L	civic:EID2680:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID4381	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	317	NA	Bosutinib	BCR-ABL F317L	civic:EID4381:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID4382	BCR-ABL F317L	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	317	NA	Bosutinib	BCR-ABL F317L	civic:EID4382:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID6215	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	317	NA	Dasatinib	BCR-ABL F317L	civic:EID6215:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID6252	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	317	NA	Imatinib Mesylate	BCR-ABL F317L	civic:EID6252:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID6270	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	317	NA	Dasatinib	BCR-ABL F317L	civic:EID6270:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID6309	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	317	NA	Dasatinib	BCR-ABL F317L	civic:EID6309:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID637	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/18818391' target='_blank'>Jabbour et al., 2008, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	317	NA	Dasatinib	BCR-ABL F317L	civic:EID637:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID638	BCR-ABL F317L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24236021' target='_blank'>Tanneeru et al., 2013, PLoS ONE</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	317	NA	Ponatinib	BCR-ABL F317L	civic:EID638:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID639	BCR-ABL F317L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/25349473' target='_blank'>Miller et al., 2014, Biologics</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	317	NA	Ponatinib	BCR-ABL F317L	civic:EID639:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID6978	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	317	NA	Imatinib Mesylate	BCR-ABL F317L	civic:EID6978:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID7030	BCR-ABL F317L	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	317	NA	Dasatinib	BCR-ABL F317L	civic:EID7030:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317L	missense_variant	EID7045	BCR-ABL F317L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	317	NA	Imatinib Mesylate	BCR-ABL F317L	civic:EID7045:ABL1:p.F317	c.949T>C	9_133748288_T_C	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317V	missense_variant	EID6208	BCR-ABL F317V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	317	NA	Dasatinib	BCR-ABL F317V	civic:EID6208:ABL1:p.F317	c.949T>G	9_133748288_T_G	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317V	missense_variant	EID6253	BCR-ABL F317V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	317	NA	Dasatinib	BCR-ABL F317V	civic:EID6253:ABL1:p.F317	c.949T>G	9_133748288_T_G	ENST00000318560	NM_005157	133748282	133748293
ABL1	9	F317C	missense_variant	EID6250	BCR-ABL F317C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	317	NA	Dasatinib	BCR-ABL F317C	civic:EID6250:ABL1:p.F317	c.950T>G	9_133748289_T_G	ENST00000318560	NM_005157	133748283	133748294
ABL1	9	F317S	missense_variant	EID6218	BCR-ABL F317S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15705718' target='_blank'>Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	317	NA	Dasatinib	BCR-ABL F317S	civic:EID6218:ABL1:p.F317	c.950T>C	9_133748289_T_C	ENST00000318560	NM_005157	133748283	133748294
ABL1	9	G321L	missense_variant	EID4788	G340L	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26758680' target='_blank'>Testoni et al., 2016, EMBO Mol Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	321	NA	Imatinib Mesylate, Dasatinib	G340L	civic:EID4788:ABL1:p.G321	c.961_962delinsCT	9_133748300_GG_CT	ENST00000318560	NM_005157	133748294	133748306
ABL1	9	N331S	missense_variant	EID4549	BCR-ABL N331S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	331	NA	Bosutinib	BCR-ABL N331S	civic:EID4549:ABL1:p.N331	c.992A>G	9_133748331_A_G	ENST00000318560	NM_005157	133748325	133748336
ABL1	9	R332W	missense_variant	EID4787	R351W	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26758680' target='_blank'>Testoni et al., 2016, EMBO Mol Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	332	NA	Dasatinib	R351W	civic:EID4787:ABL1:p.R332	c.994C>T	9_133748333_C_T	ENST00000318560	NM_005157	133748327	133748338
ABL1	9	R332W	missense_variant	EID6376	R351W	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26758680' target='_blank'>Testoni et al., 2016, EMBO Mol Med</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	332	NA	Imatinib	R351W	civic:EID6376:ABL1:p.R332	c.994C>T	9_133748333_C_T	ENST00000318560	NM_005157	133748327	133748338
ABL1	9	N336S	missense_variant	EID4769	N336S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	336	NA	Bosutinib	N336S	civic:EID4769:ABL1:p.N336	c.1007A>G	9_133748346_A_G	ENST00000318560	NM_005157	133748340	133748351
ABL1	9	N336S	missense_variant	EID6979	N336S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	336	NA	Imatinib Mesylate	N336S	civic:EID6979:ABL1:p.N336	c.1007A>G	9_133748346_A_G	ENST00000318560	NM_005157	133748340	133748351
ABL1	9	M351T	missense_variant	EID2682	BCR-ABL M351T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	351	NA	Imatinib	BCR-ABL M351T	civic:EID2682:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	NM_005157	133748385	133748396
ABL1	9	M351T	missense_variant	EID2684	BCR-ABL M351T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	351	NA	Imatinib	BCR-ABL M351T	civic:EID2684:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	NM_005157	133748385	133748396
ABL1	9	M351T	missense_variant	EID2685	BCR-ABL M351T	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	351	NA	Nilotinib	BCR-ABL M351T	civic:EID2685:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	NM_005157	133748385	133748396
ABL1	9	M351T	missense_variant	EID4394	BCR-ABL M351T	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	351	NA	Bosutinib	BCR-ABL M351T	civic:EID4394:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	NM_005157	133748385	133748396
ABL1	9	M351T	missense_variant	EID4396	BCR-ABL M351T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	351	NA	Dasatinib	BCR-ABL M351T	civic:EID4396:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	NM_005157	133748385	133748396
ABL1	9	M351T	missense_variant	EID4397	BCR-ABL M351T	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	351	NA	Dasatinib	BCR-ABL M351T	civic:EID4397:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	NM_005157	133748385	133748396
ABL1	9	M351T	missense_variant	EID6254	BCR-ABL M351T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	351	NA	Imatinib Mesylate	BCR-ABL M351T	civic:EID6254:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	NM_005157	133748385	133748396
ABL1	9	M351T	missense_variant	EID6989	BCR-ABL M351T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	351	NA	Imatinib Mesylate	BCR-ABL M351T	civic:EID6989:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	NM_005157	133748385	133748396
ABL1	9	M351T	missense_variant	EID7037	BCR-ABL M351T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	351	NA	Imatinib Mesylate	BCR-ABL M351T	civic:EID7037:ABL1:p.M351	c.1052T>C	9_133748391_T_C	ENST00000318560	NM_005157	133748385	133748396
ABL1	9	E355G	missense_variant	EID4400	BCR-ABL E355G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	355	NA	Bosutinib	BCR-ABL E355G	civic:EID4400:ABL1:p.E355	c.1064A>G	9_133748403_A_G	ENST00000318560	NM_005157	133748397	133748408
ABL1	9	E355G	missense_variant	EID4402	BCR-ABL E355G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	355	NA	Dasatinib	BCR-ABL E355G	civic:EID4402:ABL1:p.E355	c.1064A>G	9_133748403_A_G	ENST00000318560	NM_005157	133748397	133748408
ABL1	9	E355G	missense_variant	EID4403	BCR-ABL E355G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	355	NA	Dasatinib	BCR-ABL E355G	civic:EID4403:ABL1:p.E355	c.1064A>G	9_133748403_A_G	ENST00000318560	NM_005157	133748397	133748408
ABL1	9	E355G	missense_variant	EID6255	BCR-ABL E355G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	355	NA	Imatinib Mesylate	BCR-ABL E355G	civic:EID6255:ABL1:p.E355	c.1064A>G	9_133748403_A_G	ENST00000318560	NM_005157	133748397	133748408
ABL1	9	E355G	missense_variant	EID7036	BCR-ABL E355G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	355	NA	Imatinib Mesylate	BCR-ABL E355G	civic:EID7036:ABL1:p.E355	c.1064A>G	9_133748403_A_G	ENST00000318560	NM_005157	133748397	133748408
ABL1	9	F359I	missense_variant	EID4530	BCR-ABL F359I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Bosutinib	BCR-ABL F359I	civic:EID4530:ABL1:p.F359	c.1075T>A	9_133748414_T_A	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359I	missense_variant	EID4531	BCR-ABL F359I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Bosutinib	BCR-ABL F359I	civic:EID4531:ABL1:p.F359	c.1075T>A	9_133748414_T_A	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359I	missense_variant	EID4532	BCR-ABL F359I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	359	NA	Dasatinib	BCR-ABL F359I	civic:EID4532:ABL1:p.F359	c.1075T>A	9_133748414_T_A	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359I	missense_variant	EID6984	BCR-ABL F359I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Imatinib Mesylate	BCR-ABL F359I	civic:EID6984:ABL1:p.F359	c.1075T>A	9_133748414_T_A	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359V	missense_variant	EID2167	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	359	NA	Imatinib	BCR-ABL F359V	civic:EID2167:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359V	missense_variant	EID2169	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Imatinib	BCR-ABL F359V	civic:EID2169:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359V	missense_variant	EID2170	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	359	NA	Nilotinib	BCR-ABL F359V	civic:EID2170:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359V	missense_variant	EID3815	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Bosutinib	BCR-ABL F359V	civic:EID3815:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359V	missense_variant	EID3816	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Bosutinib	BCR-ABL F359V	civic:EID3816:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359V	missense_variant	EID3817	BCR-ABL F359V	Reduced Sensitivity	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Dasatinib	BCR-ABL F359V	civic:EID3817:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359V	missense_variant	EID3819	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	359	NA	Dasatinib	BCR-ABL F359V	civic:EID3819:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359V	missense_variant	EID6256	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	359	NA	Imatinib Mesylate	BCR-ABL F359V	civic:EID6256:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359V	missense_variant	EID6970	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19652056' target='_blank'>Hughes et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Nilotinib, Imatinib Mesylate	BCR-ABL F359V	civic:EID6970:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359V	missense_variant	EID6995	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Imatinib Mesylate	BCR-ABL F359V	civic:EID6995:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359V	missense_variant	EID7043	BCR-ABL F359V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Imatinib Mesylate	BCR-ABL F359V	civic:EID7043:ABL1:p.F359	c.1075T>G	9_133748414_T_G	ENST00000318560	NM_005157	133748408	133748419
ABL1	9	F359C	missense_variant	EID2854	BCR-ABL F359C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	359	NA	Imatinib Mesylate, Nilotinib	BCR-ABL F359C	civic:EID2854:ABL1:p.F359	c.1076T>G	9_133748415_T_G	ENST00000318560	NM_005157	133748409	133748420
ABL1	9	F359C	missense_variant	EID4480	BCR-ABL F359C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Bosutinib	BCR-ABL F359C	civic:EID4480:ABL1:p.F359	c.1076T>G	9_133748415_T_G	ENST00000318560	NM_005157	133748409	133748420
ABL1	9	F359C	missense_variant	EID4481	BCR-ABL F359C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Dasatinib	BCR-ABL F359C	civic:EID4481:ABL1:p.F359	c.1076T>G	9_133748415_T_G	ENST00000318560	NM_005157	133748409	133748420
ABL1	9	F359C	missense_variant	EID4482	BCR-ABL F359C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Dasatinib	BCR-ABL F359C	civic:EID4482:ABL1:p.F359	c.1076T>G	9_133748415_T_G	ENST00000318560	NM_005157	133748409	133748420
ABL1	9	F359C	missense_variant	EID6233	BCR-ABL F359C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19652056' target='_blank'>Hughes et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Imatinib Mesylate, Nilotinib	BCR-ABL F359C	civic:EID6233:ABL1:p.F359	c.1076T>G	9_133748415_T_G	ENST00000318560	NM_005157	133748409	133748420
ABL1	9	F359C	missense_variant	EID6239	BCR-ABL F359C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	359	NA	Nilotinib, Imatinib Mesylate	BCR-ABL F359C	civic:EID6239:ABL1:p.F359	c.1076T>G	9_133748415_T_G	ENST00000318560	NM_005157	133748409	133748420
ABL1	9	F359C	missense_variant	EID6985	BCR-ABL F359C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Imatinib Mesylate	BCR-ABL F359C	civic:EID6985:ABL1:p.F359	c.1076T>G	9_133748415_T_G	ENST00000318560	NM_005157	133748409	133748420
ABL1	9	F359C	missense_variant	EID7035	BCR-ABL F359C	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	359	NA	Imatinib Mesylate	BCR-ABL F359C	civic:EID7035:ABL1:p.F359	c.1076T>G	9_133748415_T_G	ENST00000318560	NM_005157	133748409	133748420
ABL1	9	L364P	missense_variant	EID4551	BCR-ABL L364P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	364	NA	Bosutinib	BCR-ABL L364P	civic:EID4551:ABL1:p.L364	c.1091T>C	9_133750260_T_C	ENST00000318560	NM_005157	133750254	133750265
ABL1	9	V379I	missense_variant	EID4704	BCR-ABL V379I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	379	NA	Dasatinib	BCR-ABL V379I	civic:EID4704:ABL1:p.V379	c.1135G>A	9_133750304_G_A	ENST00000318560	NM_005157	133750298	133750309
ABL1	9	V379I	missense_variant	EID6257	BCR-ABL V379I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	379	NA	Imatinib Mesylate	BCR-ABL V379I	civic:EID6257:ABL1:p.V379	c.1135G>A	9_133750304_G_A	ENST00000318560	NM_005157	133750298	133750309
ABL1	9	V379I	missense_variant	EID7033	BCR-ABL V379I	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	379	NA	Imatinib Mesylate	BCR-ABL V379I	civic:EID7033:ABL1:p.V379	c.1135G>A	9_133750304_G_A	ENST00000318560	NM_005157	133750298	133750309
ABL1	9	L384M	missense_variant	EID2861	L384M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	384	NA	Imatinib Mesylate, Nilotinib	L384M	civic:EID2861:ABL1:p.L384	c.1150C>A	9_133750319_C_A	ENST00000318560	NM_005157	133750313	133750324
ABL1	9	L384M	missense_variant	EID4527	L384M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	384	NA	Dasatinib	L384M	civic:EID4527:ABL1:p.L384	c.1150C>A	9_133750319_C_A	ENST00000318560	NM_005157	133750313	133750324
ABL1	9	L387M	missense_variant	EID4406	BCR-ABL L387M	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	387	NA	Dasatinib	BCR-ABL L387M	civic:EID4406:ABL1:p.L387	c.1159T>A	9_133750328_T_A	ENST00000318560	NM_005157	133750322	133750333
ABL1	9	L387F	missense_variant	EID2863	BCR-ABL L387F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	387	NA	Nilotinib	BCR-ABL L387F	civic:EID2863:ABL1:p.L387	c.1161G>C	9_133750330_G_C	ENST00000318560	NM_005157	133750324	133750335
ABL1	9	L387F	missense_variant	EID4552	BCR-ABL L387F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	387	NA	Bosutinib	BCR-ABL L387F	civic:EID4552:ABL1:p.L387	c.1161G>C	9_133750330_G_C	ENST00000318560	NM_005157	133750324	133750335
ABL1	9	L387F	missense_variant	EID6981	BCR-ABL L387F	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	387	NA	Imatinib Mesylate	BCR-ABL L387F	civic:EID6981:ABL1:p.L387	c.1161G>C	9_133750330_G_C	ENST00000318560	NM_005157	133750324	133750335
ABL1	9	H396P	missense_variant	EID4554	BCR-ABL H396P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	396	NA	Bosutinib	BCR-ABL H396P	civic:EID4554:ABL1:p.H396	c.1187A>C	9_133750356_A_C	ENST00000318560	NM_005157	133750350	133750361
ABL1	9	H396P	missense_variant	EID6240	BCR-ABL H396P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	396	NA	Nilotinib, Imatinib Mesylate	BCR-ABL H396P	civic:EID6240:ABL1:p.H396	c.1187A>C	9_133750356_A_C	ENST00000318560	NM_005157	133750350	133750361
ABL1	9	H396R	missense_variant	EID2687	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	396	NA	Imatinib	BCR-ABL H396R	civic:EID2687:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	NM_005157	133750350	133750361
ABL1	9	H396R	missense_variant	EID2689	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/15930265' target='_blank'>O'Hare et al., 2005, Cancer Res.</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	396	NA	Imatinib	BCR-ABL H396R	civic:EID2689:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	NM_005157	133750350	133750361
ABL1	9	H396R	missense_variant	EID4410	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	396	NA	Bosutinib	BCR-ABL H396R	civic:EID4410:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	NM_005157	133750350	133750361
ABL1	9	H396R	missense_variant	EID4411	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	396	NA	Bosutinib	BCR-ABL H396R	civic:EID4411:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	NM_005157	133750350	133750361
ABL1	9	H396R	missense_variant	EID4413	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	396	NA	Dasatinib	BCR-ABL H396R	civic:EID4413:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	NM_005157	133750350	133750361
ABL1	9	H396R	missense_variant	EID6258	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/16772610' target='_blank'>Bradeen et al., 2006, Blood</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	396	NA	Imatinib Mesylate	BCR-ABL H396R	civic:EID6258:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	NM_005157	133750350	133750361
ABL1	9	H396R	missense_variant	EID6988	BCR-ABL H396R	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	396	NA	Imatinib Mesylate	BCR-ABL H396R	civic:EID6988:ABL1:p.H396	c.1187A>G	9_133750356_A_G	ENST00000318560	NM_005157	133750350	133750361
ABL1	9	A397P	missense_variant	EID4710	BCR-ABL A397P	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	397	NA	Dasatinib	BCR-ABL A397P	civic:EID4710:ABL1:p.A397	c.1189G>C	9_133750358_G_C	ENST00000318560	NM_005157	133750352	133750363
ABL1	9	G398R	missense_variant	EID2864	BCR-ABL G398R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	398	NA	Nilotinib	BCR-ABL G398R	civic:EID2864:ABL1:p.G398	c.1192G>C	9_133750361_G_C	ENST00000318560	NM_005157	133750355	133750366
ABL1	9	G398R	missense_variant	EID4561	BCR-ABL G398R	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	398	NA	Dasatinib	BCR-ABL G398R	civic:EID4561:ABL1:p.G398	c.1192G>C	9_133750361_G_C	ENST00000318560	NM_005157	133750355	133750366
ABL1	9	D421G	missense_variant	EID4559	D421G	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	421	NA	Bosutinib	D421G	civic:EID4559:ABL1:p.D421	c.1262A>G	9_133750431_A_G	ENST00000318560	NM_005157	133750425	133750436
ABL1	9	E450V	missense_variant	EID4563	BCR-ABL E450V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	450	NA	Bosutinib	BCR-ABL E450V	civic:EID4563:ABL1:p.E450	c.1349A>T	9_133753880_A_T	ENST00000318560	NM_005157	133753874	133753885
ABL1	9	E453K	missense_variant	EID4565	BCR-ABL E453K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	453	NA	Bosutinib	BCR-ABL E453K	civic:EID4565:ABL1:p.E453	c.1357G>A	9_133753888_G_A	ENST00000318560	NM_005157	133753882	133753893
ABL1	9	E453Q	missense_variant	EID4486	BCR-ABL E453Q	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	453	NA	Bosutinib	BCR-ABL E453Q	civic:EID4486:ABL1:p.E453	c.1357G>C	9_133753888_G_C	ENST00000318560	NM_005157	133753882	133753893
ABL1	9	E453A	missense_variant	EID4567	BCR-ABL E453A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	453	NA	Bosutinib	BCR-ABL E453A	civic:EID4567:ABL1:p.E453	c.1358A>C	9_133753889_A_C	ENST00000318560	NM_005157	133753883	133753894
ABL1	9	E453A	missense_variant	EID6980	BCR-ABL E453A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	453	NA	Imatinib Mesylate	BCR-ABL E453A	civic:EID6980:ABL1:p.E453	c.1358A>C	9_133753889_A_C	ENST00000318560	NM_005157	133753883	133753894
ABL1	9	E459K	missense_variant	EID6310	BCR-ABL E459K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	459	NA	Dasatinib	BCR-ABL E459K	civic:EID6310:ABL1:p.E459	c.1375G>A	9_133753906_G_A	ENST00000318560	NM_005157	133753900	133753911
ABL1	9	E459K	missense_variant	EID7031	BCR-ABL E459K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	459	NA	Dasatinib	BCR-ABL E459K	civic:EID7031:ABL1:p.E459	c.1375G>A	9_133753906_G_A	ENST00000318560	NM_005157	133753900	133753911
ABL1	9	E459K	missense_variant	EID7046	BCR-ABL E459K	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/17264298' target='_blank'>Guilhot et al., 2007, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	459	NA	Imatinib Mesylate	BCR-ABL E459K	civic:EID7046:ABL1:p.E459	c.1375G>A	9_133753906_G_A	ENST00000318560	NM_005157	133753900	133753911
ABL1	9	.	splice_donor_variant&coding_sequence_variant	EID4768	C475V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Bosutinib	C475V	civic:EID4768:ABL1:p..	NA	9_133753954_TG_GT	ENST00000318560	NM_005157	133753948	133753960
ABL1	9	.	splice_donor_variant&coding_sequence_variant	EID6977	C475V	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	NA	NA	Imatinib Mesylate	C475V	civic:EID6977:ABL1:p..	NA	9_133753954_TG_GT	ENST00000318560	NM_005157	133753948	133753960
ABL1	9	P480A	missense_variant	EID4568	BCR-ABL P480A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21865346' target='_blank'>Cortes et al., 2011, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	480	NA	Bosutinib	BCR-ABL P480A	civic:EID4568:ABL1:p.P480	c.1438C>G	9_133755469_C_G	ENST00000318560	NM_005157	133755463	133755474
ABL1	9	F486S	missense_variant	EID2829	BCR-ABL F486S	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19075254' target='_blank'>Redaelli et al., 2009, J. Clin. Oncol.</a>	Chronic Myeloid Leukemia	Predictive	D: Preclinical evidence	DOID:8552	486	NA	Nilotinib	BCR-ABL F486S	civic:EID2829:ABL1:p.F486	c.1457T>C	9_133755488_T_C	ENST00000318560	NM_005157	133755482	133755493
ABL1	9	F486S	missense_variant	EID4440	BCR-ABL F486S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	486	NA	Bosutinib	BCR-ABL F486S	civic:EID4440:ABL1:p.F486	c.1457T>C	9_133755488_T_C	ENST00000318560	NM_005157	133755482	133755493
ABL1	9	F486S	missense_variant	EID4571	BCR-ABL F486S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/19779040' target='_blank'>Müller et al., 2009, Blood</a>	Chronic Myeloid Leukemia	Predictive	B: Clinical evidence	DOID:8552	486	NA	Dasatinib	BCR-ABL F486S	civic:EID4571:ABL1:p.F486	c.1457T>C	9_133755488_T_C	ENST00000318560	NM_005157	133755482	133755493
ABL1	9	F486S	missense_variant	EID6987	BCR-ABL F486S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22371878' target='_blank'>Khoury et al., 2012, Blood</a>	Chronic Myeloid Leukemia	Predictive	C: Case study	DOID:8552	486	NA	Imatinib Mesylate	BCR-ABL F486S	civic:EID6987:ABL1:p.F486	c.1457T>C	9_133755488_T_C	ENST00000318560	NM_005157	133755482	133755493
NOTCH1	9	NA	NA	EID1014	P2514FS	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/22077063' target='_blank'>Rossi et al., 2012, Blood</a>	Chronic Lymphocytic Leukemia	Prognostic	B: Clinical evidence	DOID:1040	2514	NA	NA	P2514	civic:EID1014:NOTCH1:p.P2514	NA	NA	NA	NA	139390648	139390650
NOTCH1	9	NA	NA	EID495	P2514FS	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/21670202' target='_blank'>Fabbri et al., 2011, J. Exp. Med.</a>	Chronic Lymphocytic Leukemia	Prognostic	B: Clinical evidence	DOID:1040	2514	NA	NA	P2514	civic:EID495:NOTCH1:p.P2514	NA	NA	NA	NA	139390648	139390650
NOTCH1	9	Q2444fs	frameshift_variant	EID383	V2444FS	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20007775' target='_blank'>Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	2444	NA	NA	V2444fs	civic:EID383:NOTCH1:p.Q2444	c.7330delinsACA	9_139390861_G_TGT	ENST00000277541	NM_017617	139390855	139390868
NOTCH1	9	R2327W	missense_variant	EID381	R2327W	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20007775' target='_blank'>Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	2327	NA	NA	R2327W	civic:EID381:NOTCH1:p.R2327	c.6979C>T	9_139391212_G_A	ENST00000277541	NM_017617	139391206	139391217
NOTCH1	9	H2275fs	frameshift_variant	EID382	S2275FS	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20007775' target='_blank'>Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	2275	NA	NA	S2275fs	civic:EID382:NOTCH1:p.H2275	c.6821_6822insT	9_139391369_G_GA	ENST00000277541	NM_017617	139391363	139391375
NOTCH1	9	D1642H	missense_variant	EID380	D1642H	Poor Outcome	<a href='http://www.ncbi.nlm.nih.gov/pubmed/20007775' target='_blank'>Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A.</a>	Non-small Cell Lung Carcinoma	Prognostic	B: Clinical evidence	DOID:3908	1642	NA	NA	D1642H	civic:EID380:NOTCH1:p.D1642	c.4924G>C	9_139399219_C_G	ENST00000277541	NM_017617	139399213	139399224
ARAF	X	S214C	missense_variant	EID17	S214C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24569458' target='_blank'>Imielinski et al., 2014, J. Clin. Invest.</a>	Non-small Cell Lung Carcinoma	Predictive	C: Case study	DOID:3908	214	NA	Sorafenib	S214C	civic:EID17:ARAF:p.S214	c.641C>G	X_47426121_C_G	ENST00000377045	NM_001654&NM_001256196	47426115	47426126
ARAF	X	S214C	missense_variant	EID40	S214C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24569458' target='_blank'>Imielinski et al., 2014, J. Clin. Invest.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	214	NA	Sorafenib	S214C	civic:EID40:ARAF:p.S214	c.641C>G	X_47426121_C_G	ENST00000377045	NM_001654&NM_001256196	47426115	47426126
ARAF	X	S214C	missense_variant	EID41	S214C	Sensitivity/Response	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24569458' target='_blank'>Imielinski et al., 2014, J. Clin. Invest.</a>	Non-small Cell Lung Carcinoma	Predictive	D: Preclinical evidence	DOID:3908	214	NA	Trametinib	S214C	civic:EID41:ARAF:p.S214	c.641C>G	X_47426121_C_G	ENST00000377045	NM_001654&NM_001256196	47426115	47426126
ARAF	X	S490T	missense_variant	EID1905	S490T	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27729313' target='_blank'>Hong et al., 2016, Cancer Discov</a>	Colorectal Cancer	Predictive	C: Case study	DOID:9256	490	NA	Irinotecan, Cetuximab, Vemurafenib	S490T	civic:EID1905:ARAF:p.S490	c.1468T>A	X_47429340_T_A	ENST00000377045	NM_001654&NM_001256196	47429334	47429345
AR	X	NA	NA	EID448	W742	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/12517791' target='_blank'>Hara et al., 2003, Cancer Res.</a>	Prostate Carcinoma	Predictive	D: Preclinical evidence	DOID:10286	742	NA	Bicalutamide	W742	civic:EID448:AR:p.W742	NA	NA	NA	NA	66937369	66937372
AR	X	F877L	missense_variant	EID447	F877L	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/23779130' target='_blank'>Joseph et al., 2013, Cancer Discov</a>	Prostate Cancer	Predictive	D: Preclinical evidence	DOID:10283	877	NA	ARN-509, Enzalutamide	F877L	civic:EID447:AR:p.F877	c.2629T>C	X_66943549_T_C	ENST00000374690	NM_000044	66943543	66943554
BTK	X	C481S	missense_variant	EID1770	C481S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/26182309' target='_blank'>Maddocks et al., 2015, JAMA Oncol</a>	Chronic Lymphocytic Leukemia	Predictive	B: Clinical evidence	DOID:1040	481	NA	Ibrutinib	C481S	civic:EID1770:BTK:p.C481	c.1441T>A	X_100611165_A_T	ENST00000308731	NM_000061&NM_001287344	100611159	100611170
BTK	X	C481S	missense_variant	EID436	C481S	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/24869598' target='_blank'>Woyach et al., 2014, N. Engl. J. Med.</a>	Chronic Lymphocytic Leukemia	Predictive	B: Clinical evidence	DOID:1040	481	NA	Ibrutinib	C481S	civic:EID436:BTK:p.C481	c.1441T>A	X_100611165_A_T	ENST00000308731	NM_000061&NM_001287344	100611159	100611170
BTK	X	T316A	missense_variant	EID1985	T316A	Resistance	<a href='http://www.ncbi.nlm.nih.gov/pubmed/27626698' target='_blank'>Sharma et al., 2016, Oncotarget</a>	Chronic Lymphocytic Leukemia	Predictive	C: Case study	DOID:1040	316	NA	Ibrutinib	T316A	civic:EID1985:BTK:p.T316	c.946A>G	X_100613633_T_C	ENST00000308731	NM_000061&NM_001287344	100613627	100613638
